
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2018

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____.

Commission file number: 001-14057

KINDRED HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

680 South Fourth Street Louisville, KY
(Address of principal executive offices)

61-1323993
(I.R.S. Employer
Identification No.)

40202
(Zip Code)

(502) 596-7300
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Emerging growth company
Non-accelerated filer Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class of Common Stock
Common stock, \$0.25 par value

Outstanding at April 30, 2018
91,260,624 shares

KINDRED HEALTHCARE, INC.
FORM 10-Q
INDEX

| | <u>Page</u> |
|--|-------------|
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements (Unaudited): | |
| Condensed Consolidated Statement of Operations – for the three months ended March 31, 2018 and 2017 | 3 |
| Condensed Consolidated Statement of Comprehensive Income (Loss) – for the three months ended March 31, 2018 and 2017 | 4 |
| Condensed Consolidated Balance Sheet – March 31, 2018 and December 31, 2017 | 5 |
| Condensed Consolidated Statement of Cash Flows – for the three months ended March 31, 2018 and 2017 | 6 |
| Notes to Condensed Consolidated Financial Statements | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 43 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 72 |
| Item 4. Controls and Procedures | 73 |
| PART II. OTHER INFORMATION | |
| Item 1. Legal Proceedings | 74 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 75 |
| Item 6. Exhibits | 75 |

KINDRED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)

| | Three months ended March 31, | |
|---|---------------------------------|-------------------|
| | 2018 | 2017 |
| Revenues | \$ 1,513,789 | \$ 1,539,490 |
| Salaries, wages and benefits | 845,854 | 839,813 |
| Supplies | 75,008 | 80,101 |
| Building rent | 62,488 | 64,656 |
| Equipment rent | 8,689 | 8,887 |
| Other operating expenses | 135,717 | 158,824 |
| General and administrative expenses (exclusive of depreciation and amortization expense included below) | 265,372 | 275,503 |
| Other (income) expense | (607) | 30 |
| Impairment charges | - | 474 |
| Restructuring charges | 8,109 | 10,006 |
| Depreciation and amortization | 24,789 | 29,820 |
| Interest expense | 61,032 | 59,328 |
| Investment income | (197) | (509) |
| | <u>1,486,254</u> | <u>1,526,933</u> |
| Income from continuing operations before income taxes | 27,535 | 12,557 |
| Provision for income taxes | 1,228 | 2,234 |
| Income from continuing operations | 26,307 | 10,323 |
| Discontinued operations, net of income taxes: | | |
| Income (loss) from operations | (8,770) | 5,059 |
| Loss on divestiture of operations | (5,790) | (6,166) |
| Loss from discontinued operations | <u>(14,560)</u> | <u>(1,107)</u> |
| Net income | 11,747 | 9,216 |
| Earnings attributable to noncontrolling interests: | | |
| Continuing operations | (12,792) | (10,483) |
| Discontinued operations | (660) | (4,481) |
| | <u>(13,452)</u> | <u>(14,964)</u> |
| Loss attributable to Kindred | <u>\$ (1,705)</u> | <u>\$ (5,748)</u> |
| Amounts attributable to Kindred stockholders: | | |
| Income (loss) from continuing operations | \$ 13,515 | \$ (160) |
| Loss from discontinued operations | (15,220) | (5,588) |
| Net loss | <u>\$ (1,705)</u> | <u>\$ (5,748)</u> |
| Earnings (loss) per common share: | | |
| Basic: | | |
| Income (loss) from continuing operations | \$ 0.15 | \$ - |
| Discontinued operations: | | |
| Income (loss) from operations | (0.11) | - |
| Loss on divestiture of operations | (0.06) | (0.07) |
| Loss from discontinued operations | <u>(0.17)</u> | <u>(0.07)</u> |
| Net loss | <u>\$ (0.02)</u> | <u>\$ (0.07)</u> |
| Diluted: | | |
| Income (loss) from continuing operations | \$ 0.15 | \$ - |
| Discontinued operations: | | |
| Income (loss) from operations | (0.11) | - |
| Loss on divestiture of operations | (0.06) | (0.07) |
| Loss from discontinued operations | <u>(0.17)</u> | <u>(0.07)</u> |
| Net loss | <u>\$ (0.02)</u> | <u>\$ (0.07)</u> |
| Shares used in computing earnings (loss) per common share: | | |
| Basic | 88,526 | 87,085 |
| Diluted | 88,526 | 87,085 |
| Cash dividends declared and paid per common share | \$ - | \$ 0.12 |

See accompanying notes.

KINDRED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In thousands)

| | Three months ended March 31, | |
|--|---------------------------------|------------|
| | 2018 | 2017 |
| Net income | \$ 11,747 | \$ 9,216 |
| Other comprehensive income: | | |
| Available-for-sale securities (Note 10): | | |
| Change in unrealized investment gains | - | 949 |
| Reclassification of gains realized in net income | - | (1) |
| Net change | - | 948 |
| Interest rate swaps (Note 1): | | |
| Change in unrealized gains | 4,125 | 1,026 |
| Reclassification of gains realized in net income, net of payments | (629) | (103) |
| Net change | 3,496 | 923 |
| Other comprehensive income | 3,496 | 1,871 |
| Comprehensive income | 15,243 | 11,087 |
| Earnings attributable to noncontrolling interests | (13,452) | (14,964) |
| Comprehensive income (loss) attributable to Kindred | \$ 1,791 | \$ (3,877) |

See accompanying notes.

KINDRED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited)
(In thousands, except per share amounts)

| | March 31, 2018 | December 31, 2017 |
|--|---------------------|----------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 108,759 | \$ 160,254 |
| Insurance subsidiary investments | 22,407 | 22,546 |
| Accounts receivable less allowance for loss of \$67,227 — March 31, 2018 and \$96,899 — December 31, 2017 | 1,165,044 | 1,122,532 |
| Inventories | 21,635 | 21,716 |
| Income taxes | 3,462 | 4,546 |
| Assets held for sale | 8,937 | 17,335 |
| Other (Note 13) | 69,828 | 60,610 |
| | <u>1,400,072</u> | <u>1,409,539</u> |
| Property and equipment | 1,686,791 | 1,682,965 |
| Accumulated depreciation | (961,272) | (946,986) |
| | <u>725,519</u> | <u>735,979</u> |
| Goodwill | 2,188,391 | 2,188,566 |
| Intangible assets less accumulated amortization of \$64,836 — March 31, 2018 and \$77,603 — December 31, 2017 | 601,368 | 604,338 |
| Insurance subsidiary investments | 27,771 | 28,988 |
| Other (Note 13) | 263,242 | 265,307 |
| Total assets (a) | <u>\$ 5,206,363</u> | <u>\$ 5,232,717</u> |
| LIABILITIES AND EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$ 147,143 | \$ 191,827 |
| Salaries, wages and other compensation | 337,838 | 352,179 |
| Due to third party payors | 26,772 | 35,321 |
| Professional liability risks | 60,671 | 60,767 |
| Accrued lease termination fees | 7,557 | 7,610 |
| Other accrued liabilities (Note 13) | 214,227 | 263,977 |
| Long-term debt due within one year | 14,482 | 14,638 |
| | <u>808,690</u> | <u>926,319</u> |
| Long-term debt | 3,266,364 | 3,146,972 |
| Professional liability risks | 276,551 | 276,829 |
| Deferred tax liabilities | 37,196 | 36,881 |
| Deferred credits and other liabilities (Note 13) | 492,170 | 497,954 |
| Commitments and contingencies (Note 12) | | |
| Equity: | | |
| Stockholders' equity: | | |
| Common stock, \$0.25 par value; authorized 175,000 shares; issued 91,279 shares — March 31, 2018 and 91,454 shares — December 31, 2017 | 22,820 | 22,864 |
| Capital in excess of par value | 1,714,504 | 1,713,179 |
| Accumulated other comprehensive income | 9,675 | 6,179 |
| Accumulated deficit | (1,632,432) | (1,618,896) |
| | <u>114,567</u> | <u>123,326</u> |
| Noncontrolling interests | 210,825 | 224,436 |
| Total equity | <u>325,392</u> | <u>347,762</u> |
| Total liabilities (a) and equity | <u>\$ 5,206,363</u> | <u>\$ 5,232,717</u> |

(a) The Company's consolidated assets as of March 31, 2018 and December 31, 2017 include total assets of variable interest entities of \$405.5 million and \$405.8 million, respectively, which can only be used to settle the obligations of the variable interest entities. The Company's consolidated liabilities as of March 31, 2018 and December 31, 2017 include total liabilities of variable interest entities of \$43.5 million and \$43.9 million, respectively. See note 1 of the notes to unaudited condensed consolidated financial statements.

See accompanying notes.

KINDRED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)
(In thousands)

| | Three months ended | |
|--|--------------------|------------|
| | March 31, | |
| | 2018 | 2017 |
| Cash flows from operating activities: | | |
| Net income | \$ 11,747 | \$ 9,216 |
| Add back loss from discontinued operations, net of income taxes | 14,560 | 1,107 |
| Adjustments to reconcile net income to net cash used in operating activities: | | |
| Depreciation expense | 22,322 | 25,191 |
| Amortization of intangible assets | 2,467 | 4,629 |
| Amortization of stock-based compensation costs | 4,261 | 3,026 |
| Amortization of deferred financing costs | 4,254 | 4,132 |
| Payment of capitalized lender fees related to debt amendment | - | (5,403) |
| Provision for doubtful accounts | 2,910 | 6,425 |
| Deferred income taxes | 411 | 1,227 |
| Impairment charges | - | 474 |
| Other | 270 | 6,258 |
| Change in operating assets and liabilities: | | |
| Accounts receivable | (77,785) | (79,752) |
| Inventories and other assets | (18,292) | (4,983) |
| Accounts payable | (19,680) | (10,425) |
| Income taxes | 1,084 | 2,291 |
| Due to third party payors | (8,135) | (4,745) |
| Other accrued liabilities | (38,743) | (42,973) |
| Net cash used in operating activities of discontinued operations | (34,054) | (8,293) |
| Net cash used in operating activities | (132,403) | (92,598) |
| Cash flows from investing activities: | | |
| Routine capital expenditures | (15,910) | (10,346) |
| Development capital expenditures | (3,542) | (5,433) |
| Acquisitions, net of cash acquired | - | (3,150) |
| Sale of assets | 13,225 | - |
| Purchase of insurance subsidiary investments | - | (22,308) |
| Sale of insurance subsidiary investments | - | 18,699 |
| Net change in other investments | 91 | 29 |
| Other | (233) | 154 |
| Net cash provided by (used in) investing activities of discontinued operations | 7,204 | (1,601) |
| Net cash provided by (used in) investing activities | 835 | (23,956) |
| Cash flows from financing activities: | | |
| Proceeds from borrowings under revolving credit | 429,700 | 478,600 |
| Repayment of borrowings under revolving credit | (310,200) | (343,400) |
| Repayment of term loan | (3,508) | (3,509) |
| Repayment of other long-term debt | (203) | (284) |
| Payment of deferred financing costs | (56) | (79) |
| Payment of dividend for mandatory redeemable preferred stock | - | (3,010) |
| Dividends paid | - | (10,228) |
| Contributions made by noncontrolling interests | 165 | - |
| Distributions to noncontrolling interests | (27,228) | (25,801) |
| Payroll tax payments for equity awards issuance | (3,044) | (2,255) |
| Net cash provided by financing activities | 85,626 | 90,034 |
| Change in cash, cash equivalents and restricted cash | (45,942) | (26,520) |
| Cash, cash equivalents and restricted cash at beginning of period | 218,463 | 324,168 |
| Cash, cash equivalents and restricted cash at end of period | \$ 172,521 | \$ 297,648 |
| Supplemental information: | | |
| Interest payments | \$ 76,283 | \$ 74,839 |
| Income tax refunds | 266 | 1,240 |
| Distributions to noncontrolling interests: | | |
| Continuing operations | (11,038) | (8,785) |
| Discontinued operations | (16,190) | (17,016) |

See accompanying notes.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION

Business

Kindred Healthcare, Inc. is a healthcare services company that through its subsidiaries operates a home health, hospice and community care business, transitional care (“TC”) hospitals, inpatient rehabilitation hospitals (“IRFs”), and a contract rehabilitation services business across the United States (collectively, the “Company” or “Kindred”). At March 31, 2018, the Company’s Kindred at Home division primarily provided home health, hospice, and community care services from 606 sites of service in 40 states. The Company’s hospital division operated 75 TC hospitals (certified as long-term acute care (“LTAC”) hospitals under the Medicare program) in 17 states. The Company’s Kindred Rehabilitation Services division operated 19 IRFs and 98 hospital-based acute rehabilitation units (“ARUs”) (certified as IRFs), and provided rehabilitation services primarily in hospitals and long-term care settings in 45 states.

Recently issued accounting requirements

In February 2018, the Financial Accounting Standards Board (the “FASB”) issued authoritative guidance which permits a company to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) on items within accumulated other comprehensive income to retained earnings. The new guidance is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. The Company will not elect to early adopt and the adoption of this standard is not expected to have a material impact on the Company’s business, financial position, results of operations or liquidity.

In August 2017, the FASB issued authoritative guidance with the objective of improving the financial reporting of hedging relationships under United States generally accepted accounting principles (“GAAP”) to better portray economic results and to simplify the application of the current hedge accounting guidance. The new guidance is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s business, financial position, results of operations or liquidity.

In January 2017, the FASB issued authoritative guidance that simplifies the measurement of goodwill impairment to a single-step test. The guidance removed step two of the goodwill impairment test, which required a hypothetical purchase price allocation. The measurement of goodwill impairment is now the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Under the revised guidance, failing step one will always result in goodwill impairment. The new guidance is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted. The Company adopted the new guidance on January 1, 2017 on a prospective basis. If the Company fails step one of the goodwill impairment test under the new guidance, the results could materially impact the Company’s financial position and results of operations but not its business or liquidity.

In June 2016, the FASB issued authoritative guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance is effective for annual periods beginning after December 15, 2019 and early adoption is permitted beginning after December 15, 2018. The adoption of this standard is not expected to have a material impact on the Company’s business, financial position, results of operations, or liquidity.

In February 2016, the FASB issued amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The lease liability will be equal to the present value of lease payments, with the right-of-use asset based upon the lease liability. The classification criteria for distinguishing between finance (or capital) leases and operating leases are substantially similar to the previous lease guidance, but with no explicit bright lines. As such, operating leases will result in straight-line rent expense similar to current practice. For short-term leases (term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The guidance is effective for annual and interim periods beginning after December 15, 2018, and will require application of the new guidance at the beginning of the earliest comparable period presented. The Company will not elect early adoption and will apply the modified retrospective approach as required. The adoption of this standard is expected to have a material impact on the Company’s financial position. The Company does not expect an impact on its business, results of operations or liquidity.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

Revenue recognition

On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) 606, *Revenue from Contracts with Customers*, and all of the related amendments (the “New Revenue Standard”). The New Revenue Standard requires entities to recognize the amount of revenue it expects for the transfer of goods or services to customers. The adoption of this standard had an immaterial impact on the Company’s reported total revenues as compared to what reported amounts would have been under the prior standard, and the Company expects the impact of adoption in future periods will be immaterial. The Company’s accounting policies under the New Revenue Standard were applied prospectively and are noted below.

Revenues are recognized as performance obligations are satisfied, which is over time as patient services are rendered throughout the length of stay, in an amount that reflects the consideration the Company expects to receive in exchange for services. A performance obligation is defined as a promise in a contract to transfer a distinct good or service to the customer. Substantially all of the Company’s contracts with patients and customers have a single performance obligation as the promise to transfer services is not distinct or separately identifiable from other promises in the contract.

The transaction price for the Company’s contracts represents its best estimate of the consideration the Company expects to receive and includes assumptions regarding variable consideration as applicable. These variable considerations include estimated amounts due from patients and third party payors for healthcare services provided, including anticipated settlements under reimbursement agreements with Medicare, Medicaid, Medicare Advantage, Medicaid Managed, and other third party payors. Revenues under third party agreements are subject to examination and retroactive adjustment. Provisions for estimated third party adjustments are provided in the period the related services are rendered to the extent it is probable that a significant reversal of cumulative revenue will not occur. Any remaining differences between the amounts accrued and subsequent settlements are recorded in the periods in which the interim or final settlements are determined.

A summary of revenues by payor type follows (in thousands):

| | Three months ended | |
|--------------------|---------------------|---------------------|
| | March 31, | |
| | 2018 | 2017 |
| Medicare | \$ 791,842 | \$ 814,768 |
| Medicaid | 93,765 | 105,427 |
| Medicare Advantage | 142,224 | 116,503 |
| Medicaid Managed | 55,861 | 51,013 |
| Other | 452,063 | 475,385 |
| | 1,535,755 | 1,563,096 |
| Eliminations | (21,966) | (23,606) |
| | <u>\$ 1,513,789</u> | <u>\$ 1,539,490</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

Revenue recognition (Continued)

A summary of revenues by business segment follows (in thousands):

| | Three months ended | |
|--|---------------------|---------------------|
| | March 31, | |
| | 2018 | 2017 |
| Revenues: | | |
| Kindred at Home: | | |
| Home health | \$ 453,759 | \$ 450,831 |
| Hospice | 183,628 | 179,378 |
| | <u>637,387</u> | <u>630,209</u> |
| Hospital division | 547,630 | 556,646 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 178,219 | 178,115 |
| RehabCare | 172,519 | 198,126 |
| | <u>350,738</u> | <u>376,241</u> |
| | 1,535,755 | 1,563,096 |
| Eliminations: | | |
| Kindred Hospital Rehabilitation Services | (19,321) | (21,148) |
| RehabCare | (1,993) | (1,878) |
| Hospitals | (652) | (580) |
| | <u>(21,966)</u> | <u>(23,606)</u> |
| | <u>\$ 1,513,789</u> | <u>\$ 1,539,490</u> |

ASC 606 adoption impact

On January 1, 2018, the Company adopted the New Revenue Standard using the modified retrospective transition method. The Company recognized the cumulative effect of initially applying the New Revenue Standard to all contracts not completed as of the date of adoption, resulting in an \$11.8 million adjustment, net of taxes, on January 1, 2018 to accounts receivable and accumulated deficit. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

The impact of adoption of the New Revenue Standard was primarily related to the following: (i) recognizing contractual revenues due to variable considerations subject to estimation during the period of service within the Kindred at Home division (included within the Medicare and Medicare Advantage payor types) and (ii) recognizing contractual revenues earlier due to variable considerations arising from the historical collectability of the Company's hospital division's private payor portfolio (included within the other payor type).

The Company reclassified approximately \$3.8 million of other operating expenses to contractual revenues for the three months ended March 31, 2018 as a result of the New Revenue Standard. The Company reclassified the net hospice room and board charges previously recorded as other operating expenses to contractual revenues. In accordance with the New Revenue Standard definition of performance obligations, the Company does not view the room and board charges as separate and distinct from the patient services, and as such, classifies the net charges as contractual revenues. The remaining reclassifications resulted from certain bad debts considered implicit price concessions or contractual revenues under the New Revenue Standard, while the remaining bad debts recorded in other operating expenses are related to credit risk or limitations on a customer's ability to pay.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

ASC 606 adoption impact (Continued)

The impact of adoption on the Company's accompanying unaudited condensed consolidated statement of operations and unaudited condensed consolidated balance sheet was as follows (in thousands):

| | Three months ended March 31, 2018 | | |
|---|--|--|-----------------------------|
| | As reported | Without adoption of ASC 606 | Effect of change |
| Statement of operations: | | | |
| Revenues | \$ 1,513,789 | \$ 1,517,196 | \$ (3,407) |
| Other operating expenses | 135,717 | 139,581 | (3,864) |
| Income from continuing operations before income taxes | 27,535 | 27,078 | 457 |
| As of March 31, 2018 | | | |
| Balance sheet: | | | |
| Current assets: | | | |
| Accounts receivable less allowance for loss | \$ 1,165,044 | \$ 1,176,354 | \$ (11,310) |
| Equity: | | | |
| Accumulated deficit | \$ (1,632,432) | \$ (1,621,122) | \$ (11,310) |

Equity

The following table sets forth the changes in equity attributable to noncontrolling interests and equity attributable to Kindred stockholders for the three months ended March 31, 2018 and 2017 (in thousands):

| | Amounts attributable to Kindred stockholders | Noncontrolling interests | Total equity |
|---|---|-------------------------------------|---------------------|
| For the three months ended March 31, 2018 | | | |
| Balance at December 31, 2017 | \$ 123,326 | \$ 224,436 | \$ 347,762 |
| Adoption of the New Revenue Standard as of January 1, 2018 | (11,767) | - | (11,767) |
| Comprehensive income (loss): | | | |
| Net income (loss) | (1,705) | 13,452 | 11,747 |
| Other comprehensive income | 3,496 | - | 3,496 |
| | 1,791 | 13,452 | 15,243 |
| Shares tendered by employees for statutory tax withholdings upon issuance of common stock | (3,044) | - | (3,044) |
| Stock-based compensation amortization | 4,261 | - | 4,261 |
| Distributions to noncontrolling interests | - | (27,228) | (27,228) |
| Contributions made by noncontrolling interests | - | 165 | 165 |
| Balance at March 31, 2018 | <u>\$ 114,567</u> | <u>\$ 210,825</u> | <u>\$ 325,392</u> |
| For the three months ended March 31, 2017 | | | |
| Balance at December 31, 2016 | \$ 812,551 | \$ 228,970 | \$ 1,041,521 |
| Comprehensive income (loss): | | | |
| Net income (loss) | (5,748) | 14,964 | 9,216 |
| Other comprehensive income | 1,871 | - | 1,871 |
| | (3,877) | 14,964 | 11,087 |
| Shares tendered by employees for statutory tax withholdings upon issuance of common stock | (2,255) | - | (2,255) |
| Stock-based compensation amortization | 3,132 | - | 3,132 |
| Dividends paid | (10,228) | - | (10,228) |
| Distributions to noncontrolling interests | - | (25,801) | (25,801) |
| Balance at March 31, 2017 | <u>\$ 799,323</u> | <u>\$ 218,133</u> | <u>\$ 1,017,456</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

Cash, cash equivalents and restricted cash

Beginning in 2018, the Company adopted the authoritative guidance that simplifies the disclosure of restricted cash within the statement of cash flows. The following table provides a reconciliation of cash and cash equivalents, as reported in our accompanying unaudited condensed consolidated balance sheet, to cash, cash equivalents and restricted cash, as reported in our accompanying unaudited condensed consolidated statement of cash flows (in thousands):

| | March 31, 2018 | December 31, 2017 |
|--|-------------------|----------------------|
| Cash and cash equivalents | \$ 108,759 | \$ 160,254 |
| Restricted cash: | | |
| Insurance subsidiary investments (current) | 22,407 | 22,546 |
| Other assets (current) | 425 | 1,675 |
| Insurance subsidiary investments (long-term) | 27,771 | 28,988 |
| Other assets (long-term) | 13,159 | 5,000 |
| Cash, cash equivalents and restricted cash | <u>\$ 172,521</u> | <u>\$ 218,463</u> |

Property and equipment

Beginning April 1, 2017, the Company changed the estimated useful life of certain information technology equipment and software based upon a detailed review of actual utilization. Following the acquisition of Gentiva Health Services, Inc. (“Gentiva”), a home health and hospice company acquired by the Company on February 2, 2015 (the “Gentiva Merger”), the Company made significant investments in information technology and software. The actual usage and longevity of these assets supports longer lives than previously estimated. The change in estimate extended the expected useful life by one to two years depending on the asset category and has been accounted for prospectively. The impact from this change in accounting estimate was an increase to income from continuing operations before income taxes of approximately \$3.5 million in the first quarter of 2018.

Derivative financial instruments

In January 2016, the Company entered into three interest rate swap agreements to hedge its floating interest rate on an aggregate of \$325 million of debt outstanding under its Term Loan Facility (as defined in Note 11), which replaced the previous \$225 million aggregate swap that expired on January 11, 2016. The interest rate swaps have an effective date of January 11, 2016, and expire on January 9, 2021. The Company is required to make payments based upon a fixed interest rate of 1.862% and 1.855% calculated on the notional amount of \$175 million and \$150 million, respectively. In exchange, the Company will receive interest on \$325 million at a variable interest rate that is based upon the three-month London Interbank Offered Rate (“LIBOR”), subject to a minimum rate of 1.0%.

In March 2014, the Company entered into an interest rate swap agreement to hedge its floating interest rate on an aggregate of \$400 million of debt outstanding under its Term Loan Facility. On April 8, 2014, the Company completed a novation of a portion of its \$400 million swap agreement to two new counterparties, each in the amount of \$125 million. The original swap contract was not amended, terminated, or otherwise modified. The interest rate swap had an effective date of April 9, 2014, expired on April 9, 2018, and applied to the Term Loan Facility. The Company made payments based upon a fixed interest rate of 1.867% calculated on the notional amount of \$400 million. In exchange, the Company received interest on \$400 million at a variable interest rate that was based upon the three-month LIBOR, subject to a minimum rate of 1.0%.

The interest rate swaps were assessed for hedge effectiveness for accounting purposes and the Company determined the interest rate swaps qualify for cash flow hedge accounting treatment at March 31, 2018. The Company records the effective portion of the gain or loss on these derivative financial instruments in accumulated other comprehensive income (loss) as a component of stockholders’ equity and records the ineffective portion of the gain or loss on these derivative financial instruments as interest expense. For the three months ended March 31, 2018 and 2017, there was no ineffectiveness related to the interest rate swaps.

The aggregate fair value of the interest rate swaps recorded in other current assets was \$6.6 million and \$2.5 million at March 31, 2018 and December 31, 2017, respectively. The fair value was determined by reference to a third party valuation and is considered a Level 2 input within the fair value hierarchy.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

Variable interest entities

The Company follows the provisions of the authoritative guidance for determining whether an entity is a variable interest entity (“VIE”). In order to determine if the Company is a primary beneficiary of a VIE for financial reporting purposes, it must consider whether it has the power to direct activities of the VIE that most significantly impact the performance of the VIE and whether the Company has the obligation to absorb losses or the right to receive returns that would be significant to the VIE. The Company consolidates a VIE when it is the primary beneficiary.

Of the Company’s 19 operating IRFs, 17 are partnerships subject to an operating and management services agreement. Under GAAP, the Company determined that 14 of these 17 partnerships qualify as VIEs and concluded that the Company is the primary beneficiary in all but one partnership. The Company holds an ownership interest and acts as manager in each of the partnerships. Through the management services agreement, the Company is delegated necessary responsibilities to provide management services, administrative services and direction of the day-to-day operations. Based upon the Company’s assessment of the most significant activities of the IRFs, the manager has the ability to direct the majority of those activities in 13 of the partnerships.

The analysis upon which the consolidation determination rests can be complex, can involve uncertainties, and requires judgment on various matters, some of which could be subject to different interpretations.

The carrying amounts and classifications of the assets and liabilities of the consolidated VIEs are as follows (in thousands):

| | March 31, 2018 | December 31, 2017 |
|--|-------------------|----------------------|
| Assets: | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 48,575 | \$ 43,734 |
| Accounts receivable, net | 43,252 | 47,034 |
| Inventories | 1,541 | 1,541 |
| Other | 2,337 | 2,899 |
| | <u>95,705</u> | <u>95,208</u> |
| Property and equipment, net | 13,645 | 14,160 |
| Goodwill | 275,375 | 275,375 |
| Intangible assets, net | 20,793 | 21,002 |
| Other | 6 | 6 |
| Total assets | <u>\$ 405,524</u> | <u>\$ 405,751</u> |
| Liabilities: | | |
| Current liabilities: | | |
| Accounts payable | \$ 26,716 | \$ 26,533 |
| Salaries, wages and other compensation | 2,468 | 3,092 |
| Other accrued liabilities | 3,942 | 4,066 |
| Long-term debt due within one year | 448 | 604 |
| | <u>33,574</u> | <u>34,295</u> |
| Long-term debt | 330 | 378 |
| Deferred credits and other liabilities | 9,643 | 9,235 |
| Total liabilities | <u>\$ 43,547</u> | <u>\$ 43,908</u> |

Other information

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions for quarterly reports on Form 10-Q of Regulation S-X and do not include all of the disclosures normally required by GAAP or those normally required in annual reports on Form 10-K. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on Form 10-K. The accompanying condensed consolidated balance sheet at December 31, 2017 was derived from audited consolidated financial statements, but does not include all disclosures required by GAAP.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION (Continued)

Other information (Continued)

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the Company's customary accounting practices. Management believes that financial information included herein reflects all adjustments necessary for a fair statement of interim results and, except as otherwise disclosed, all such adjustments are of a normal and recurring nature.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include amounts based upon the estimates and judgments of management. Actual amounts may differ from those estimates.

Reclassifications

Certain prior period amounts have been reclassified to conform with the current period presentation.

NOTE 2 – PLANNED ACQUISITION OF KINDRED

Merger Agreement

On December 19, 2017, the Company announced that its Board of Directors (the "Board") approved a definitive agreement under which the Company will be acquired by a consortium of three companies: TPG Capital ("TPG"), Welsh, Carson, Anderson & Stowe ("WCAS") and Humana Inc. ("Humana"). Subject to the terms and conditions of an Agreement and Plan of Merger (the "Merger Agreement") among the Company, Kentucky Hospital Holdings, LLC ("HospitalCo Parent"), Kentucky Homecare Holdings, Inc. ("Parent") and Kentucky Homecare Merger Sub, Inc. ("Merger Sub"), Merger Sub will be merged with and into Kindred (the "Merger"), with Kindred continuing as the surviving company in the Merger (the "Surviving Entity"). See Note 5 for a description of restructuring charges associated with the Merger.

At the effective time of the Merger, each share of the Company's common stock, par value \$0.25 per share ("Common Stock") issued and outstanding immediately prior to the effective time of the Merger (other than shares held by Parent, HospitalCo Parent, Merger Sub or Kindred and their respective wholly owned subsidiaries (which will be cancelled) and shares that are owned by stockholders who have properly exercised and perfected a demand for appraisal rights under Delaware law), will be cancelled and converted into the right to receive \$9.00 in cash, without interest.

The Merger Agreement contains customary representations, warranties and covenants for a transaction of this nature. The Merger Agreement also contains customary covenants, including, among others, covenants (i) providing for the Company and its respective subsidiaries to conduct business in all material respects in the ordinary course and not to take certain actions without Merger Sub's consent and (ii) for each of the parties to use reasonable best efforts to cause the transactions contemplated by the Merger Agreement to be consummated. Additionally, the Merger Agreement provides for customary pre-closing covenants, including covenants not to solicit proposals relating to alternative transactions or, subject to certain exceptions, enter into discussions concerning or provide information in connection with alternative transactions, covenants to call and hold a meeting of the Company's stockholders and a covenant to recommend that its stockholders adopt the Merger Agreement, subject to certain exceptions to permit the Company's directors to satisfy their applicable fiduciary duties.

Consummation of the Merger is subject to various conditions, including, among others, adoption of the Merger Agreement by the requisite vote of the Company's stockholders (this condition was satisfied on April 5, 2018), the receipt of certain licensure and regulatory approvals, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (this condition was satisfied on February 20, 2018), the consummation of the purchase of the two remaining skilled nursing facilities from Ventas, Inc. ("Ventas") and payment of corresponding expense reimbursement to Ventas (this condition was satisfied on December 21, 2017), the satisfaction of the closing conditions to the Separation Agreement (as defined below) and certain related entity conversions, the absence of any material adverse effect on each of the Company, its home health, hospice and community care business, and its TC hospitals, IRFs and contract rehabilitation services business, and certain other customary closing conditions.

The Merger Agreement also contains certain termination rights for the Company and Merger Sub (including if the Merger is not consummated by August 17, 2018 (the "End Date")) and provides that upon termination of the Merger Agreement under specified circumstances, including, among others, following a change in recommendation of the Board or its termination of the Merger Agreement to enter into a written definitive agreement for a "superior proposal," the Company will be required to pay Merger Sub a termination fee of \$29 million and reimburse the documented out-of-pocket expenses of Parent, HospitalCo Parent and certain of their affiliates in connection with the Merger Agreement up to \$10 million.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 2 – PLANNED ACQUISITION OF KINDRED (Continued)

Merger Agreement (Continued)

Parent will be required to pay the Company a reverse termination fee of \$61.5 million, and to reimburse certain of the Company's expenses, including the reasonable and documented out-of-pocket expenses the Company incurred in connection with the implementation of the Separation Transactions (as defined in the Separation Agreement), up to \$13.5 million, in the event the Merger Agreement is terminated (i) by the Company, subject to certain limitations set forth in the Merger Agreement, if (A) there has been a breach of a representation, warranty or covenant of Parent or Merger Sub that would cause the related closing condition to be incapable of being satisfied or cured by the End Date or, if curable, is not cured by Parent or Merger Sub by the earlier of 30 days after receipt of written notice of such breach and the End Date, (B) the conditions to Parent, HospitalCo Parent and Merger Sub's obligations to consummate the closing have been satisfied (other than those conditions that by their terms are to be satisfied at or immediately prior to the closing, provided that such conditions are then capable of being satisfied at the closing), the Company has irrevocably confirmed to Parent in writing that the Company is prepared and able to consummate the closing, and Parent and Merger Sub fail to consummate the Merger by the later of the date the closing should have occurred and three business days following the date of the notice from the Company described above, or (ii) by the Company or Parent if the Merger has not occurred by the End Date and at the time of termination all of the conditions to Parent, HospitalCo Parent and Merger Sub's obligations to consummate the closing have been satisfied (other than those conditions that by their terms are to be satisfied by actions taken at the closing, provided that such conditions are then capable of being satisfied at the closing) other than those relating to obtaining specified licensure and regulatory approvals and/or there being any injunction or other order by a governmental entity charged with jurisdiction over the granting of such approvals.

In connection with the Merger Agreement, Parent and HospitalCo Parent have obtained equity and debt financing commitments for the transactions contemplated by the Merger Agreement and the Separation Agreement, the aggregate proceeds of which will be sufficient to consummate the transactions contemplated by the Merger Agreement and the Separation Agreement on the closing date, including the payment of any amounts required to be paid by Parent pursuant to the Merger Agreement on the closing date, the repayment of the Company's existing indebtedness, and the payment of all fees and expenses reasonably expected to be incurred in connection therewith. Pursuant to equity commitment letters executed and delivered concurrently with the Merger Agreement, subject to the terms and conditions set forth therein, Humana, TPG, WCAS and Port-aux-Choix Private Investments Inc. ("PSP"), have committed, severally but not jointly, to capitalize Parent, and TPG, WCAS and PSP have committed, severally but not jointly, to capitalize HospitalCo Parent, with the aggregate amount of the equity financing. In addition, each of Humana, TPG, WCAS and PSP have provided us limited guarantees, guaranteeing Parent's obligation to pay the reverse termination fee and certain other reimbursement obligations of the Parent and Merger Sub pursuant to the Merger Agreement.

Separation Agreement

Concurrently with the execution and delivery of the Merger Agreement, on December 19, 2017, Kindred, Parent, HospitalCo Parent, and Kentucky Hospital Merger Sub, Inc., entered into a Separation Agreement (the "Separation Agreement"), pursuant to which, promptly following the effective time of the Merger, the Surviving Entity will be separated from the Company's home health, hospice and community care services business and acquired by HospitalCo Parent.

The Separation Agreement relates to, among other things (i) certain restructuring transactions that are to take place with respect to the Company and its subsidiaries, (ii) procedures concerning the transfer of certain assets used and employees employed in the Company's respective businesses and (iii) the allocation of costs and expenses related to the separation of the Surviving Entity from the Homecare Business (as defined in the Separation Agreement). The Separation Agreement requires, among other things, the Company to take certain actions and expend certain efforts prior to the closing of the Merger in preparation for such separation transactions.

NOTE 3 – DIVESTITURES

Skilled nursing facility business exit

On June 30, 2017, the Company entered into a definitive agreement with BM Eagle Holdings, LLC, a joint venture led by affiliates of BlueMountain Capital Management, LLC ("BlueMountain"), under which the Company agreed to sell its skilled nursing facility business for \$700 million in cash (the "SNF Divestiture"). The SNF Divestiture included 89 nursing centers with 11,308 licensed beds and seven assisted living facilities with 380 licensed beds in 18 states. Through March 31, 2018, the Company completed the sale or closed 86 of the skilled nursing facilities and all seven of the assisted living facilities.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 3 – DIVESTITURES (Continued)

Skilled nursing facility business exit (Continued)

Thirty-six of the skilled nursing facilities were previously leased from Ventas (the “Ventas Properties”). The Company had an option to acquire the real estate of the Ventas Properties for aggregate consideration of \$700 million, which the Company exercised as it closed on the sale of the Ventas Properties in connection with the SNF Divestiture during 2017. On each respective closing date, the Company paid to Ventas the allocable portion of the \$700 million purchase price for the Ventas Properties and Ventas conveyed the real estate for the applicable Ventas Property to BlueMountain or its designee.

The completion of the sales of the remaining three nursing centers is subject to customary conditions to closing, including the receipt of all licensure, regulatory and other approvals. The Company expects that all of the remaining closings will be completed during 2018.

In accordance with authoritative guidance for assets held for sale and discontinued operations accounting, the skilled nursing facility business is reported as assets held for sale and was moved to discontinued operations for all periods presented. See Note 4.

During the first quarter of 2018, the Company recorded \$5.8 million of pretax charges related to the SNF Divestiture, including \$3.7 million of transaction and other costs and \$2.1 million of retention costs. During the first quarter of 2017, the Company recorded \$6.2 million of pretax charges related to the SNF Divestiture, including \$5.8 million of retention costs and \$0.4 million of transaction and other costs.

In connection with the SNF Divestiture, the Company entered into an interim management agreement in the third quarter of 2017 with certain affiliates of BlueMountain in the state of California whereby the Company would lease its license of certain operations to such affiliates until licensure approval is obtained. Because the Company has continuing involvement in the business through purveying certain rights of ownership of the assets while under the interim management agreement and license sublease, the Company does not meet the requirements for a sale-leaseback transaction as described in ASC 840-40, *Leases - Sale-Leaseback Transactions*. Under the failed-sale-leaseback accounting model, the Company is deemed under GAAP to still own certain real estate assets sold to BlueMountain, which the Company must continue to reflect in its consolidated balance sheet and depreciate over the assets’ remaining useful life. The Company also must treat a portion of the pretax cash proceeds from the SNF Divestiture as though it were the result of a \$140.8 million other long-term liability financing obligation in its accompanying unaudited condensed consolidated balance sheet, and also must defer a \$17.9 million gain associated with some of these assets until continuing involvement ceases. The lease will terminate upon licensure approval, at which time the Company will cease to recognize the remaining other long-term liability financing obligation, as well as the remaining net book value of the real estate assets and will recognize the gain.

NOTE 4 – DISCONTINUED OPERATIONS

In accordance with the authoritative guidance for the impairment or disposal of long-lived assets, the divestitures of unprofitable businesses have been accounted for as discontinued operations. Accordingly, the operating results of these businesses and the losses or impairments associated with these transactions were classified as discontinued operations, net of income taxes, in the accompanying unaudited condensed consolidated statement of operations for all periods. Effective January 1, 2015, the authoritative guidance modified the requirements for reporting discontinued operations. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company’s operations and financial results. At March 31, 2018, the Company had three nursing centers held for sale classified as discontinued operations.

In connection with the SNF Divestiture, direct overhead and the profits from applicable RehabCare contracts servicing the Company’s skilled nursing facility business that were not retained with new operators were moved to discontinued operations for all periods presented. The Company has reclassified certain retained businesses and expenses previously reported in the nursing center division to other business segments, including hospital-based sub-acute units and a skilled nursing facility to the hospital division and a small therapy business to the Kindred Hospital Rehabilitation Services operating segment for all periods presented. See Note 3.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 4 – DISCONTINUED OPERATIONS (Continued)

The following table summarizes (in thousands) the SNF Divestiture liability activity (included in current liabilities) during the three months ended March 31, 2018, which does not include non-cash charges of \$3.2 million related to other costs:

| | Retention | Transaction and other costs | Total |
|--|-----------------|--------------------------------|-----------------|
| Liability balance at December 31, 2017 | \$ 5,436 | \$ 5,600 | \$ 11,036 |
| Expense | 2,117 | 486 | 2,603 |
| Payments | <u>(3,723)</u> | <u>(2,669)</u> | <u>(6,392)</u> |
| Liability balance at March 31, 2018 | <u>\$ 3,830</u> | <u>\$ 3,417</u> | <u>\$ 7,247</u> |

A summary of discontinued operations follows (in thousands):

| | Three months ended March 31, | |
|---|---------------------------------|-------------------|
| | 2018 | 2017 |
| Revenues | \$ 9,198 | \$ 255,683 |
| Salaries, wages and benefits | 6,293 | 95,424 |
| Supplies | 248 | 10,513 |
| Building rent | 1,693 | 20,438 |
| Equipment rent | 34 | 2,097 |
| Other operating expenses | 3,354 | 72,583 |
| General and administrative expenses | 4,966 | 43,954 |
| Other income | (285) | (264) |
| Impairment charges | - | 683 |
| Depreciation and amortization | 1,699 | 5,140 |
| Interest expense | 1 | 5 |
| Investment income | (35) | (17) |
| | <u>17,968</u> | <u>250,556</u> |
| Income (loss) from operations before income taxes | (8,770) | 5,127 |
| Provision for income taxes | - | 68 |
| Income (loss) from operations | (8,770) | 5,059 |
| Loss on divestiture of operations | <u>(5,790)</u> | <u>(6,166)</u> |
| Loss from discontinued operations | (14,560) | (1,107) |
| Earnings attributable to noncontrolling interests | (660) | (4,481) |
| Loss attributable to Kindred | <u>\$ (15,220)</u> | <u>\$ (5,588)</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 4 – DISCONTINUED OPERATIONS (Continued)

The following table sets forth certain discontinued operating data by business segment (in thousands):

| | Three months ended | |
|--|--------------------|-------------------|
| | March 31, | |
| | 2018 | 2017 |
| Revenues: | | |
| Nursing center division | \$ 8,646 | \$ 255,181 |
| Hospital division | 552 | 502 |
| | <u>\$ 9,198</u> | <u>\$ 255,683</u> |
| Segment adjusted operating income (loss): | | |
| Nursing center division | \$ (5,908) | \$ 32,506 |
| Hospital division | 530 | 967 |
| | <u>\$ (5,378)</u> | <u>\$ 33,473</u> |
| Rent: | | |
| Nursing center division: | | |
| Building rent | \$ 1,217 | \$ 19,973 |
| Equipment rent | 34 | 2,097 |
| | <u>1,251</u> | <u>22,070</u> |
| Hospital division: | | |
| Building rent | 476 | 465 |
| Equipment rent | - | - |
| | <u>476</u> | <u>465</u> |
| Totals: | | |
| Building rent | 1,693 | 20,438 |
| Equipment rent | 34 | 2,097 |
| | <u>\$ 1,727</u> | <u>\$ 22,535</u> |
| Depreciation and amortization: | | |
| Nursing center division | \$ 1,699 | \$ 5,140 |
| Hospital division | - | - |
| | <u>\$ 1,699</u> | <u>\$ 5,140</u> |

The following table sets forth a summary of assets held for sale related to the SNF Divestiture (in thousands):

| | March 31, 2018 | December 31, 2017 |
|--|-------------------|----------------------|
| Long-term assets: | | |
| Property and equipment, net | \$ 7,071 | \$ 15,711 |
| Other | 1,866 | 1,624 |
| | <u>8,937</u> | <u>17,335</u> |
| Current liabilities (included in other accrued liabilities) | <u>(417)</u> | <u>(417)</u> |
| | <u>\$ 8,520</u> | <u>\$ 16,918</u> |

NOTE 5 – RESTRUCTURING CHARGES

The Company has initiated various restructuring activities whereby it has incurred costs associated with reorganizing its operations, including the divestiture, swap, closure and consolidation of its business, facilities and branches, reduced headcount and realigned operations in order to improve operations, cost efficiencies and capital structure in response to changes in the healthcare industry, increasing leverage and to partially mitigate reductions in reimbursement rates from third party payors. The costs associated with these activities are reported as restructuring charges in the accompanying unaudited condensed consolidated statement of operations and would have been recorded as general and administrative expense or rent expense if not classified as restructuring charges.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 5 – RESTRUCTURING CHARGES (Continued)

The following table sets forth the restructuring charges incurred by business segment (in thousands):

| | Three months ended | |
|--|--------------------|------------------|
| | March 31, | |
| | 2018 | 2017 |
| Kindred at Home: | | |
| Home health | \$ 291 | \$ 5,932 |
| Hospice | 519 | 2,386 |
| | 810 | 8,318 |
| Hospital division | 923 | 972 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | - | - |
| RehabCare | - | - |
| | - | - |
| Support center | 6,376 | 716 |
| | <u>\$ 8,109</u> | <u>\$ 10,006</u> |

Restructuring Activities

Planned Acquisition of Kindred

During the fourth quarter of 2017, the Company announced that the Board had approved the Merger Agreement as described in Note 2. The costs incurred related to the Merger Agreement are expected to be substantially completed in 2018.

The composition of the restructuring costs that the Company has incurred for these restructuring initiatives is as follows (in thousands):

| | Three months ended | |
|-------------------------|--------------------|-------------|
| | March 31, | |
| | 2018 | 2017 |
| Merger costs | \$ 6,143 | \$ - |
| Retention and severance | 407 | - |
| | <u>\$ 6,550</u> | <u>\$ -</u> |

The following table (in thousands) summarizes the Merger restructuring liability activity (included in other accrued liabilities):

| | Merger costs | |
|--|--------------|--------------|
| Liability balance at December 31, 2017 | \$ | 7,907 |
| Expense | | 6,143 |
| Payments | | (9,659) |
| Liability balance at March 31, 2018 | <u>\$</u> | <u>4,391</u> |

LTAC Hospital Portfolio Repositioning 2017 Plan

During the third quarter of 2017, the Company approved phase two of the LTAC hospital portfolio repositioning plan that incorporated the closure and conversion of certain LTAC hospitals as part of its mitigation strategies in response to the new patient criteria for LTAC hospitals under the Pathway for SGR Reform Act of 2013 (the “LTAC Legislation”). The activities related to the LTAC hospital portfolio repositioning 2017 plan will be substantially completed in 2018.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 5 – RESTRUCTURING CHARGES (Continued)

Restructuring Activities (Continued)

LTAC Hospital Portfolio Repositioning 2017 Plan (Continued)

The composition of the restructuring charges that the Company has incurred for these activities is as follows (in thousands):

| | Three months ended March 31, | |
|-------------------------|---------------------------------|-------------|
| | 2018 | 2017 |
| Lease termination costs | \$ 451 | \$ - |
| Asset write-offs | 418 | - |
| Gain on disposal | (370) | - |
| Severance | (48) | - |
| | <u>\$ 451</u> | <u>\$ -</u> |

The following table (in thousands) summarizes the Company's LTAC hospital portfolio repositioning 2017 plan liability activity (included in current liabilities, and deferred credits and other liabilities) during the three months ended March 31, 2018, which does not include non-cash charges of \$0.1 million related to asset write-offs and gain on disposal. The lease termination costs were recorded as a liability discounted at the Company's credit-adjusted risk-free rate through the end of 2025, which is the original lease term of the leased hospital.

| | Lease termination costs | |
|--|-------------------------|---------------|
| Liability balance at December 31, 2017 | \$ | 31,645 |
| Expense | | 451 |
| Payments | | (1,265) |
| Liability balance at March 31, 2018 | <u>\$</u> | <u>30,831</u> |

LTAC Hospital Portfolio Repositioning 2016 Plan

During the first quarter of 2016, the Company approved the LTAC hospital portfolio repositioning 2016 plan that incorporated the divestiture, swap or closure of certain LTAC hospitals as part of its mitigation strategies to prepare for new patient criteria for LTAC hospitals under the LTAC Legislation. The activities related to the LTAC hospital portfolio repositioning 2016 plan were substantially completed during 2016.

The composition of the restructuring charges that the Company has incurred for these activities is as follows (in thousands):

| | Three months ended March 31, | |
|-------------------------|---------------------------------|---------------|
| | 2018 | 2017 |
| Lease termination costs | \$ 472 | \$ 740 |
| Facility closure costs | - | 232 |
| | <u>\$ 472</u> | <u>\$ 972</u> |

The following table (in thousands) summarizes the Company's LTAC hospital portfolio repositioning 2016 plan liability activity (included in current liabilities, and deferred credits and other liabilities) during the three months ended March 31, 2018. The majority of the lease termination costs were recorded as a liability discounted at the Company's credit-adjusted risk-free rate through the end of 2025, which is the original lease term of the leased hospitals.

| | Lease termination costs | |
|--|-------------------------|---------------|
| Liability balance at December 31, 2017 | \$ | 33,945 |
| Expense | | 472 |
| Payments | | (2,628) |
| Liability balance at March 31, 2018 | <u>\$</u> | <u>31,789</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 5 – RESTRUCTURING CHARGES (Continued)

Restructuring Activities (Continued)

Kindred at Home 2017 Efficiency Initiative

During the first quarter of 2017, the Kindred at Home division approved and initiated a cost and operations efficiency initiative to address increases in labor costs associated with competitive labor markets and the integration of pay practices from acquisitions across the Kindred at Home portfolio. This initiative includes the consolidation and closure of under-performing branches and a reduction in force associated with the restructuring of divisional and regional support teams. These activities were substantially completed during 2017.

The composition of the restructuring costs that the Company has incurred for these considerations is as follows (in thousands):

| | Three months ended | |
|-------------------------|--------------------|-----------------|
| | March 31, | |
| | 2018 | 2017 |
| Asset write-offs | \$ 319 | \$ 2,888 |
| Lease termination costs | 194 | 616 |
| Loss on disposal | 50 | - |
| Severance | 12 | 1,417 |
| | <u>\$ 575</u> | <u>\$ 4,921</u> |

The following table (in thousands) summarizes the related restructuring liability activity (included in current liabilities) during the three months ended March 31, 2018, which does not include non-cash charges of \$0.4 million related to asset write-offs and loss on disposal:

| | Lease termination costs | |
|--|-------------------------|------------|
| Liability balance at December 31, 2017 | \$ | 960 |
| Expense | | 194 |
| Payments | | (227) |
| Liability balance at March 31, 2018 | <u>\$</u> | <u>927</u> |

Kindred at Home Branch Consolidations and Closures

During the first quarter of 2015, the Company approved and initiated branch consolidations and closures in specific markets to improve operations and cost efficiencies in the Kindred at Home division. The branch consolidations and closures included branches that served both the home health and hospice business segment operations. Gentiva initiated similar branch consolidations and closures prior to the Gentiva Merger and these activities and acquired liabilities are included herein. These activities were substantially completed during 2016.

The composition of the restructuring costs that the Company has incurred for these consolidations is as follows (in thousands):

| | Three months ended | |
|-------------------------|--------------------|-----------------|
| | March 31, | |
| | 2018 | 2017 |
| Lease termination costs | \$ 61 | \$ 549 |
| Asset write-offs | - | 2,240 |
| Severance | - | 608 |
| | <u>\$ 61</u> | <u>\$ 3,397</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 6 – EARNINGS (LOSS) PER SHARE AND DIVIDENDS

Earnings (loss) per common share are based upon the weighted average number of common shares outstanding during the respective periods. The Company follows the provisions of the authoritative guidance for determining whether instruments granted in share-based payment transactions are participating securities, which requires that unvested restricted stock that entitles the holder to receive nonforfeitable dividends before vesting be included as a participating security in the basic and diluted earnings per common share calculation pursuant to the two-class method. Because the Company reported a loss from continuing operations attributable to the Company for the three months ended March 31, 2017, there was no allocation to participating unvested restricted stockholders for such period.

| | Three months ended March 31, | | | |
|--|------------------------------|--------------------|-------------------|-------------------|
| | 2018 | | 2017 | |
| | Basic | Diluted | Basic | Diluted |
| Earnings (loss): | | | | |
| Amounts attributable to Kindred stockholders: | | | | |
| Income (loss) from continuing operations: | | | | |
| As reported in Statement of Operations | \$ 13,515 | \$ 13,515 | \$ (160) | \$ (160) |
| Allocation to participating unvested restricted stockholders | (447) | (447) | - | - |
| Available to common stockholders | <u>\$ 13,068</u> | <u>\$ 13,068</u> | <u>\$ (160)</u> | <u>\$ (160)</u> |
| Discontinued operations, net of income taxes: | | | | |
| Income (loss) from operations: | | | | |
| As reported in Statement of Operations | \$ (9,430) | \$ (9,430) | \$ 578 | \$ 578 |
| Allocation to participating unvested restricted stockholders | 312 | 312 | - | - |
| Available to common stockholders | <u>\$ (9,118)</u> | <u>\$ (9,118)</u> | <u>\$ 578</u> | <u>\$ 578</u> |
| Loss on divestiture of operations: | | | | |
| As reported in Statement of Operations | \$ (5,790) | \$ (5,790) | \$ (6,166) | \$ (6,166) |
| Allocation to participating unvested restricted stockholders | 191 | 191 | - | - |
| Available to common stockholders | <u>\$ (5,599)</u> | <u>\$ (5,599)</u> | <u>\$ (6,166)</u> | <u>\$ (6,166)</u> |
| Loss from discontinued operations: | | | | |
| As reported in Statement of Operations | \$ (15,220) | \$ (15,220) | \$ (5,588) | \$ (5,588) |
| Allocation to participating unvested restricted stockholders | 503 | 503 | - | - |
| Available to common stockholders | <u>\$ (14,717)</u> | <u>\$ (14,717)</u> | <u>\$ (5,588)</u> | <u>\$ (5,588)</u> |
| Net loss: | | | | |
| As reported in Statement of Operations | \$ (1,705) | \$ (1,705) | \$ (5,748) | \$ (5,748) |
| Allocation to participating unvested restricted stockholders | 56 | 56 | - | - |
| Available to common stockholders | <u>\$ (1,649)</u> | <u>\$ (1,649)</u> | <u>\$ (5,748)</u> | <u>\$ (5,748)</u> |
| Shares used in the computation: | | | | |
| Weighted average shares outstanding - basic computation | <u>88,526</u> | 88,526 | <u>87,085</u> | 87,085 |
| Dilutive effect of employee stock options | | - | | - |
| Dilutive effect of tangible equity units | | - | | - |
| Adjusted weighted average shares outstanding - diluted computation | | <u>88,526</u> | | <u>87,085</u> |
| Earnings (loss) per common share: | | | | |
| Income (loss) from continuing operations | \$ 0.15 | \$ 0.15 | \$ - | \$ - |
| Discontinued operations: | | | | |
| Income (loss) from operations | (0.11) | (0.11) | - | - |
| Loss on divestiture of operations | (0.06) | (0.06) | (0.07) | (0.07) |
| Loss from discontinued operations | <u>(0.17)</u> | <u>(0.17)</u> | <u>(0.07)</u> | <u>(0.07)</u> |
| Net loss | <u>\$ (0.02)</u> | <u>\$ (0.02)</u> | <u>\$ (0.07)</u> | <u>\$ (0.07)</u> |
| Number of antidilutive stock options and tangible equity units excluded from shares used in the diluted earnings (loss) per common share computation | | 557 | | 1,380 |

During the three months ending March 31, 2017, the Company paid a cash dividend of \$0.12 per common share. The Board elected to discontinue paying dividends on the Company's Common Stock following the March 31, 2017 payment and instead redirected funds to repay debt and invest in growth.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 6 – EARNINGS (LOSS) PER SHARE AND DIVIDENDS (Continued)

The Company made an installment payment on the Company's 172,500 tangible equity units (the "Units") of \$18.75 per Unit on March 1, 2017. Each Unit was composed of a prepaid stock purchase contract (a "Purchase Contract") and one share of 7.25% Mandatory Redeemable Preferred Stock, Series A (the "Mandatory Redeemable Preferred Stock") which had a final preferred stock installment payment date of December 1, 2017. On December 1, 2017, the remaining holders of 87,379 Purchase Contracts were mandatorily redeemed. As a result, holders thereof received 50.6329 shares of Common Stock per Purchase Contract, resulting in approximately 4.4 million shares of Common Stock being issued on such date. Holders of the Mandatory Redeemable Preferred Stock were previously entitled to receive a quarterly "preferred stock installment payment" in cash, shares of Common Stock, or a combination thereof. All shares of Mandatory Redeemable Preferred Stock were redeemed on December 1, 2017 as planned pursuant to their terms.

NOTE 7 – BUSINESS SEGMENT DATA

The Company is organized into three operating divisions: the Kindred at Home division, the hospital division, and the Kindred Rehabilitation Services division. Based upon the authoritative guidance for business segments, the Company's operating divisions represent five reportable operating segments, including (1) home health services, (2) hospice services, (3) hospitals, (4) Kindred Hospital Rehabilitation Services, and (5) RehabCare. These reportable operating segments are consistent with information used by the Company's President and Chief Executive Officer and its Chief Operating Officer to assess performance and allocate resources. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies.

The Company has reclassified certain retained businesses and expenses previously reported in the nursing center division, including hospital-based sub-acute units and a skilled nursing facility to the hospital division and a small therapy business to the Kindred Hospital Rehabilitation Services operating segment for all periods presented.

For segment purposes, the Company defines segment adjusted operating income as earnings before interest, income taxes, depreciation, amortization, and total rent reported for each of the Company's operating segments, excluding impairment charges, restructuring charges, and the allocation of support center overhead.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 7 – BUSINESS SEGMENT DATA (Continued)

The following table sets forth certain data by business segment (in thousands):

| | Three months ended | |
|---|---------------------|---------------------|
| | March 31, | |
| | 2018 | 2017 |
| Revenues: | | |
| Kindred at Home: | | |
| Home health | \$ 453,759 | \$ 450,831 |
| Hospice | 183,628 | 179,378 |
| | <u>637,387</u> | <u>630,209</u> |
| Hospital division | 547,630 | 556,646 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 178,219 | 178,115 |
| RehabCare | 172,519 | 198,126 |
| | <u>350,738</u> | <u>376,241</u> |
| | 1,535,755 | 1,563,096 |
| Eliminations: | | |
| Kindred Hospital Rehabilitation Services | (19,321) | (21,148) |
| RehabCare | (1,993) | (1,878) |
| Hospitals | (652) | (580) |
| | <u>(21,966)</u> | <u>(23,606)</u> |
| | <u>\$ 1,513,789</u> | <u>\$ 1,539,490</u> |
| Income from continuing operations: | | |
| Segment adjusted operating income: | | |
| Kindred at Home: | | |
| Home health | \$ 59,512 | \$ 63,750 |
| Hospice | 28,943 | 27,581 |
| | <u>88,455</u> | <u>91,331</u> |
| Hospital division | 104,250 | 93,438 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 53,409 | 51,760 |
| RehabCare | 3,931 | 8,704 |
| | <u>57,340</u> | <u>60,464</u> |
| Support center expenses | (57,600) | (60,014) |
| Impairment charges | - | (474) |
| Restructuring charges | (6,931) | (8,101) |
| Building rent | (62,488) | (64,656) |
| Equipment rent | (8,689) | (8,887) |
| Restructuring charges - rent | (1,178) | (1,905) |
| Depreciation and amortization | (24,789) | (29,820) |
| Interest, net | (60,835) | (58,819) |
| Income from continuing operations before income taxes | 27,535 | 12,557 |
| Provision for income taxes | 1,228 | 2,234 |
| | <u>\$ 26,307</u> | <u>\$ 10,323</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 7 – BUSINESS SEGMENT DATA (Continued)

| | Three months ended | |
|---|--------------------|------------------|
| | March 31, | |
| | 2018 | 2017 |
| Rent: | | |
| Kindred at Home: | | |
| Home health: | | |
| Building | \$ 8,025 | \$ 8,147 |
| Equipment | 272 | 306 |
| | <u>8,297</u> | <u>8,453</u> |
| Hospice: | | |
| Building | 4,278 | 4,256 |
| Equipment | 78 | 84 |
| | <u>4,356</u> | <u>4,340</u> |
| Hospital division: | | |
| Building | 41,072 | 43,271 |
| Equipment | 7,289 | 7,474 |
| | <u>48,361</u> | <u>50,745</u> |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services: | | |
| Building | 8,647 | 8,423 |
| Equipment | 526 | 375 |
| | <u>9,173</u> | <u>8,798</u> |
| RehabCare: | | |
| Building | 340 | 323 |
| Equipment | 494 | 621 |
| | <u>834</u> | <u>944</u> |
| Support center: | | |
| Building | 126 | 236 |
| Equipment | 30 | 27 |
| | <u>156</u> | <u>263</u> |
| Totals: | | |
| Building | 62,488 | 64,656 |
| Equipment | 8,689 | 8,887 |
| | <u>\$ 71,177</u> | <u>\$ 73,543</u> |
| Depreciation and amortization: | | |
| Kindred at Home: | | |
| Home health | \$ 2,101 | \$ 3,128 |
| Hospice | 867 | 1,285 |
| | <u>2,968</u> | <u>4,413</u> |
| Hospital division | 10,042 | 10,874 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 3,566 | 3,843 |
| RehabCare | 427 | 1,845 |
| | <u>3,993</u> | <u>5,688</u> |
| Support center | 7,786 | 8,845 |
| | <u>\$ 24,789</u> | <u>\$ 29,820</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 7 – BUSINESS SEGMENT DATA (Continued)

| | Three months ended | |
|--|--------------------|------------------|
| | March 31, | |
| | 2018 | 2017 |
| Capital expenditures, excluding acquisitions (including discontinued operations): | | |
| Kindred at Home: | | |
| Home health: | | |
| Routine | \$ 1,835 | \$ 1,038 |
| Development | - | - |
| | <u>1,835</u> | <u>1,038</u> |
| Hospice: | | |
| Routine | 655 | 629 |
| Development | - | - |
| | <u>655</u> | <u>629</u> |
| Hospital division: | | |
| Routine | 6,924 | 3,123 |
| Development | 102 | - |
| | <u>7,026</u> | <u>3,123</u> |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services: | | |
| Routine | 1,197 | 418 |
| Development | 610 | 482 |
| | <u>1,807</u> | <u>900</u> |
| RehabCare: | | |
| Routine | 315 | 187 |
| Development | - | - |
| | <u>315</u> | <u>187</u> |
| Support center: | | |
| Routine: | | |
| Information systems | 4,837 | 4,109 |
| Other | 147 | 842 |
| | <u>4,984</u> | <u>4,951</u> |
| Development | 2,830 | 4,951 |
| | <u>7,814</u> | <u>9,902</u> |
| Discontinued operations - nursing centers: | | |
| Routine | 500 | 1,595 |
| Development | - | 6 |
| | <u>500</u> | <u>1,601</u> |
| Totals: | | |
| Routine | 16,410 | 11,941 |
| Development | 3,542 | 5,439 |
| | <u>\$ 19,952</u> | <u>\$ 17,380</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 7 – BUSINESS SEGMENT DATA (Continued)

| | March 31, 2018 | December 31, 2017 |
|---|---------------------|----------------------|
| Assets at end of period (including discontinued operations): | | |
| Kindred at Home: | | |
| Home health | \$ 1,547,395 | \$ 1,540,010 |
| Hospice | 912,179 | 913,230 |
| | <u>2,459,574</u> | <u>2,453,240</u> |
| Hospital division | 1,023,054 | 990,011 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 826,174 | 828,310 |
| RehabCare | 199,364 | 189,469 |
| | <u>1,025,538</u> | <u>1,017,779</u> |
| Support center | 520,669 | 522,677 |
| Discontinued operations - nursing centers | 177,528 | 249,010 |
| | <u>\$ 5,206,363</u> | <u>\$ 5,232,717</u> |
| Goodwill: | | |
| Kindred at Home: | | |
| Home health | \$ 917,239 | \$ 917,239 |
| Hospice | 646,154 | 646,329 |
| | <u>1,563,393</u> | <u>1,563,568</u> |
| Hospital division | 125,045 | 125,045 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 499,953 | 499,953 |
| RehabCare | - | - |
| | <u>499,953</u> | <u>499,953</u> |
| | <u>\$ 2,188,391</u> | <u>\$ 2,188,566</u> |

NOTE 8 – INCOME TAXES

The Tax Reform Act, which was enacted on December 22, 2017, is generally effective in 2018 and makes broad and significantly complex changes to the federal corporate tax system, including the reduction in the U.S. federal corporate income tax rate from 35% to 21% and the limitation on the deductibility of interest expense. The Company estimated the impact of the Tax Reform Act to deferred income taxes on its December 31, 2017 balance sheet in accordance with its understanding of the Tax Reform Act and guidance available as of the filing of the Form 10-K for the year ended December 31, 2017. As a result, the Company recorded an estimated \$130.5 million income tax benefit related to reducing certain deferred income tax liabilities in the fourth quarter of 2017.

In December 2017, the FASB issued authoritative guidance to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. In accordance with this authoritative guidance, the Company has determined that the \$130.5 million income tax benefit recorded in connection with the assessment of the valuation allowance is a provisional amount and a reasonable estimate that may change. Additional work is necessary to complete a more detailed analysis of the Tax Reform Act.

At each balance sheet date, management assesses all available positive and negative evidence to determine whether a valuation allowance is needed against its deferred tax assets. The authoritative guidance requires evidence related to events that have actually happened to be weighted more significantly than evidence that is projected or expected to happen. A significant piece of negative evidence according to this weighting standard is if there are cumulative losses in the two most recent years and the current year, which was the case for the Company at March 31, 2018 and December 31, 2017. Accordingly, a full valuation allowance continues to be recorded at both March 31, 2018 and December 31, 2017. The amount of deferred tax asset considered realizable, however, could be adjusted if the weighting of the positive and negative evidence changes.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 8 – INCOME TAXES (Continued)

The Company has deferred tax liabilities related to tax amortization of acquired indefinite-lived intangible assets because these assets are not amortized for financial reporting purposes. The tax amortization in current and future years created a deferred tax liability which will reverse at the time of ultimate sale or book impairment. Prior to the Tax Reform Act, the uncertain timing of this reversal and the temporary difference associated with certain indefinite-lived intangible assets could not be considered a source of future taxable income for purposes of determining the valuation allowance. As such, certain deferred tax liabilities could not be used to offset deferred tax assets. As a result of the Tax Reform Act, a portion of the Company's federal indefinite-lived intangible assets can be used as a source of income. The Company has a net deferred tax liability of \$37.2 million and \$36.9 million as of March 31, 2018 and December 31, 2017, respectively, representing indefinite-lived intangible assets. The deferred tax liability at March 31, 2018 and December 31, 2017 is comprised of the entire state portion of indefinite-lived intangible assets and a portion of the Company's federal indefinite-lived intangible assets that could not be used as a source of income.

The Company's effective income tax rate was 4.5% and 17.8% in the first quarter of 2018 and 2017, respectively. The reduction in the effective income tax rate in the first quarter of 2018 was primarily attributable to the reduction in the U.S. federal corporate income tax rate and the net operating loss carryforward period being eliminated under the Tax Reform Act.

NOTE 9 – INSURANCE RISKS

In October 2017, in connection with the review of the Company's insurance programs as part of the SNF Divestiture, the Company restructured the funding and retention mechanisms of recent policy years of its professional liability and workers compensation insurance programs (the "Insurance Restructuring") provided through the Company's wholly owned limited purpose insurance subsidiary, Cornerstone Insurance Company ("Cornerstone"). With respect to professional liability, certain funding mechanisms and reinsurance agreements were modified such that approximately \$106 million of cash deposits maintained by Cornerstone and \$4 million of other cash deposits were released to the parent company. In addition, approximately \$115 million of workers compensation restricted cash collateral deposits were replaced with letters of credit (see Note 11) and approximately \$21 million of other workers compensation cash deposits were released to the parent company. In aggregate, the Company used the approximately \$246 million generated from the Insurance Restructuring and \$35 million of the distributions received from Cornerstone as a result of improved underwriting results during the last two quarters of 2017 to repay in its entirety the Company's ABL Facility (as defined in Note 11) balance and to increase cash reserves at December 31, 2017.

As a result of the Insurance Restructuring, on a per-claim basis the Company maintains a self-insured retention and Cornerstone insures all losses in excess of this retention for professional liability. Cornerstone maintains commercial reinsurance through unaffiliated commercial reinsurers for these losses in excess of the Company's retention. The Insurance Restructuring had no impact upon the financial risk transfer aspect of Cornerstone's reinsurance agreements with its third party reinsurers. As a result of the Insurance Restructuring, on a per-claim basis the Company maintains a deductible under commercial insurance policies for workers compensation which provide coverage up to statutory limits in each state. The Insurance Restructuring had no impact upon the financial risk transfer aspect of these third party insurance agreements. The provisions for loss for these professional liability and workers compensation risks are based upon management's best available information, including actuarially determined estimates of loss.

The allowance for professional liability risks includes an estimate of the expected cost to settle reported claims and an amount, based upon past experiences, for losses incurred but not reported. These risks are necessarily based upon estimates and, while management believes that the provision for loss is adequate, the ultimate liability may be in excess of, or less than, the amounts recorded. To the extent that expected ultimate claims costs vary from historical provisions for loss, future earnings will be charged or credited.

The provision for loss for insurance risks, including the cost of coverage maintained with unaffiliated commercial reinsurance and insurance carriers, follows (in thousands):

| | Three months ended | |
|-------------------------|--------------------|-----------|
| | March 31, | |
| | 2018 | 2017 |
| Professional liability: | | |
| Continuing operations | \$ 11,874 | \$ 12,031 |
| Discontinued operations | 941 | 7,504 |
| Workers compensation: | | |
| Continuing operations | \$ 10,497 | \$ 14,332 |
| Discontinued operations | 457 | 2,763 |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 9 – INSURANCE RISKS (Continued)

A summary of the assets and liabilities related to insurance risks included in the accompanying unaudited condensed consolidated balance sheet follows (in thousands):

| | March 31, 2018 | | | December 31, 2017 | | |
|------------------------------------|------------------------|----------------------|------------|------------------------|----------------------|------------|
| | Professional liability | Workers compensation | Total | Professional liability | Workers compensation | Total |
| Assets: | | | | | | |
| Current: | | | | | | |
| Insurance subsidiary investments | \$ 17,591 | \$ 4,816 | \$ 22,407 | \$ 17,577 | \$ 4,969 | \$ 22,546 |
| Reinsurance and other recoverables | 1,106 | 850 | 1,956 | 3,331 | 969 | 4,300 |
| Other | - | 50 | 50 | - | 50 | 50 |
| | 18,697 | 5,716 | 24,413 | 20,908 | 5,988 | 26,896 |
| Non-current: | | | | | | |
| Insurance subsidiary investments | 8,265 | 19,506 | 27,771 | 9,576 | 19,412 | 28,988 |
| Reinsurance and other recoverables | 106,676 | 97,578 | 204,254 | 103,058 | 97,624 | 200,682 |
| Deposits | 92 | 1,949 | 2,041 | 27 | 1,949 | 1,976 |
| | 115,033 | 119,033 | 234,066 | 112,661 | 118,985 | 231,646 |
| | \$ 133,730 | \$ 124,749 | \$ 258,479 | \$ 133,569 | \$ 124,973 | \$ 258,542 |
| Liabilities: | | | | | | |
| Allowance for insurance risks: | | | | | | |
| Current | \$ 60,671 | \$ 42,209 | \$ 102,880 | \$ 60,767 | \$ 42,394 | \$ 103,161 |
| Non-current | 276,551 | 199,617 | 476,168 | 276,829 | 201,002 | 477,831 |
| | \$ 337,222 | \$ 241,826 | \$ 579,048 | \$ 337,596 | \$ 243,396 | \$ 580,992 |

In connection with the Insurance Restructuring, the provision for loss for professional liability risks is no longer discounted and no longer funded to Comerstone. Prior to the Insurance Restructuring, provisions for loss for professional liability risks retained by Comerstone were discounted based upon actuarial estimates of claim payment patterns using a discount rate of 1%. The discount rate was based upon the risk-free interest rate for the respective year. Amounts equal to the discounted loss provision were funded annually. The Company does not fund the portion of professional liability risks related to estimated claims that have been incurred but not reported. Accordingly, these liabilities are not discounted.

In connection with the Insurance Restructuring, the provision for loss for workers compensation risks is no longer funded to Comerstone.

NOTE 10 – INSURANCE SUBSIDIARY INVESTMENTS

The Company maintains a portfolio of insurance subsidiary investments, consisting principally of cash and cash equivalents for the payment of claims and expenses related to professional liability and workers compensation risks maintained by its limited purpose insurance subsidiary. These investments are reported at fair value.

The Company's insurance subsidiary cash and cash equivalents were \$50.2 million and \$51.5 million at March 31, 2018 and December 31, 2017, respectively. The Company's insurance subsidiary cash and cash equivalents included money market funds of \$4.9 million at both March 31, 2018 and December 31, 2017.

Since the Company's insurance subsidiary investments are restricted for a limited purpose, they are classified in the accompanying unaudited condensed consolidated balance sheet based upon the expected current and long-term cash requirements of the Company's limited purpose insurance subsidiary.

The Company considered the severity and duration of its unrealized losses at March 31, 2017 for various investments held in its insurance subsidiary investment portfolio and determined that these unrealized losses were temporary and did not record any impairment losses related to these investments.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 11– LONG-TERM DEBT

Term Loan Facility

As used herein, “Term Loan Facility” means the Company’s \$1.35 billion term loan credit facility provided pursuant to the terms and provisions of that certain Sixth Amended and Restated Term Loan Credit Agreement dated as of March 14, 2017 (the “Term Loan Amendment Agreement”), among the Company, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. All obligations under the Term Loan Facility are fully and unconditionally guaranteed, subject to certain customary release provisions, by substantially all of the Company’s wholly owned, domestic material subsidiaries, as well as certain non-wholly owned domestic subsidiaries as the Company may determine from time to time in its sole discretion.

The Term Loan Facility (1) matures on April 9, 2021, (2) contains financial maintenance covenants in the form of a maximum total leverage ratio, a minimum fixed charge coverage ratio and a maximum amount of annual capital expenditures, (3) imposes restrictions on the Company’s ability to incur debt and liens and make acquisitions, investments and payments on equity and junior debt, and (4) provides for interest rate margins of 3.50% for LIBOR borrowings (subject to a floor of 1.00%) and 2.50% for base rate borrowings.

On March 14, 2017, the Company entered into the Term Loan Amendment Agreement that amended and restated the Term Loan Facility to, among other things, (1) make adjustments to certain covenants and definitions to better accommodate the SNF Divestiture, (2) provide the Company with increased leverage covenant flexibility for an interim period, (3) increase the applicable margin on the outstanding borrowings from 3.25% to 3.50% for LIBOR borrowings and from 2.25% to 2.50% for base rate borrowings, (4) require a maximum leverage ratio of no more than 5.00 to 1.00 for use of the \$50 million annual dividend basket, and (5) provide for a prepayment premium of 1.00% in connection with any repricing transaction within six months of the closing date. In accordance with the authoritative guidance on debt, the Company accounted for the amendment as a debt modification.

ABL Facility

As used herein, “ABL Facility” means the Company’s \$900 million asset-based loan revolving credit facility provided pursuant to the terms and provisions of that certain Fourth Amended and Restated ABL Credit Agreement dated as of June 14, 2016 among the Company, the lenders party thereto from time to time, and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, as amended on September 27, 2017. All obligations under the ABL Facility are fully and unconditionally guaranteed, subject to certain customary release provisions, by substantially all of the Company’s wholly owned, domestic material subsidiaries, as well as certain non-wholly owned domestic subsidiaries as the Company may determine from time to time in its sole discretion.

The ABL Facility (1) matures on April 9, 2019, (2) contains financial maintenance covenants in the form of a minimum fixed charge coverage ratio and a maximum amount of annual capital expenditures, (3) imposes restrictions on the Company’s ability to incur debt and liens and make acquisitions, investments and payments on equity and junior debt, (4) provides for interest rate margins of 2.00% to 2.50% for LIBOR borrowings and 1.00% to 1.50% for base rate borrowings (in each case depending on average daily excess availability), and (5) employs a borrowing base calculation to determine total available capacity thereunder. As of March 31, 2018, \$156.0 million of letters of credit were outstanding under the ABL Facility.

On September 27, 2017, the Company entered into an amendment to the ABL Facility to update the provisions pertaining to letters of credit issued thereunder.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 12 – CONTINGENCIES

Management continually evaluates contingencies based upon the best available information. In addition, allowances for losses are provided currently for disputed items that have continuing significance, such as certain third party reimbursements and deductions that continue to be claimed in current cost reports and tax returns.

Management believes that allowances for losses have been provided to the extent necessary and that its assessment of contingencies is reasonable.

Principal contingencies are described below.

Revenues – Certain third party payments are subject to examination by agencies administering the various reimbursement programs. The Company is contesting certain issues raised in audits of prior year cost reports and the denial of payment by third parties to the Company's customers.

Professional liability risks – The Company has provided for losses for professional liability risks based upon management's best available information including actuarially determined estimates. Ultimate claims costs may differ from the provisions for loss. See Note 9.

Legal and regulatory proceedings – The Company is a party to various legal actions and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including investigations resulting from the Company's obligation to self-report suspected violations of law). The Company cannot predict the ultimate outcome of pending litigation and regulatory and other governmental and internal audits and investigations. The U.S. Department of Justice (the "DOJ"), the Centers for Medicare and Medicaid Services ("CMS") or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties (some of which may not be covered by insurance), which may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations, and liquidity. See Note 16.

Other indemnifications – In the ordinary course of business, the Company enters into contracts containing standard indemnification provisions and indemnifications specific to a transaction, such as a disposal of an operating facility. These indemnifications may cover claims related to employment-related matters, governmental regulations, environmental issues, and tax matters, as well as patient, third party payor, supplier, and contractual relationships. The Company also is subject to indemnity claims under contracts with its Kindred Rehabilitation Services division customers related to the provision of its services. Obligations under these indemnities generally are initiated by a breach of the terms of a contract or by a third party claim or event. These indemnifications could potentially subject the Company to damages and other payments which may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations, or liquidity.

Income taxes – The Company is subject to various federal and state income tax audits in the ordinary course of business. Such audits could result in increased tax payments, interest, and penalties.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 13 – BALANCE SHEET INFORMATION

Supplemental information related to the balance sheet follows (in thousands):

| | <u>March 31,</u> <u>2018</u> | <u>December 31,</u> <u>2017</u> |
|--|---------------------------------|------------------------------------|
| Other current assets: | | |
| Prepaid assets | \$ 51,243 | \$ 36,377 |
| Other | 18,585 | 24,233 |
| | <u>69,828</u> | <u>60,610</u> |
| Other long-term assets: | | |
| Reinsurance and other recoverables | \$ 204,254 | \$ 200,682 |
| Other | 58,988 | 64,625 |
| | <u>263,242</u> | <u>265,307</u> |
| Other accrued liabilities: | | |
| Patient accounts | \$ 67,593 | \$ 74,244 |
| Accrued interest | 54,528 | 73,839 |
| Taxes other than income | 18,092 | 26,375 |
| Accrued room and board | 14,852 | 16,064 |
| Accrued divestiture costs | 13,713 | 24,872 |
| Accrued litigation contingency | 10,565 | 11,504 |
| Other | 34,884 | 37,079 |
| | <u>214,227</u> | <u>263,977</u> |
| Deferred credits and other liabilities: | | |
| Accrued workers compensation | \$ 199,617 | \$ 201,002 |
| Sale-leaseback financing obligation related to the SNF Divestiture (see Note 3) | 140,790 | 140,790 |
| Straight line rent accruals | 51,797 | 51,222 |
| Accrued lease termination fees | 50,616 | 52,354 |
| Other | 49,350 | 52,586 |
| | <u>\$ 492,170</u> | <u>\$ 497,954</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 14 – FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company follows the provisions of the authoritative guidance for fair value measurements, which addresses how companies should measure fair value when they are required to use a fair value measure for recognition or disclosure purposes under GAAP.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The guidance related to fair value measures establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:

- Level 1** Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity securities and derivative contracts that are traded in an active exchange market, as well as certain U.S. Treasury, other U.S. Government and agency asset backed debt securities that are highly liquid and are actively traded in over-the-counter markets.
- Level 2** Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, and other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3** Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The Company's assets and liabilities measured at fair value on a recurring and non-recurring basis and any associated losses are summarized below (in thousands):

| | <u>Fair value measurements</u> | | | <u>Assets/liabilities at fair value</u> | <u>Total losses</u> |
|---|--------------------------------|-----------------|-------------------|---|---------------------|
| | <u>Level 1</u> | <u>Level 2</u> | <u>Level 3</u> | | |
| March 31, 2018 | | | | | |
| Recurring: | | | | | |
| Assets: | | | | | |
| Money market funds | \$ 6,279 | \$ - | \$ - | \$ 6,279 | \$ - |
| Deposits held in money market funds | 110 | - | - | 110 | - |
| Interest rate swaps | - | 6,634 | - | 6,634 | - |
| | <u>\$ 6,389</u> | <u>\$ 6,634</u> | <u>\$ -</u> | <u>\$ 13,023</u> | <u>\$ -</u> |
| Liabilities: | | | | | |
| Contingent consideration liability | <u>\$ -</u> | <u>\$ -</u> | <u>\$ (3,417)</u> | <u>\$ (3,417)</u> | <u>\$ -</u> |
| December 31, 2017 | | | | | |
| Recurring: | | | | | |
| Assets: | | | | | |
| Money market funds | \$ 6,354 | \$ - | \$ - | \$ 6,354 | \$ - |
| Deposits held in money market funds | 17,012 | - | - | 17,012 | - |
| Interest rate swaps | - | 2,508 | - | 2,508 | - |
| | <u>\$ 23,366</u> | <u>\$ 2,508</u> | <u>\$ -</u> | <u>\$ 25,874</u> | <u>\$ -</u> |
| Liabilities: | | | | | |
| Contingent consideration liability | <u>\$ -</u> | <u>\$ -</u> | <u>\$ (3,375)</u> | <u>\$ (3,375)</u> | <u>\$ -</u> |
| Non-recurring: | | | | | |
| Assets: | | | | | |
| Property and equipment | \$ - | \$ - | \$ 327,400 | \$ 327,400 | \$ (2,062) |
| Goodwill | - | - | 125,045 | 125,045 | (236,265) |
| Intangible assets - Kindred at Home | - | - | 19,795 | 19,795 | (3,501) |
| Intangible assets - Hospitals | - | - | - | - | (3,804) |
| Intangible assets - Kindred Rehabilitation Services | - | - | 500 | 500 | (135,188) |
| Kindred at Home building available for sale | - | - | - | - | (474) |
| Hospitals available for sale | - | - | 15,430 | 15,430 | (1,153) |
| | <u>\$ -</u> | <u>\$ -</u> | <u>\$ 488,170</u> | <u>\$ 488,170</u> | <u>\$ (382,447)</u> |
| Liabilities | <u>\$ -</u> | <u>\$ -</u> | <u>\$ -</u> | <u>\$ -</u> | <u>\$ -</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 14 – FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Recurring measurements

The Company maintains a portfolio of insurance subsidiary investments, consisting principally of cash and cash equivalents for the payment of claims and expenses related to professional liability and workers compensation risks maintained by its limited purpose insurance subsidiary.

The Company's insurance subsidiary cash and cash equivalents were \$50.2 million and \$51.5 million at March 31, 2018 and December 31, 2017, respectively. The Company's insurance subsidiary cash and cash equivalents included money market funds of \$4.9 million at both March 31, 2018 and December 31, 2017.

The Company had \$1.4 million of money market funds at both March 31, 2018 and December 31, 2017 related to a deferred compensation plan that is maintained for certain of the Company's current and former employees.

The Company's deposits held in money market funds consist primarily of cash and cash equivalents held for the Company's general corporate purposes.

The fair value of money market funds is based upon quoted market prices and is generally classified as Level 1. The Company's investment advisors obtain and review pricing for each security. The Company is responsible for the determination of fair value and as such the Company reviews the pricing information from its advisors in determining reasonable estimates of fair value. Based upon the Company's internal review procedures, there were no adjustments to the prices during the three months ended March 31, 2017.

The Company acquired a contingent consideration liability in the Gentiva Merger from a prior acquisition by Gentiva with an initial estimated fair value of \$7.9 million. The fair value is determined using a discounted cash flow approach primarily utilizing Level 3 inputs which includes observable market discount rates, fixed payment schedules, and assumptions based on achieving certain predefined performance criteria. As of March 31, 2018, the fair value of the contingent consideration liability was \$3.4 million. A one percent change in the discount rate used to calculate the accretion of the present value of the contingent consideration liability would have an impact on the fair value of less than \$0.1 million.

The fair value of the derivative asset associated with the interest rate swaps is estimated using industry-standard valuation models, which are Level 2 measurements. Such models project future cash flows and discount the future amounts to a present value using market-based observable inputs, including interest rate curves.

The following table presents the carrying amounts and estimated fair values of the Company's financial instruments. The carrying value is equal to fair value for financial instruments that are based upon quoted market prices or current market rates. The Company's long-term debt is based upon Level 2 inputs.

| (In thousands) | March 31, 2018 | | December 31, 2017 | |
|---|-----------------------|-------------------|--------------------------|-------------------|
| | Carrying value | Fair value | Carrying value | Fair value |
| Cash and cash equivalents | \$ 108,759 | \$ 108,759 | \$ 160,254 | \$ 160,254 |
| Insurance subsidiary investments | 50,178 | 50,178 | 51,534 | 51,534 |
| Long-term debt, including amounts due within one year (excluding capital lease obligations totaling \$0.3 million at both March 31, 2018 and December 31, 2017) | 3,280,589 | 3,409,606 | 3,161,298 | 3,316,136 |

Non-recurring measurements

During the first quarter of 2017, the Company recorded an asset impairment charge of \$0.4 million related to a valuation adjustment for a building within the Kindred at Home division. The fair value of the building was measured using Level 3 inputs, primarily replacement cost.

During the first quarter of 2017, the Company also recorded an asset impairment charge of \$0.7 million related to the SNF Divestiture which is recorded in discontinued operations. The fair value of property and equipment was measured using Level 3 inputs, primarily replacement costs.

Each of the impairment charges discussed above reflects the amount by which the carrying value of the assets exceeded its estimated fair value at each impairment date.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The Company’s \$750 million aggregate principal amount of 8.00% Senior Notes due 2020 (the “Notes due 2020”), \$500 million aggregate principal amount of 6.375% Senior Notes due 2022 (the “Notes due 2022”) and \$600 million aggregate principal amount of 8.75% Senior Notes due 2023 (the “Notes due 2023”) are fully and unconditionally guaranteed by substantially all of the Company’s domestic 100% owned subsidiaries. The equity method has been used with respect to the parent company’s investment in subsidiaries.

The following unaudited condensed consolidating financial data present the financial position of the parent company/issuer, the guarantor subsidiaries and the non-guarantor subsidiaries as of March 31, 2018 and December 31, 2017, and the respective results of operations and cash flows for the three months ended March 31, 2018 and March 31, 2017.

Condensed Consolidating Statement of Operations and Comprehensive Income (Loss)

| (In thousands) | Three months ended March 31, 2018 | | | | |
|--|--|-----------------------------------|---------------------------------------|--|---------------------|
| | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Revenues | \$ - | \$ 1,337,486 | \$ 176,303 | \$ - | \$ 1,513,789 |
| Salaries, wages and benefits | - | 779,843 | 66,011 | - | 845,854 |
| Supplies | - | 64,542 | 10,466 | - | 75,008 |
| Building rent | - | 49,517 | 12,971 | - | 62,488 |
| Equipment rent | - | 7,367 | 1,322 | - | 8,689 |
| Other operating expenses | - | 122,710 | 13,007 | - | 135,717 |
| General and administrative expenses | - | 229,343 | 36,029 | - | 265,372 |
| Other (income) expense | - | 113 | (720) | - | (607) |
| Restructuring charges | - | 8,109 | - | - | 8,109 |
| Depreciation and amortization | - | 22,678 | 2,111 | - | 24,789 |
| Management fees | - | (2,231) | 2,231 | - | - |
| Intercompany interest (income) expense from affiliates | 2,290 | (16,271) | 13,981 | - | - |
| Interest expense | 60,987 | 37 | 8 | - | 61,032 |
| Investment income | - | (98) | (99) | - | (197) |
| Equity in net income of consolidating affiliates | (61,572) | - | - | 61,572 | - |
| | <u>1,705</u> | <u>1,265,659</u> | <u>157,318</u> | <u>61,572</u> | <u>1,486,254</u> |
| Income (loss) from continuing operations before income taxes | (1,705) | 71,827 | 18,985 | (61,572) | 27,535 |
| Provision for income taxes | - | 840 | 388 | - | 1,228 |
| Income (loss) from continuing operations | (1,705) | 70,987 | 18,597 | (61,572) | 26,307 |
| Discontinued operations, net of income taxes: | | | | | |
| Income (loss) from operations | - | (9,641) | 871 | - | (8,770) |
| Loss on divestiture of operations | - | (5,790) | - | - | (5,790) |
| Income (loss) from discontinued operations | - | (15,431) | 871 | - | (14,560) |
| Net income (loss) | (1,705) | 55,556 | 19,468 | (61,572) | 11,747 |
| Earnings attributable to noncontrolling interests: | | | | | |
| Continuing operations | - | - | (12,792) | - | (12,792) |
| Discontinued operations | - | - | (660) | - | (660) |
| | - | - | (13,452) | - | (13,452) |
| Income (loss) attributable to Kindred | \$ (1,705) | \$ 55,556 | \$ 6,016 | \$ (61,572) | \$ (1,705) |
| Comprehensive income | \$ 1,791 | \$ 55,556 | \$ 19,468 | \$ (61,572) | \$ 15,243 |
| Comprehensive income attributable to Kindred | \$ 1,791 | \$ 55,556 | \$ 6,016 | \$ (61,572) | \$ 1,791 |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Operations and Comprehensive Income (Loss) (Continued)

| (In thousands) | Three months ended March 31, 2017 | | | | |
|--|--|-----------------------------------|---------------------------------------|--|---------------------|
| | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Revenues | \$ - | \$ 1,368,044 | \$ 197,047 | \$ (25,601) | \$ 1,539,490 |
| Salaries, wages and benefits | - | 780,325 | 59,488 | - | 839,813 |
| Supplies | - | 69,544 | 10,557 | - | 80,101 |
| Building rent | - | 50,960 | 13,696 | - | 64,656 |
| Equipment rent | - | 7,534 | 1,353 | - | 8,887 |
| Other operating expenses | - | 144,497 | 14,327 | - | 158,824 |
| General and administrative expenses | - | 232,159 | 68,945 | (25,601) | 275,503 |
| Other (income) expense | - | 447 | (417) | - | 30 |
| Impairment charges | - | 474 | - | - | 474 |
| Restructuring charges | - | 10,006 | - | - | 10,006 |
| Depreciation and amortization | - | 27,258 | 2,562 | - | 29,820 |
| Management fees | - | (2,753) | 2,753 | - | - |
| Intercompany interest (income) expense from affiliates | (58,665) | 46,596 | 12,069 | - | - |
| Interest expense (income) | 59,448 | (136) | 16 | - | 59,328 |
| Investment income | - | (62) | (447) | - | (509) |
| Equity in net loss of consolidating affiliates | 4,965 | - | - | (4,965) | - |
| | <u>5,748</u> | <u>1,366,849</u> | <u>184,902</u> | <u>(30,566)</u> | <u>1,526,933</u> |
| Income (loss) from continuing operations before income taxes | (5,748) | 1,195 | 12,145 | 4,965 | 12,557 |
| Provision for income taxes | - | 1,770 | 464 | - | 2,234 |
| Income (loss) from continuing operations | (5,748) | (575) | 11,681 | 4,965 | 10,323 |
| Discontinued operations, net of income taxes: | | | | | |
| Income from discontinued operations | - | 606 | 4,453 | - | 5,059 |
| Loss on divestiture of operations | - | (6,166) | - | - | (6,166) |
| Income (loss) from discontinued operations | - | (5,560) | 4,453 | - | (1,107) |
| Net income (loss) | (5,748) | (6,135) | 16,134 | 4,965 | 9,216 |
| Earnings attributable to noncontrolling interests: | | | | | |
| Continuing operations | - | - | (10,483) | - | (10,483) |
| Discontinued operations | - | - | (4,481) | - | (4,481) |
| | - | - | (14,964) | - | (14,964) |
| Income (loss) attributable to Kindred | <u>\$ (5,748)</u> | <u>\$ (6,135)</u> | <u>\$ 1,170</u> | <u>\$ 4,965</u> | <u>\$ (5,748)</u> |
| Comprehensive income (loss) | <u>\$ (3,877)</u> | <u>\$ (6,135)</u> | <u>\$ 17,082</u> | <u>\$ 4,017</u> | <u>\$ 11,087</u> |
| Comprehensive income (loss) attributable to Kindred | <u>\$ (3,877)</u> | <u>\$ (6,135)</u> | <u>\$ 2,118</u> | <u>\$ 4,017</u> | <u>\$ (3,877)</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Balance Sheet

| (In thousands) | As of March 31, 2018 | | | | |
|--|---------------------------|---------------------------|-------------------------------|---|---------------------|
| | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| ASSETS | | | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | \$ - | \$ 22,700 | \$ 86,059 | \$ - | \$ 108,759 |
| Insurance subsidiary investments | - | - | 22,407 | - | 22,407 |
| Accounts receivable, net | - | 1,037,891 | 127,153 | - | 1,165,044 |
| Inventories | - | 17,628 | 4,007 | - | 21,635 |
| Income taxes | - | 2,571 | 891 | - | 3,462 |
| Assets held for sale | - | 8,937 | - | - | 8,937 |
| Other | 6,634 | 58,201 | 4,993 | - | 69,828 |
| | <u>6,634</u> | <u>1,147,928</u> | <u>245,510</u> | <u>-</u> | <u>1,400,072</u> |
| Property and equipment, net | - | 673,092 | 52,427 | - | 725,519 |
| Goodwill | - | 1,839,670 | 348,721 | - | 2,188,391 |
| Intangible assets, net | - | 556,066 | 45,302 | - | 601,368 |
| Insurance subsidiary investments | - | - | 27,771 | - | 27,771 |
| Investments in subsidiaries | 3,445,472 | - | - | (3,445,472) | - |
| Intercompany receivable | - | 653,180 | - | (653,180) | - |
| Deferred tax assets | - | - | 1,036 | (1,036) | - |
| Other | 4,554 | 104,156 | 154,532 | - | 263,242 |
| | <u>\$ 3,456,660</u> | <u>\$ 4,974,092</u> | <u>\$ 875,299</u> | <u>\$ (4,099,688)</u> | <u>\$ 5,206,363</u> |
| LIABILITIES AND EQUITY | | | | | |
| Current liabilities: | | | | | |
| Accounts payable | \$ - | \$ 112,637 | \$ 34,506 | \$ - | \$ 147,143 |
| Salaries, wages and other compensation | - | 320,959 | 16,879 | - | 337,838 |
| Due to third party payors | - | 26,720 | 52 | - | 26,772 |
| Professional liability risks | - | 46,165 | 14,506 | - | 60,671 |
| Accrued lease termination fees | - | 7,557 | - | - | 7,557 |
| Other accrued liabilities | 54,528 | 146,914 | 12,785 | - | 214,227 |
| Long-term debt due within one year | 14,034 | - | 448 | - | 14,482 |
| | <u>68,562</u> | <u>660,952</u> | <u>79,176</u> | <u>-</u> | <u>808,690</u> |
| Long-term debt | 3,266,034 | - | 330 | - | 3,266,364 |
| Intercompany payable | 7,497 | - | 645,683 | (653,180) | - |
| Professional liability risks | - | 142,092 | 134,459 | - | 276,551 |
| Deferred tax liabilities | - | 38,232 | - | (1,036) | 37,196 |
| Deferred credits and other liabilities | - | 429,024 | 63,146 | - | 492,170 |
| Commitments and contingencies | | | | | |
| Equity (deficit): | | | | | |
| Stockholders' equity (deficit) | 114,567 | 3,703,792 | (258,320) | (3,445,472) | 114,567 |
| Noncontrolling interests | - | - | 210,825 | - | 210,825 |
| | <u>114,567</u> | <u>3,703,792</u> | <u>(47,495)</u> | <u>(3,445,472)</u> | <u>325,392</u> |
| | <u>\$ 3,456,660</u> | <u>\$ 4,974,092</u> | <u>\$ 875,299</u> | <u>\$ (4,099,688)</u> | <u>\$ 5,206,363</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Balance Sheet (Continued)

| As of December 31, 2017 | | | | | |
|--|---------------------------|---------------------------|-------------------------------|---|---------------------|
| (In thousands) | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| ASSETS | | | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | \$ - | \$ 40,893 | \$ 119,361 | \$ - | \$ 160,254 |
| Insurance subsidiary investments | - | - | 22,546 | - | 22,546 |
| Accounts receivable, net | - | 993,907 | 128,625 | - | 1,122,532 |
| Inventories | - | 17,714 | 4,002 | - | 21,716 |
| Income taxes | - | 3,467 | 1,079 | - | 4,546 |
| Assets held for sale | - | 16,555 | 780 | - | 17,335 |
| Other | 2,508 | 51,980 | 6,122 | - | 60,610 |
| | <u>2,508</u> | <u>1,124,516</u> | <u>282,515</u> | <u>-</u> | <u>1,409,539</u> |
| Property and equipment, net | - | 682,276 | 53,703 | - | 735,979 |
| Goodwill | - | 1,839,845 | 348,721 | - | 2,188,566 |
| Intangible assets, net | - | 558,827 | 45,511 | - | 604,338 |
| Insurance subsidiary investments | - | - | 28,988 | - | 28,988 |
| Investment in subsidiaries | 3,405,029 | - | - | (3,405,029) | - |
| Intercompany receivable | - | 691,980 | - | (691,980) | - |
| Deferred tax assets | - | - | 1,036 | (1,036) | - |
| Other | 5,699 | 112,808 | 146,800 | - | 265,307 |
| | <u>\$ 3,413,236</u> | <u>\$ 5,010,252</u> | <u>\$ 907,274</u> | <u>\$ (4,098,045)</u> | <u>\$ 5,232,717</u> |
| LIABILITIES AND EQUITY | | | | | |
| Current liabilities: | | | | | |
| Accounts payable | \$ - | \$ 133,031 | \$ 58,796 | \$ - | \$ 191,827 |
| Salaries, wages and other compensation | - | 334,729 | 17,450 | - | 352,179 |
| Due to third party payors | - | 35,269 | 52 | - | 35,321 |
| Professional liability risks | - | 46,274 | 14,493 | - | 60,767 |
| Accrued lease termination fees | - | 7,610 | - | - | 7,610 |
| Other accrued liabilities | 73,840 | 172,402 | 17,735 | - | 263,977 |
| Long-term debt due within one year | 14,034 | - | 604 | - | 14,638 |
| | <u>87,874</u> | <u>729,315</u> | <u>109,130</u> | <u>-</u> | <u>926,319</u> |
| Long-term debt | 3,146,594 | - | 378 | - | 3,146,972 |
| Intercompany payable | 55,442 | - | 636,538 | (691,980) | - |
| Professional liability risks | - | 142,479 | 134,350 | - | 276,829 |
| Deferred tax liabilities | - | 37,917 | - | (1,036) | 36,881 |
| Deferred credits and other liabilities | - | 434,105 | 63,849 | - | 497,954 |
| Commitments and contingencies | | | | | |
| Equity (deficit): | | | | | |
| Stockholders' equity (deficit) | 123,326 | 3,666,436 | (261,407) | (3,405,029) | 123,326 |
| Noncontrolling interests | - | - | 224,436 | - | 224,436 |
| | <u>123,326</u> | <u>3,666,436</u> | <u>(36,971)</u> | <u>(3,405,029)</u> | <u>347,762</u> |
| | <u>\$ 3,413,236</u> | <u>\$ 5,010,252</u> | <u>\$ 907,274</u> | <u>\$ (4,098,045)</u> | <u>\$ 5,232,717</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Cash Flows

| (In thousands) | Three months ended March 31, 2018 | | | | |
|--|--|-----------------------------------|---------------------------------------|--|---------------------|
| | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Net cash used in operating activities | \$ (72,252) | \$ (47,370) | \$ (12,781) | \$ - | \$ (132,403) |
| Cash flows from investing activities: | | | | | |
| Routine capital expenditures | - | (14,637) | (1,273) | - | (15,910) |
| Development capital expenditures | - | (3,542) | - | - | (3,542) |
| Sale of assets | - | 13,225 | - | - | 13,225 |
| Net change in other investments | - | 91 | - | - | 91 |
| Other | - | (233) | - | - | (233) |
| Net cash provided by investing activities of discontinued operations | - | 7,204 | - | - | 7,204 |
| Net cash provided by (used in) investing activities | - | 2,108 | (1,273) | - | 835 |
| Cash flows from financing activities: | | | | | |
| Proceeds from borrowings under revolving credit | 429,700 | - | - | - | 429,700 |
| Repayment of borrowings under revolving credit | (310,200) | - | - | - | (310,200) |
| Repayment of term loan | (3,508) | - | - | - | (3,508) |
| Repayment of other long-term debt | - | - | (203) | - | (203) |
| Payment of deferred financing costs | (56) | - | - | - | (56) |
| Contributions made by noncontrolling interests | - | - | 165 | - | 165 |
| Distributions to noncontrolling interests | - | - | (27,228) | - | (27,228) |
| Payroll tax payments for equity awards issuance | - | (3,044) | - | - | (3,044) |
| Net change in intercompany accounts | (43,684) | 37,468 | 6,216 | - | - |
| Net cash provided by (used in) financing activities | 72,252 | 34,424 | (21,050) | - | 85,626 |
| Change in cash, cash equivalents and restricted cash | - | (10,838) | (35,104) | - | (45,942) |
| Cash, cash equivalents and restricted cash at beginning of period | - | 47,046 | 171,417 | - | 218,463 |
| Cash, cash equivalents and restricted cash at end of period | <u>\$ -</u> | <u>\$ 36,208</u> | <u>\$ 136,313</u> | <u>\$ -</u> | <u>\$ 172,521</u> |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Cash Flows (Continued)

| | Three months ended March 31, 2017 | | | | |
|---|-----------------------------------|---------------------------|-------------------------------|---|--------------|
| (In thousands) | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Net cash used in operating activities | \$ (24,006) | \$ (61,383) | \$ (7,209) | \$ - | \$ (92,598) |
| Cash flows from investing activities: | | | | | |
| Routine capital expenditures | - | (9,549) | (797) | - | (10,346) |
| Development capital expenditures | - | (5,433) | - | - | (5,433) |
| Acquisitions, net of cash acquired | - | (3,150) | - | - | (3,150) |
| Purchase of insurance subsidiary investments | - | - | (22,308) | - | (22,308) |
| Sale of insurance subsidiary investments | - | - | 18,699 | - | 18,699 |
| Net change in other investments | - | 29 | - | - | 29 |
| Return of contributed surplus from Cornerstone | - | 8,000 | - | (8,000) | - |
| Other | - | 154 | - | - | 154 |
| Net cash used in investing activities of discontinued operations | - | (1,362) | (239) | - | (1,601) |
| Net cash used in investing activities | - | (11,311) | (4,645) | (8,000) | (23,956) |
| Cash flows from financing activities: | | | | | |
| Proceeds from borrowings under revolving credit | 478,600 | - | - | - | 478,600 |
| Repayment of borrowings under revolving credit | (343,400) | - | - | - | (343,400) |
| Repayment of term loan | (3,509) | - | - | - | (3,509) |
| Repayment of other long-term debt | - | - | (284) | - | (284) |
| Payment of deferred financing costs | (79) | - | - | - | (79) |
| Payment of dividend for Mandatory Redeemable Preferred Stock | (3,010) | - | - | - | (3,010) |
| Dividends paid | (10,228) | - | - | - | (10,228) |
| Distributions to noncontrolling interests | - | - | (25,801) | - | (25,801) |
| Payroll tax payments for equity awards issuance | - | (2,255) | - | - | (2,255) |
| Return of contributed surplus from Cornerstone | - | - | (8,000) | 8,000 | - |
| Net change in intercompany accounts | (94,368) | 81,706 | 12,662 | - | - |
| Net cash provided by (used in) financing activities | 24,006 | 79,451 | (21,423) | 8,000 | 90,034 |
| Change in cash, cash equivalents and restricted cash | - | 6,757 | (33,277) | - | (26,520) |
| Cash, cash equivalents and restricted cash at beginning of period | - | 27,242 | 296,926 | - | 324,168 |
| Cash, cash equivalents and restricted cash at end of period | \$ - | \$ 33,999 | \$ 263,649 | \$ - | \$ 297,648 |

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 15 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

The following table provides a reconciliation of cash and cash equivalents, as reported in our accompanying unaudited condensed consolidated balance sheet, to cash, cash equivalents and restricted cash, as reported in our accompanying unaudited condensed consolidated statement of cash flows:

| As of March 31, 2018 | | | | | |
|--|---------------------------|---------------------------|-------------------------------|---|-------------------|
| (In thousands) | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Cash and cash equivalents | \$ - | \$ 22,700 | \$ 86,059 | \$ - | \$ 108,759 |
| Restricted cash: | | | | | |
| Insurance subsidiary investments (current) | - | - | 22,407 | - | 22,407 |
| Other assets (current) | - | 349 | 76 | - | 425 |
| Insurance subsidiary investments (long-term) | - | - | 27,771 | - | 27,771 |
| Other assets (long-term) | - | 13,159 | - | - | 13,159 |
| Cash, cash equivalents and restricted cash | <u>\$ -</u> | <u>\$ 36,208</u> | <u>\$ 136,313</u> | <u>\$ -</u> | <u>\$ 172,521</u> |
| As of December 31, 2017 | | | | | |
| (In thousands) | Parent company/ issuer | Guarantor subsidiaries | Non-guarantor subsidiaries | Consolidating and eliminating adjustments | Consolidated |
| Cash and cash equivalents | \$ - | \$ 40,893 | \$ 119,361 | \$ - | \$ 160,254 |
| Restricted cash: | | | | | |
| Insurance subsidiary investments (current) | - | - | 22,546 | - | 22,546 |
| Other assets (current) | - | 1,153 | 522 | - | 1,675 |
| Insurance subsidiary investments (long-term) | - | - | 28,988 | - | 28,988 |
| Other assets (long-term) | - | 5,000 | - | - | 5,000 |
| Cash, cash equivalents and restricted cash | <u>\$ -</u> | <u>\$ 47,046</u> | <u>\$ 171,417</u> | <u>\$ -</u> | <u>\$ 218,463</u> |

NOTE 16 – LEGAL AND REGULATORY PROCEEDINGS

The Company provides services in a highly regulated industry and is subject to various legal actions and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including investigations resulting from the Company's obligation to self-report suspected violations of law). These matters could (1) require the Company to pay substantial damages, fines, penalties or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under the Company's insurance policies where coverage applies and is available; (2) cause the Company to incur substantial expenses; (3) require significant time and attention from the Company's management; (4) subject the Company to sanctions, including possible exclusions from the Medicare and Medicaid programs; and (5) cause the Company to close or sell one or more facilities or otherwise modify the way the Company conducts business. The ultimate resolution of these matters, whether as a result of litigation or settlement, could have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

In accordance with authoritative accounting guidance related to loss contingencies, the Company records an accrued liability for litigation and regulatory matters that are both probable and reasonably estimable. Additional losses in excess of amounts accrued may be reasonably possible. The Company reviews loss contingencies that are reasonably possible and determines whether an estimate of the possible loss or range of loss, individually or in aggregate, can be disclosed in the Company's consolidated financial statements. These estimates are based upon currently available information for those legal and regulatory proceedings in which the Company is involved, taking into account the Company's best estimate of losses for those matters for which such estimate can be made. The Company's estimates involve significant judgment and a variety of assumptions, given that (1) these legal and regulatory proceedings may be in early stages; (2) discovery may not be completed; (3) damages sought in these legal and regulatory proceedings can be unsubstantiated or indeterminate; (4) the matters often involve legal uncertainties or evolving areas of law; (5) there are often significant facts in dispute; and/or (6) there is a wide range of possible outcomes. Accordingly, the Company's estimated loss or range of loss may change from time to time, and actual losses may be more or less than the current estimate. At this time, except as otherwise specifically noted, no estimate of the possible loss or range of loss, individually or in the aggregate, in excess of the amounts accrued, if any, can be made regarding the matters described below.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 16 – LEGAL AND REGULATORY PROCEEDINGS (Continued)

Set forth below are descriptions of the Company's significant legal proceedings.

Medicare and Medicaid payment reviews, audits, and investigations—As a result of the Company's participation in the Medicare and Medicaid programs, the Company faces and is currently subject to various governmental and internal reviews, audits, and investigations to verify the Company's compliance with these programs and applicable laws and regulations. The Company is routinely subject to audits under various government programs, such as the CMS Recovery Audit Contractor program, in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments to healthcare providers under the Medicare program. In addition, the Company, like other healthcare providers, is subject to ongoing investigations by the U.S. Department of Health and Human Services Office of Inspector General (the "OIG"), the DOJ and state attorneys general into the billing of services provided to Medicare and Medicaid patients, including whether such services were properly documented and billed, whether services provided were medically necessary, and general compliance with conditions of participation in the Medicare and Medicaid programs. Private pay sources such as third party insurance and managed care entities also often reserve the right to conduct audits. The Company's costs to respond to and defend any such reviews, audits, and investigations are significant and are likely to increase in the current enforcement environment. These audits and investigations may require the Company to refund or retroactively adjust amounts that have been paid under the relevant government program or by other payors. Further, an adverse review, audit, or investigation also could result in other adverse consequences, particularly if the underlying conduct is found to be pervasive or systemic. These consequences include (1) state or federal agencies imposing fines, penalties, and other sanctions on the Company; (2) loss of the Company's right to participate in the Medicare or Medicaid programs or one or more third party payor networks; (3) indemnity claims asserted by customers and others for which the Company provides services; and (4) damage to the Company's reputation in various markets, which could adversely affect the Company's ability to attract patients, customers and employees.

Whistleblower lawsuits—The Company is also subject to *qui tam* or "whistleblower" lawsuits under the federal False Claims Act and comparable state laws for allegedly submitting fraudulent bills for services to the Medicare and Medicaid programs. These lawsuits can result in monetary damages, fines, attorneys' fees, and the award of bounties to private *qui tam* plaintiffs who successfully bring these lawsuits and to the respective government programs. The Company also could be subject to civil penalties (including the loss of the Company's licenses to operate one or more facilities or healthcare activities), criminal penalties (for violations of certain laws and regulations), and exclusion of one or more facilities or healthcare activities from participation in the Medicare, Medicaid, and other federal and state healthcare programs. The lawsuits are in various stages of adjudication or investigation and involve a wide variety of claims and potential outcomes.

Employment-related lawsuits—The Company's operations are subject to a variety of federal and state employment-related laws and regulations, including but not limited to the U.S. Fair Labor Standards Act, Equal Employment Opportunity laws, and enforcement policies of the Equal Employment Opportunity Commission, the Office of Civil Rights and state attorneys general, federal and state wage and hour laws, and a variety of laws enacted by the federal and state governments that govern these and other employment-related matters. Accordingly, the Company is currently subject to employee-related claims, class actions and other lawsuits and proceedings in connection with the Company's operations, including but not limited to those related to alleged wrongful discharge, illegal discrimination, and violations of equal employment and federal and state wage and hour laws. Because labor represents such a large portion of the Company's operating costs, noncompliance with these evolving federal and state laws and regulations could subject the Company to significant back pay awards, fines, and additional lawsuits and proceedings. These claims, lawsuits, and proceedings are in various stages of adjudication or investigation and involve a wide variety of claims and potential outcomes.

A purported wage and hour class action lawsuit is currently pending against the Company in federal district court for the Northern District of California. This lawsuit pertains to alleged errors made by the Company with respect to minimum wage and overtime payments resulting from a piece-rate payment system. The Company tentatively settled this lawsuit in December 2017 for \$12.0 million, subject to final court approval. The Company is responsible for \$7.5 million of the tentative settlement amount, as well as legal expenses, with insurance funding the remaining \$4.5 million. In connection with this lawsuit, the Company recorded a \$2.0 million loss provision in the first quarter of 2017, an additional \$3.0 million loss provision in the third quarter of 2017, and an additional \$2.5 million loss provision in the fourth quarter of 2017, for a total loss reserve of \$7.5 million. The Company continues to deny the allegations made in this lawsuit and will defend this action and any related claims vigorously if the court does not approve the settlement.

KINDRED HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

NOTE 16 – LEGAL AND REGULATORY PROCEEDINGS (Continued)

Minimum staffing lawsuits—Various states in which the Company operates have established minimum staffing requirements or may establish minimum staffing requirements in the future. While the Company seeks to comply with all applicable staffing requirements, the regulations in this area are complex and the Company may experience compliance issues from time to time. Failure to comply with such minimum staffing requirements may result in one or more facilities failing to meet the conditions of participation under relevant federal and state healthcare programs and the imposition of significant fines, damages, or other sanctions.

Shareholder actions—The Company is also subject to lawsuits and other shareholder actions brought from time to time. A shareholder derivative action (the “Complaint”) was previously pending against certain of the Company’s current and former officers and directors in circuit court for Jefferson County, Kentucky. The Complaint also named the Company as a nominal defendant. The Complaint alleged that the named current and former officers and directors breached their respective duties of good faith, loyalty, and candor, and other general fiduciary duties owed to the Company and its shareholders by, among other things, failing to exercise reasonable and prudent supervision over the management, policies, and controls of the Company in order to detect practices that existed at RehabCare resulting in the Company having to enter into two separate settlement agreements with the DOJ. The Complaint was settled in January 2018 in exchange for the Company’s agreement to pay the plaintiff \$950,000 in fees and expenses. The Company previously recorded a loss reserve of \$1.0 million in the third quarter of 2017 related to this matter.

Six purported class action complaints related to the Merger were filed on behalf of putative classes of the Company’s public stockholders (the “Merger Complaints”). Four of these complaints were filed in the United States District Court for the District of Delaware: *Sehrgosha v. Kindred Healthcare, Inc., et al.*, filed on February 8, 2018; *Carter v. Kindred Healthcare, Inc., et al.*, filed on February 14, 2018; *Rosenfeld v. Kindred Healthcare, Inc., et al.*, filed on February 15, 2018; and *Einhorn v. Kindred Healthcare, Inc., et al.*, filed on February 21, 2018. The remaining two complaints were filed in the United States District Court for the Western District of Kentucky: *Tompkins v. Kindred Healthcare, Inc., et al.*, filed on February 9, 2018; and *Buskirk v. Kindred Healthcare, Inc., et al.*, filed on February 13, 2018. The Company and individual members of the Board are named as defendants in each of the actions. The *Tompkins* action also names as defendants TPG, WCAS, Humana, Parent, HospitalCo Parent and Merger Sub. The Merger Complaints generally allege that the defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by failing to disclose material information in the Company’s preliminary proxy statement filed on February 5, 2018. The Merger Complaints seek, among other things, injunctive relief prohibiting the stockholder vote to approve the Merger and unspecified compensatory damages and attorneys’ fees. On March 5, 2018, the plaintiffs jointly agreed to voluntarily dismiss the Merger Complaints in exchange for the Company’s agreement to file supplemental disclosures with the SEC. The supplemental disclosures were filed on March 6, 2018. Negotiations concerning legal fees are ongoing.

On March 8, 2018, shareholder Brigade Leveraged Capital Structures Fund Ltd (“Brigade Capital”) filed a stockholder complaint in the Court of Chancery for the State of Delaware against the Company, each of the Board members, TPG, WCAS, and Humana alleging that the Company and the Board engaged in a flawed sales process, and filed a proxy and supplemental proxy that contain materially misleading disclosures and material omissions. Brigade Capital also filed a motion to expedite proceedings in support of anticipated motion to preliminarily enjoin the March 29, 2018 shareholder vote. The court permitted limited expedited discovery on one allegation concerning a potential conflict of interest involving one board member, and conducted a hearing on the injunction motion on March 27, 2018. Following argument, the court denied Brigade Capital’s request for injunctive relief, but required the Company to hold the scheduled shareholder vote open for five additional business days (or to reschedule the shareholder vote five business days later) to permit shareholders to perfect their appraisal rights, should they so choose. On April 23, 2018, Brigade Capital filed its notice of dismissal with the court dismissing this matter with prejudice.

Ordinary course matters—In addition to the matters described above, the Company is subject to investigations, claims, and lawsuits in the ordinary course of business, including investigations resulting from the Company’s obligation to self-report suspected violations of law and professional liability claims, particularly in the Company’s hospital operations and former nursing center operations. In many of these claims, plaintiffs’ attorneys are seeking significant fines and compensatory and punitive damages in addition to attorneys’ fees. The Company maintains professional and general liability insurance in amounts and coverage that management believes are sufficient for the Company’s operations. However, the Company’s insurance may not cover all claims against the Company or the full extent of its liability.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement

This Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward-looking statements include, but are not limited to, all statements regarding the Company's ability to complete the Merger and the expected timing of such Merger, as well as the Company's ability to realize the anticipated benefits from the Merger, all statements regarding the Company's expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management, government investigations, regulatory matters, and statements containing words such as "anticipate," "approximate," "believe," "plan," "estimate," "expect," "project," "could," "would," "should," "will," "intend," "hope," "may," "potential," "upside," "seek," "continue," and other similar expressions. Statements in this report concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses, dividends or other financial items, and product or services-line growth, and expected outcome of government investigations and other regulatory matters, together with other statements that are not historical facts, are forward-looking statements that are estimates reflecting the Company's best judgment based upon currently available information.

Such forward-looking statements are inherently uncertain, and stockholders and other potential investors must recognize that actual results may differ materially from the Company's expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties, and other factors, many of which the Company is unable to predict or control, that may cause the Company's actual results, performance, or plans to differ materially from any future results, performance, or plans expressed or implied by such forward-looking statements. Risks and uncertainties related to the Merger include, but are not limited to, the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the failure of the parties to satisfy conditions to completion of the Merger, including the failure of the parties to obtain required regulatory approvals; the risk that regulatory or other approvals are delayed or are subject to terms and conditions that are not anticipated; changes in the Company's business or in the Company's or its businesses' operating prospects; changes in healthcare and other laws and regulations; the impact of the announcement of, or failure to complete, the Merger on the Company's relationships with employees, customers, vendors and other business partners; and litigation related to the Merger. These statements involve risks, uncertainties, and other factors discussed below and detailed from time to time in the Company's filings with the SEC.

In addition to the factors set forth above, other factors that may affect the Company's plans, results, or stock price include, without limitation:

- the impact of healthcare reform, which will initiate significant changes to the United States healthcare system, including potential material changes to the delivery of healthcare services and the reimbursement paid for such services by the government or other third party payors, including reforms resulting from the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the "ACA") or future deficit reduction measures adopted at the federal or state level. Healthcare reform is impacting each of the Company's businesses in some manner. Potential future efforts in the U.S. Congress to repeal, amend, modify, or retract funding for various aspects of the ACA create additional uncertainty about the ultimate impact of the ACA on the Company and the healthcare industry. Due to the substantial regulatory changes that will need to be implemented by CMS and others, and the numerous processes required to implement these reforms, the Company cannot predict which healthcare initiatives will be implemented at the federal or state level, the timing of any such reforms, or the effect such reforms or any other future legislation or regulation will have on the Company's business, financial position, results of operations, and liquidity,
- the Company's ability to adjust to the new patient criteria for LTAC hospitals under the LTAC Legislation, which reduces the population of patients eligible for reimbursement under the Medicare prospective payment system for LTAC hospitals ("LTAC PPS") and changes the basis upon which the Company is paid for other patients,
- changes in the reimbursement rates or the methods or timing of payment from third party payors, including commercial payors and the Medicare and Medicaid programs, changes arising from and related to LTAC PPS, including potential changes in the Medicare payment rules, and changes in Medicare and Medicaid reimbursement for the Company's home health and hospice operations, TC hospitals, and IRFs,
- the Company's significant level of indebtedness, including the Company's ability to meet its substantial debt service requirements, and its impact on the Company's funding costs, operating flexibility, and ability to fund ongoing operations, development capital expenditures, or other strategic acquisitions with additional borrowings,
- the Company's ability to comply with the terms of its corporate integrity agreement with the OIG,
- the Company's ability to complete the Merger, and realize the anticipated benefits from the Merger,

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Cautionary Statement (Continued)

- the diversion of management and employee time, the use of resources and the incurrence of significant costs in seeking to complete the Merger,
- the effects of additional legislative changes and government regulations, interpretation of regulations, and changes in the nature and enforcement of regulations governing the healthcare industry,
- the ability of the Company's hospitals and other healthcare services to adjust to medical necessity reviews,
- the Company's ability to successfully pursue its development activities, including through acquisitions, and successfully integrate new operations, including the realization of anticipated revenues, economies of scale, cost savings, and productivity gains associated with such operations, as and when planned, including the potential impact of unanticipated issues, expenses, and liabilities associated with those activities,
- the Company's obligations under various laws to self-report suspected violations of law to various government agencies (including any associated obligation to refund overpayments to government payors, fines, and other sanctions),
- the failure of the Company's facilities and other operations to meet applicable licensure and certification requirements,
- the consolidation or cost containment efforts of managed care organizations, other third party payors, conveners, and referral sources,
- the Company's ability to control costs, particularly labor and employee benefit costs,
- increased operating costs due to shortages in qualified nurses, therapists, and other healthcare personnel,
- the Company's ability to successfully reduce (by divestiture of operations or otherwise) its exposure to professional liability and other claims,
- the costs of defending and insuring against alleged professional liability and other claims and investigations (including those related to pending investigations and whistleblower and wage and hour class action lawsuits against the Company) and the Company's ability to predict the estimated costs and reserves related to such claims and investigations, including the impact of differences in actuarial assumptions and estimates compared to eventual outcomes,
- the Company's ability to comply with its rental and debt agreements, including payment of amounts owed thereunder and compliance with the covenants contained therein, including under the Company's master lease agreement with Ventas,
- the Company's inability to maintain the security and functionality of its information systems, or to defend against or otherwise prevent a cybersecurity attack or breach,
- the condition of the financial markets, including volatility and weakness in the equity, capital, and credit markets, which could limit the availability and terms of debt and equity financing sources to fund the requirements of the Company's businesses, or which could negatively impact the Company's investment portfolio,
- national, regional, and industry-specific economic, financial, business, and political conditions, including their effect on the availability and cost of labor, credit, materials, and other services,
- the Company's ability to attract and retain key executives and other healthcare personnel,
- the Company's ability to successfully dispose of unprofitable facilities,
- events or circumstances that could result in the impairment of an asset or other charges,
- changes in GAAP or practices, and changes in tax accounting or tax laws (or authoritative interpretations relating to any of these matters), including a new lease accounting standard that will significantly increase balance sheet assets and liabilities on and after January 1, 2019, and
- the Company's ability to maintain an effective system of internal control over financial reporting.

Many of these factors are beyond the Company's control. The Company cautions investors that any forward-looking statements made by the Company are not guarantees of future performance. The Company disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

General

The accompanying unaudited condensed consolidated financial statements, including the notes thereto, should be read in conjunction with the following discussion and analysis.

The Company is a healthcare services company that through its subsidiaries operates a home health, hospice and community care business, TC hospitals, IRFs, and a contract rehabilitation services business across the United States. At March 31, 2018, the Company's Kindred at Home division primarily provided home health, hospice, and community care services from 606 sites of service in 40 states. The Company's hospital division operated 75 TC hospitals (5,553 licensed beds) in 17 states. The Company's Kindred Rehabilitation Services division operated 19 IRFs (995 licensed beds) and 98 hospital-based ARUs, and provided rehabilitation services primarily in hospitals and long-term care settings in 45 states.

Planned Acquisition of Kindred

On December 19, 2017, the Company announced that the Board approved a definitive agreement under which the Company will be acquired by a consortium of three companies: TPG, WCAS and Humana. Subject to the terms and conditions of the Merger Agreement among the Company, HospitalCo Parent, Parent and Merger Sub, Merger Sub will be merged with and into Kindred, with Kindred continuing as the Surviving Entity. Concurrently with the execution and delivery of the Merger Agreement, the Company, Parent, HospitalCo Parent, and Kentucky Hospital Merger Sub, Inc., entered into the Separation Agreement, pursuant to which, promptly following the effective time of the Merger, the Surviving Entity will be separated from the Company's home health, hospice and community care services business and acquired by HospitalCo Parent. See note 2 of the notes to unaudited condensed consolidated financial statements.

Skilled nursing facility business exit

On June 30, 2017, the Company entered into a definitive agreement with BlueMountain under which the Company agreed to sell its skilled nursing facility business for \$700 million in cash (previously defined as the SNF Divestiture). In connection with the SNF Divestiture, the results of operations of the skilled nursing facility business, which previously were reported in the nursing center division, and the losses or impairments associated with the SNF Divestiture, have been classified as discontinued operations for all periods presented. In addition, direct overhead and the profits from applicable RehabCare contracts servicing the Company's skilled nursing facility business that were not retained with new operators were moved to discontinued operations for all periods presented. The Company has reclassified certain retained businesses and expenses previously reported in the nursing center division to other business segments, including hospital-based sub-acute units and a skilled nursing facility to the hospital division and a small therapy business to the Kindred Hospital Rehabilitation Services operating segment for all periods presented. See notes 3 and 4 of the notes to unaudited condensed consolidated financial statements.

Discontinued operations

The Company has completed several strategic divestitures to improve its future operating results. For accounting purposes, the operating results of these businesses and the losses or impairments associated with these transactions were classified as discontinued operations, net of income taxes, in the accompanying unaudited condensed consolidated statement of operations for all periods. Effective January 1, 2015, the authoritative guidance modified the requirements for reporting discontinued operations. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results.

Critical Accounting Policies

Management's discussion and analysis of financial condition and results of operations are based upon the Company's consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires the use of estimates and judgments that affect the reported amounts and related disclosures of commitments and contingencies. The Company relies on historical experience and on various other assumptions that management believes to be reasonable under the circumstances to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Critical Accounting Policies (Continued)

Valuation of long-lived assets, goodwill, and intangible assets

Long-lived assets and intangible assets with finite lives

The Company reviews the carrying value of certain long-lived assets and finite lived intangible assets with respect to any events or circumstances that indicate an impairment or an adjustment to the amortization period is necessary. If circumstances suggest that the recorded amounts cannot be recovered based upon estimated future undiscounted cash flows, the carrying values of such assets are reduced to fair value.

In assessing the carrying values of long-lived assets, the Company estimates future cash flows at the lowest level for which there are independent, identifiable cash flows. For this purpose, these cash flows are aggregated based upon the contractual agreements underlying the operation of the facility or group of facilities. Generally, an individual facility for hospitals or IRFs, skilled nursing rehabilitation services reporting unit, hospital rehabilitation services reporting unit, or sites of service at a geographical location level within the Kindred at Home division are considered the lowest level for which there are independent, identifiable cash flows. However, to the extent that groups of facilities are leased under a master lease agreement in which the operations of a facility and compliance with the lease terms are interdependent upon other facilities in the agreement (including the Company's ability to renew the lease or divest a particular property), the Company defines the group of facilities under a master lease agreement, or a renewal bundle in a master lease, as the lowest level for which there are independent, identifiable cash flows. Accordingly, the estimated cash flows of all facilities within a master lease agreement, or within a renewal bundle in a master lease, are aggregated for purposes of evaluating the carrying values of long-lived assets.

The Company's intangible assets with finite lives, such as customer relationship assets, trade names, leasehold interests, and non-compete agreements, are amortized in accordance with the authoritative guidance for goodwill and other intangible assets, primarily using the straight-line method over their estimated useful lives ranging from two to 15 years.

During the first quarter of 2017, the Company recorded an asset impairment charge of \$0.4 million related to a valuation adjustment for a building within the Kindred at Home division. The charge reflects the amount by which the carrying value of the building exceeded its estimated fair value. The fair value of the building was measured using Level 3 inputs, primarily replacement cost.

Goodwill

In accordance with the authoritative guidance for goodwill and other intangible assets, the Company is required to perform an impairment test for goodwill and indefinite-lived intangible assets at least annually or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. The Company performs its annual goodwill impairment test on October 1 each fiscal year for each of its reporting units.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Critical Accounting Policies (Continued)

Valuation of long-lived assets, goodwill, and intangible assets (Continued)

Goodwill (Continued)

A reporting unit is either an operating segment or one level below the operating segment, referred to as a component. When the components within the Company's operating segments have similar economic characteristics, the Company aggregates the components of its operating segments into one reporting unit. Accordingly, the Company has determined that its reporting units are home health, hospice, community care, hospitals, hospital rehabilitation services, IRFs, and RehabCare. The community care reporting unit is included in the home health operating segment of the Kindred at Home division. The hospital rehabilitation services and IRFs reporting units are both included in the Kindred Hospital Rehabilitation Services operating segment of the Kindred Rehabilitation Services division. The carrying value of goodwill for each of the Company's reporting units at March 31, 2018 and December 31, 2017 follows (in thousands):

| | March 31, 2018 | December 31, 2017 |
|---|---------------------------|------------------------------|
| Kindred at Home: | | |
| Home health | \$ 746,613 | \$ 746,613 |
| Hospice | 646,154 | 646,329 |
| Community care | 170,626 | 170,626 |
| | <u>1,563,393</u> | <u>1,563,568</u> |
| Hospitals | 125,045 | 125,045 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Service contracts | 173,618 | 173,618 |
| IRFs | 326,335 | 326,335 |
| RehabCare | - | - |
| | <u>499,953</u> | <u>499,953</u> |
| | <u>\$ 2,188,391</u> | <u>\$ 2,188,566</u> |

In January 2017, the FASB issued authoritative guidance that simplifies the measurement of goodwill impairment to a single-step test. The guidance removed step two of the goodwill impairment test, which required a hypothetical purchase price allocation. The measurement of goodwill impairment is now the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Under the revised guidance, failing step one will always result in goodwill impairment. The Company adopted the new guidance on January 1, 2017 on a prospective basis.

Since quoted market prices for the Company's reporting units are not available, the Company applies judgment in determining the fair value of these reporting units for purposes of performing the goodwill impairment test. The Company relies on widely accepted valuation techniques, including discounted cash flow and market multiple analyses approaches, which capture both the future income potential of the reporting unit and the market behaviors and actions of market participants in the industry that includes the reporting unit. These types of analyses require the Company to make assumptions and estimates regarding future cash flows, industry-specific economic factors and the profitability of future business strategies. The discounted cash flow approach uses a projection of estimated operating results and cash flows that are discounted using a weighted average cost of capital. Under the discounted cash flow approach, the projection uses management's best estimates of economic and market conditions over the projected period for each reporting unit including growth rates in the number of admissions, patient days, reimbursement rates, operating costs, rent expense, and capital expenditures. Other significant estimates and assumptions include terminal value growth rates, changes in working capital requirements, and weighted average cost of capital. The market multiple analysis estimates fair value by applying cash flow multiples to the reporting unit's operating results. The multiples are derived from comparable publicly traded companies with similar operating and investment characteristics to the reporting units.

As part of the annual impairment test as of October 1, 2017, it was determined the community care reporting unit carrying value was within 12% of its fair value. The Company performed a sensitivity analysis on this reporting unit and determined that a 0.5% increase to the weighted average cost of capital would result in the fair value being lower than the carrying value. Adverse changes in the operating environment and related key assumptions used to determine the fair value of the Company's reporting units and indefinite-lived intangible assets or declines in the value of the Company's Common Stock may result in future impairment charges for a portion or all of these assets. Specifically, if the rate of growth of government and commercial revenues earned by the Company's reporting units were to be less than projected, if healthcare reforms were to negatively impact the Company's business, if

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Critical Accounting Policies (Continued)

Valuation of long-lived assets, goodwill, and intangible assets (Continued)

Goodwill (Continued)

weighted average cost of capital increases, or if recent increases in labor costs materially exceed the Company's projections in its reporting units or business segments, an impairment charge of a portion or all of these assets may be required. An impairment charge could have a material adverse effect on the Company's business, financial position and results of operations, but would not be expected to have an impact on the Company's cash flows or liquidity.

Indefinite-lived intangible assets

The Company's indefinite-lived intangible assets consist of trade names, Medicare certifications, and certificates of need. The fair values of the Company's indefinite-lived intangible assets are derived from current market data, including comparable sales or royalty rates, and projections at a facility, geographical location level or reporting unit, which include management's best estimates of economic and market conditions over the projected period. Significant assumptions include growth rates in the number of admissions, patient days, reimbursement rates, operating costs, total rent expense, capital expenditures, terminal value growth rates, changes in working capital requirements, weighted average cost of capital, and opportunity costs.

The annual impairment tests for the Company's indefinite-lived intangible assets are performed as of May 1 and October 1 each fiscal year. Medicare certifications in the Company's home health, hospice and IRFs reporting units, and trade names in the Company's hospice and community care reporting units (aggregating approximately \$124 million and \$21 million, respectively), were within 1% of their fair value at October 1, 2017 after the annual impairment test. The majority of the \$124 million Medicare certifications value and \$21 million trade name value related to the Gentiva Merger and the Company's acquisition of 11 IRFs in January 2015 from Centerre Healthcare Corporation, which were each appraised during 2015.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations

For segment purposes, the Company defines segment adjusted operating income as earnings before interest, income taxes, depreciation, amortization, and total rent reported for each of the Company's operating segments, excluding impairment charges, restructuring charges, and the allocation of support center overhead.

A summary of the Company's operating data follows (unaudited):

| <u>(In thousands)</u> | Three months ended March 31, | |
|---|---------------------------------|--------------|
| | 2018 | 2017 |
| Revenues: | | |
| Kindred at Home: | | |
| Home health | \$ 453,759 | \$ 450,831 |
| Hospice | 183,628 | 179,378 |
| | 637,387 | 630,209 |
| Hospital division | 547,630 | 556,646 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 178,219 | 178,115 |
| RehabCare | 172,519 | 198,126 |
| | 350,738 | 376,241 |
| | 1,535,755 | 1,563,096 |
| Eliminations: | | |
| Kindred Hospital Rehabilitation Services | (19,321) | (21,148) |
| RehabCare | (1,993) | (1,878) |
| Hospitals | (652) | (580) |
| | (21,966) | (23,606) |
| | \$ 1,513,789 | \$ 1,539,490 |
| Income from continuing operations: | | |
| Segment adjusted operating income: | | |
| Kindred at Home: | | |
| Home health | \$ 59,512 | \$ 63,750 |
| Hospice | 28,943 | 27,581 |
| | 88,455 | 91,331 |
| Hospital division | 104,250 | 93,438 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services | 53,409 | 51,760 |
| RehabCare | 3,931 | 8,704 |
| | 57,340 | 60,464 |
| Support center expenses | (57,600) | (60,014) |
| Impairment charges | - | (474) |
| Restructuring charges | (6,931) | (8,101) |
| Building rent | (62,488) | (64,656) |
| Equipment rent | (8,689) | (8,887) |
| Restructuring charges - rent | (1,178) | (1,905) |
| Depreciation and amortization | (24,789) | (29,820) |
| Interest, net | (60,835) | (58,819) |
| Income from continuing operations before income taxes | 27,535 | 12,557 |
| Provision for income taxes | 1,228 | 2,234 |
| | \$ 26,307 | \$ 10,323 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Operating data:

| | Three months ended March 31, | |
|--|---------------------------------|------------|
| | 2018 | 2017 |
| Kindred at Home: | | |
| Home health: | | |
| Sites of service (at end of period) | 375 | 379 |
| Revenue mix %: | | |
| Medicare | 72.8 | 76.7 |
| Medicaid | 1.5 | 1.7 |
| Commercial and other | 13.1 | 11.5 |
| Commercial paid at episodic rates | 12.6 | 10.1 |
| Episodic revenues (\$ 000s) | \$ 328,634 | \$ 326,881 |
| Total admissions | 94,913 | 94,510 |
| Same-store total admissions | 94,697 | 94,446 |
| Total episodic admissions | 73,206 | 73,270 |
| Same-store total episodic admissions | 73,022 | 73,233 |
| Medicare episodic admissions | 60,294 | 62,404 |
| Total episodes | 114,658 | 114,964 |
| Episodes per admission | 1.57 | 1.57 |
| Revenue per episode | \$ 2,866 | \$ 2,843 |
| Hospice: | | |
| Sites of service (at end of period) | 176 | 180 |
| Admissions | 13,853 | 13,649 |
| Same-store admissions | 13,701 | 13,436 |
| Average length of stay | 96 | 96 |
| Patient days | 1,217,227 | 1,193,061 |
| Average daily census | 13,525 | 13,256 |
| Revenue per patient day | \$ 151 | \$ 150 |
| Community care and other revenues (included in home health business segment) (\$ 000s) | \$ 68,959 | \$ 74,095 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Operating data (Continued):

| | Three months ended March 31, | |
|--|---------------------------------|----------------|
| | 2018 | 2017 |
| Hospitals (excluding sub-acute units and skilled nursing facility): | | |
| End of period data: | | |
| Number of transitional care hospitals | 75 | 82 |
| Number of licensed beds | 5,553 | 6,107 |
| Revenue mix %: | | |
| Medicare | 49.7 | 52.8 |
| Medicaid | 3.6 | 3.9 |
| Medicare Advantage | 14.1 | 12.2 |
| Medicaid Managed | 10.1 | 9.1 |
| Commercial insurance and other | 22.5 | 22.0 |
| Patient criteria data: | | |
| Revenues: | | |
| Compliant patients | 93.7% | 86.0% |
| Site neutral | 6.3% | 14.0% |
| Revenues per patient day: | | |
| Compliant patients | \$ 1,861 | \$ 1,816 |
| Site neutral | 1,057 | 1,041 |
| Total | 1,776 | 1,645 |
| Admissions: | | |
| Medicare | 6,201 | 7,529 |
| Medicaid | 310 | 354 |
| Medicare Advantage | 1,464 | 1,354 |
| Medicaid Managed | 936 | 851 |
| Commercial insurance and other | 1,522 | 1,614 |
| | <u>10,433</u> | <u>11,702</u> |
| Patient days: | | |
| Medicare | 156,561 | 187,738 |
| Medicaid | 11,463 | 13,334 |
| Medicare Advantage | 46,098 | 41,020 |
| Medicaid Managed | 33,697 | 32,713 |
| Commercial insurance and other | 51,341 | 53,695 |
| | <u>299,160</u> | <u>328,500</u> |
| Average length of stay: | | |
| Medicare | 25.2 | 24.9 |
| Medicaid | 37.0 | 37.7 |
| Medicare Advantage | 31.5 | 30.3 |
| Medicaid Managed | 36.0 | 38.4 |
| Commercial insurance and other | 33.7 | 33.3 |
| Weighted average | 28.7 | 28.1 |
| Revenues per admission: | | |
| Medicare | \$ 42,618 | \$ 37,867 |
| Medicaid | 61,546 | 60,091 |
| Medicare Advantage | 51,063 | 48,555 |
| Medicaid Managed | 57,536 | 57,736 |
| Commercial insurance and other | 78,476 | 73,750 |
| Weighted average | 50,935 | 46,170 |
| Revenues per patient day: | | |
| Medicare | \$ 1,688 | \$ 1,519 |
| Medicaid | 1,664 | 1,595 |
| Medicare Advantage | 1,622 | 1,603 |
| Medicaid Managed | 1,598 | 1,502 |
| Commercial insurance and other | 2,326 | 2,217 |
| Weighted average | 1,776 | 1,645 |
| Medicare case mix index (discharged patients only) | 1.224 | 1.172 |
| Average daily census | 3,324 | 3,650 |
| Occupancy % | 66.7 | 67.6 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Operating data (Continued):

| | Three months ended | |
|---------------------------------------|--------------------|----------------|
| | 2018 | 2017 |
| Same-hospital data: | | |
| End of period data: | | |
| Number of transitional care hospitals | 75 | 75 |
| Number of licensed beds | 5,553 | 5,553 |
| Revenue mix %: | | |
| Medicare | 49.7 | 52.6 |
| Medicaid | 3.6 | 3.8 |
| Medicare Advantage | 14.1 | 12.1 |
| Medicaid Managed | 10.1 | 9.4 |
| Commercial insurance and other | 22.5 | 22.1 |
| Patient criteria data: | | |
| Revenues: | | |
| Compliant patients | 93.7% | 86.4% |
| Site neutral | 6.3% | 13.6% |
| Revenues per patient day: | | |
| Compliant patients | \$ 1,863 | \$ 1,818 |
| Site neutral | 1,055 | 1,051 |
| Total | 1,778 | 1,654 |
| Admissions: | | |
| Medicare | 6,201 | 7,054 |
| Medicaid | 310 | 325 |
| Medicare Advantage | 1,464 | 1,273 |
| Medicaid Managed | 936 | 829 |
| Commercial insurance and other | 1,522 | 1,520 |
| | <u>10,433</u> | <u>11,001</u> |
| Patient days: | | |
| Medicare | 156,561 | 176,507 |
| Medicaid | 11,463 | 12,357 |
| Medicare Advantage | 46,098 | 38,520 |
| Medicaid Managed | 33,697 | 31,982 |
| Commercial insurance and other | 51,341 | 51,086 |
| | <u>299,160</u> | <u>310,452</u> |
| Average length of stay: | | |
| Medicare | 25.2 | 25.0 |
| Medicaid | 37.0 | 38.0 |
| Medicare Advantage | 31.5 | 30.3 |
| Medicaid Managed | 36.0 | 38.6 |
| Commercial insurance and other | 33.7 | 33.6 |
| Weighted average | 28.7 | 28.2 |
| Revenues per admission: | | |
| Medicare | \$ 42,626 | \$ 38,305 |
| Medicaid | 61,477 | 59,603 |
| Medicare Advantage | 51,053 | 48,898 |
| Medicaid Managed | 57,580 | 58,086 |
| Commercial insurance and other | 78,786 | 74,650 |
| Weighted average | 50,986 | 46,672 |
| Revenues per patient day: | | |
| Medicare | \$ 1,688 | \$ 1,531 |
| Medicaid | 1,665 | 1,568 |
| Medicare Advantage | 1,621 | 1,616 |
| Medicaid Managed | 1,598 | 1,506 |
| Commercial insurance and other | 2,336 | 2,221 |
| Weighted average | 1,778 | 1,654 |
| Average daily census | 3,324 | 3,449 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Operating data (Continued):

| | Three months ended | |
|---|--------------------|------------|
| | March 31, | |
| | 2018 | 2017 |
| Kindred Rehabilitation Services: | | |
| Kindred Hospital Rehabilitation Services: | | |
| Freestanding IRFs: | | |
| End of period data: | | |
| Number of IRFs | 19 | 19 |
| Number of licensed beds | 995 | 995 |
| Discharges (a) | 5,029 | 4,775 |
| Occupancy % (a) | 73.2 | 71.4 |
| Average length of stay (a) | 12.5 | 12.8 |
| Revenue per discharge (a) | \$ 20,020 | \$ 20,097 |
| Contract services: | | |
| Sites of service (at end of period): | | |
| Inpatient rehabilitation units (ARUs) | 98 | 101 |
| LTAC hospitals | 103 | 119 |
| Sub-acute units | 4 | 7 |
| Outpatient units | 123 | 129 |
| | <u>328</u> | <u>356</u> |
| Revenue per site | \$ 232,321 | \$ 227,100 |
| RehabCare: | | |
| Sites of service (at end of period) | 1,580 | 1,703 |
| Revenue per site | \$ 109,189 | \$ 116,340 |

(a) Excludes non-consolidating IRF.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Kindred at Home

Home health

Revenues increased 1% to \$454 million in the first quarter of 2018 compared to \$451 million for the same period in 2017, primarily the result of a slight increase in admissions in the first quarter of 2018 compared to the same period a year ago and a 1% increase in revenue per episode.

Segment adjusted operating income margin declined to 13.1% in the first quarter of 2018 compared to 14.1% for the same period in 2017. The decrease in segment adjusted operating income margin was primarily attributable to a \$6 million increase in employee health insurance costs and, to a lesser extent, a shift in revenue mix from Medicare to managed care and commercial insurance business. Medicare revenue mix declined to 72.8% in the first quarter of 2018 from 76.7% for the same period in 2017. The increase in employee health insurance costs, which occurred in each of the Company's business segments in the first quarter of 2018, was primarily attributable to an increase in high cost outlier claims and a general increase in utilization.

Hospice

Revenues increased 2% to \$183 million in the first quarter of 2018 compared to \$179 for the same period in 2017, primarily as a result of a 2% increase in average daily census and a 1% increase in revenue per patient day.

Segment adjusted operating income margins increased to 15.8% in the first quarter of 2018 compared to 15.4% in the same period in 2017. The increase was primarily attributable to operating efficiencies associated with increased volumes and the closure of unprofitable branches.

Direct labor cost per patient day decreased 1% in the first quarter of 2018 compared to the same period in 2017. Employee benefit costs increased 6% in the first quarter of 2018 compared to the same period in 2017, primarily as a result of a \$2 million increase in employee health insurance expense.

Hospital division

Revenues declined 2% to \$548 million in the first quarter of 2018 compared to \$557 million for the same period in 2017, primarily as a result of the closure of seven LTAC hospitals beginning in the second quarter of 2017 (which eliminated \$27 million of revenues earned in the first quarter of 2017). Same-hospital admissions declined 5% in the first quarter of 2018 compared to the same period in 2017, primarily due to a 50% decline in same-hospital Medicare site neutral admissions. On a same-hospital basis, post-intensive care ("PIC") revenues were 93.7% of total revenues for the first quarter of 2018 compared to 86.4% in the same period in 2017. As a result of the growth in PIC revenues and decline in Medicare site neutral revenues, same-hospital revenue per patient day increased 7% in the first quarter of 2018 compared to the same period in 2017.

Segment adjusted operating income margins increased to 19.0% in the first quarter of 2018 compared to 16.8% for the same period in 2017, primarily as a result of the growth in PIC revenues and related growth in revenue per patient day. Same-hospital operating costs per patient day increased 5% in the first quarter of 2018 compared to the same period in 2017, primarily due to an increase in acuity from the growth in PIC volumes and an increase in average wage rates.

Average hourly wage rates increased 5% in the first quarter of 2018 compared to the same period in 2017, primarily as a result of pay rate increases. Employee benefit costs increased 4% in the first quarter of 2018 compared to the same period in 2017, primarily as a result of a \$3 million increase in employee health insurance expense, partially offset by a decrease in workers compensation expense.

Professional liability costs were \$9 million in the first quarter of both 2018 and 2017.

Kindred Rehabilitation Services

Kindred Hospital Rehabilitation Services

Revenues for the IRFs increased 5% to \$101 million in the first quarter of 2018 compared to \$96 million the same period in 2017, primarily as a result of a 5% increase in inpatient rehabilitation discharges. Revenues for hospital rehabilitation contract services declined 6% to \$77 million in the first quarter of 2018 compared to \$82 million the same period in 2017, primarily as a result of a 13% decline in LTAC hospital contract services sites of service.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Kindred Rehabilitation Services (Continued)

Kindred Hospital Rehabilitation Services (Continued)

Segment adjusted operating income margins increased to 30.0% in the first quarter of 2018 compared to 29.1% for the same period in 2017. The increase was primarily a result of a 5% increase in inpatient rehabilitation discharges previously mentioned and improved operating efficiencies, offset by the decline in LTAC hospital contract services sites of service.

Employee benefit costs increased 7% in the first quarter of 2018 compared to the same period in 2017, primarily as a result of a \$1 million increase in employee health insurance expense, partially offset by a decrease in workers compensation expense.

RehabCare

Revenues declined 13% to \$173 million in the first quarter of 2018 compared to \$198 million for the same period in 2017. The decline in revenues was primarily attributable to a net loss of customer contract sites of service. The number of RehabCare sites of service at March 31, 2018 was 1,580 compared to 1,703 at March 31, 2017. The net loss of customer contract sites of service was primarily attributable to the strategic termination of unprofitable customer contract sites, the SNF Divestiture and competition.

Segment adjusted operating income margins declined to 2.3% in the first quarter of 2018 compared to 4.4% for the same period in 2017, primarily due to the net loss of customer contract sites of service.

Employee benefit costs declined 7% in the first quarter of 2018 compared to the same period in 2017, primarily as a result of the net loss of customer contract sites of service, partially offset by an increase of \$2 million in employee health insurance expense.

Support center expenses

Segment adjusted operating income for the Company's operating divisions excludes allocations of support center overhead. These costs aggregated \$58 million and \$60 million in the first quarter of 2018 and 2017, respectively. The decline in support center overhead was primarily attributable to cost saving initiatives associated with the SNF Divestiture. As a percentage of consolidated revenues, support center overhead totaled 3.8% and 3.9% in the first quarter of 2018 and 2017, respectively.

Restructuring costs

The Company has initiated various restructuring activities whereby it has incurred costs associated with reorganizing its operations, including the divestiture, swap, closure and consolidation of its business, facilities and branches, reduced headcount and realigned operations in order to improve operations, cost efficiencies and capital structure in response to changes in the healthcare industry, increasing leverage and to partially mitigate reductions in reimbursement rates from third party payors. The costs associated with these activities are reported as restructuring charges in the accompanying unaudited condensed consolidated statement of operations and would have been recorded as general and administrative expense or rent expense if not classified as restructuring charges.

Planned Acquisition of Kindred

During the fourth quarter of 2017, the Company announced that the Board had approved the Merger Agreement as described in note 2 of the notes to unaudited condensed consolidated financial statements. The costs incurred related to the Merger Agreement are expected to be substantially completed in 2018. The additional costs cannot be reasonably estimated at this time.

Restructuring charges that the Company incurred related to these initiatives consisted of \$6 million for merger costs and \$0.4 million for retention and severance in the first quarter of 2018.

LTAC Hospital Portfolio Repositioning 2017 Plan

During the third quarter of 2017, the Company approved phase two of the LTAC hospital portfolio repositioning plan that incorporated the closure and conversion of certain LTAC hospitals as part of its mitigation strategies in response to the new patient criteria for LTAC hospitals under the LTAC Legislation. The activities related to the LTAC hospital portfolio repositioning 2017 plan will be substantially completed in 2018. The additional costs cannot be reasonably estimated at this time.

Restructuring charges that the Company incurred related to the LTAC hospital portfolio repositioning 2017 plan consisted of \$0.5 million for lease termination costs, \$0.4 million for asset write-offs and \$0.4 million for gain on disposal in the first quarter of 2018.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Results of Operations – Continuing Operations (Continued)

Restructuring costs (Continued)

LTAC Hospital Portfolio Repositioning 2016 Plan

During the first quarter of 2016, the Company approved the LTAC hospital portfolio repositioning 2016 plan that incorporated the divestiture, swap or closure of certain LTAC hospitals as part of its mitigation strategies to prepare for new patient criteria for LTAC hospitals under the LTAC Legislation. The activities related to the LTAC hospital portfolio repositioning 2016 plan were substantially completed during 2016.

Restructuring charges that the Company incurred related to the LTAC hospital portfolio repositioning 2016 plan consisted of \$0.5 million for lease termination costs in the first quarter of 2018 and \$0.7 million for lease termination costs and \$0.2 million for facility closure costs in the first quarter of 2017.

Kindred at Home 2017 Efficiency Initiative

During the first quarter of 2017, the Kindred at Home division approved and initiated a cost and operations efficiency initiative to address increases in labor costs associated with competitive labor markets and the integration of pay practices from acquisitions across the Kindred at Home portfolio. This initiative includes the consolidation and closure of under-performing branches and a reduction in force associated with the restructuring of divisional and regional support teams. These activities were substantially completed during 2017.

Restructuring charges related to these initiatives consisted of \$0.3 million for asset write-offs, \$0.2 million for lease termination costs, and \$0.1 million for loss on disposal in the first quarter of 2018. Restructuring charges related to these initiatives consisted of \$0.6 million for lease termination costs, \$3 million for asset write-offs, and \$1 million for severance in the first quarter of 2017.

Kindred at Home Branch Consolidations and Closures

During the first quarter of 2015, the Company approved and initiated branch consolidations and closures in specific markets to improve operations and cost efficiencies in the Kindred at Home division. The branch consolidations and closures included branches that served both the home health and hospice business segment operations. Gentiva initiated similar branch consolidations and closures prior to the Gentiva Merger and these activities and acquired liabilities are included herein. These activities were substantially completed during 2016.

Restructuring charges related to these consolidations and closures consisted of \$0.6 million for lease termination costs, \$2 million for asset write-offs, and \$1 million for severance in the first quarter of 2017.

Other expenses

Total rent expense declined 3% to \$71 million in the first quarter of 2018 compared to \$74 million in the first quarter 2017. The decline was primarily attributable to the closure of seven LTAC hospitals beginning in the second quarter of 2017.

Depreciation and amortization expense declined 17% to \$25 million in the first quarter of 2018 compared to \$30 million in first quarter of 2017. The decline was primarily attributable to a change in estimate in the depreciable life of certain information technology equipment and software effective April 1, 2017 which reduced depreciation expense by approximately \$3 million in the first quarter of 2018.

Interest expense increased 3% to \$61 million in the first quarter of 2018 compared to \$59 million in the first quarter of 2017, primarily as a result of an increase in interest rates.

Consolidated results

Income from continuing operations before income taxes aggregated \$27 million in the first quarter of 2018 compared to \$12 million in the first quarter of 2017. Income from continuing operations attributable to the Company aggregated \$13 million in the first quarter of 2018 compared to loss from continuing operations attributable to the Company of \$0.2 million for the same period in 2017. The increases in both income from continuing operations before income taxes and income from continuing operations attributable to the Company were primarily attributable to improved operating performance in the hospital division and lower support center costs. Restructuring charges negatively impacted consolidated pretax operating results by \$8 million in the first quarter of 2018. Restructuring charges and impairment charges negatively impacted consolidated pretax operating results by \$10 million in the first quarter of 2017.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations – Discontinued Operations

Loss from discontinued operations aggregated \$9 million in the first quarter of 2018 compared to income from discontinued operations of \$5 million for the same period in 2017. The Company recorded a net loss on divestiture of operations of \$6 million in the first quarter of 2018, primarily related to the SNF Divestiture, including \$4 million of transaction and other costs and \$2 million of retention costs. The Company recorded a net loss on divestiture of operations of \$6 million in the first quarter of 2017, primarily related to the SNF Divestiture retention costs.

Liquidity

Operating cash flows

Cash flows used in operations (including discontinued operations) was \$132 million for the first quarter of 2018 compared to \$93 million for the same period in 2017. The decrease in operating cash flows for the first quarter of 2018 was primarily attributable to a \$26 million decrease in discontinued operations operating cash flows primarily associated with wind-down activities related to the SNF Divestiture and miscellaneous working capital timing differences associated with continuing operations cash flows. Cash flows are seasonally the lowest in the first quarter of each year due to working capital growth, semi-annual interest payments on the Notes due 2020 and the Notes due 2023, and annual incentive bonus payments. Operating cash flows for continuing operations for the first quarter of 2018 were also negatively impacted by \$13 million for severance, retention, lease termination, and transaction payments. Operating cash flows for discontinued operations for the first quarter of 2018 were negatively impacted by \$6 million for severance, retention and transaction payments. Operating cash flows for continuing operations for the first quarter of 2017 were also negatively impacted by \$20 million for litigation, severance, retention, transaction, debt refinancing, lease termination payments, and business interruption settlements. Operating cash flows for discontinued operations for the first quarter of 2017 were negatively impacted by \$1 million for severance, retention, and transaction payments.

The Company utilizes its ABL Facility to meet working capital needs and finance its acquisition and development activities. As a result, the Company typically carries minimal amounts of cash on its consolidated balance sheet. Based upon the Company's expected operating cash flows and the availability of borrowings under the ABL Facility (\$409 million at March 31, 2018), management believes that the Company has the necessary financial resources to satisfy its expected short-term and long-term liquidity needs.

In connection with the SNF Divestiture, the Company entered into an interim management agreement in the third quarter of 2017 with certain affiliates of BlueMountain in the state of California whereby the Company would lease its license of certain operations to such affiliates until licensure approval is obtained. Because the Company has continuing involvement in the business through purveying certain rights of ownership of the assets while under the interim management agreement and license sublease, the Company does not meet the requirements for a sale-leaseback transaction as described in ASC 840-40, *Leases - Sale-Leaseback Transactions*. Under the failed-sale-leaseback accounting model, the Company is deemed under GAAP to still own certain real estate assets sold to BlueMountain, which the Company must continue to reflect in its consolidated balance sheet and depreciate over the assets' remaining useful life. The Company also must treat a portion of the pretax cash proceeds from the SNF Divestiture as though it were the result of a \$141 million other long-term liability financing obligation in its accompanying unaudited condensed consolidated balance sheet, and also must defer a \$18 million gain associated with some of these assets until continuing involvement ceases. The lease will terminate upon licensure approval, at which time the Company will cease to recognize the remaining other long-term liability financing obligation, as well as the remaining net book value of the real estate assets and will recognize the gain.

Dividends and other payments

During the three months ended March 31, 2017, the Company paid a cash dividend of \$0.12 per common share. The Board elected to discontinue paying dividends on the Company's Common Stock following the March 31, 2017 payment and instead redirected funds to repay debt and invest in growth.

The Company made an installment payment on the Units of \$18.75 per Unit on March 1, 2017. Each Unit was composed of a Purchase Contract and one share of Mandatory Redeemable Preferred Stock which had a final preferred stock installment payment date of December 1, 2017. On December 1, 2017, the remaining holders of 87,379 Purchase Contracts were mandatorily redeemed. As a result, holders thereof received 50.6329 shares of Common Stock per Purchase Contract, resulting in approximately 4.4 million shares of Common Stock being issued on such date. Holders of the Mandatory Redeemable Preferred Stock were previously entitled to receive a quarterly "preferred stock installment payment" in cash, shares of Common Stock, or a combination thereof. All shares of Mandatory Redeemable Preferred Stock were redeemed on December 1, 2017 as planned pursuant to their terms.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Liquidity (Continued)

Term Loan Amendment Agreement

On March 14, 2017, the Company entered into the Term Loan Amendment Agreement that amended and restated the Term Loan Facility to, among other things, (1) make adjustments to certain covenants and definitions to better accommodate the SNF Divestiture, (2) provide the Company with increased leverage covenant flexibility for an interim period, (3) increase the applicable margin on the outstanding borrowings from 3.25% to 3.50% for LIBOR borrowings and from 2.25% to 2.50% for base rate borrowings, (4) require a maximum leverage ratio of no more than 5.00 to 1.00 for use of the \$50 million annual dividend basket, and (5) provide for a prepayment premium of 1.00% in connection with any repricing transaction within six months of the closing date. In accordance with the authoritative guidance on debt, the Company accounted for the amendment as a debt modification.

ABL Facility

On September 27, 2017, the Company entered into an amendment to the ABL Facility to update the provisions pertaining to letters of credit issued thereunder.

Interest rate swaps

In January 2016, the Company entered into three interest rate swap agreements to hedge its floating interest rate on an aggregate of \$325 million of debt outstanding under its Term Loan Facility. The interest rate swaps have an effective date of January 11, 2016, and expire on January 9, 2021. The Company is required to make payments based upon a fixed interest rate of 1.862% and 1.855% calculated on the notional amount of \$175 million and \$150 million, respectively. In exchange, the Company will receive interest on \$325 million at a variable interest rate that is based upon the three-month LIBOR, subject to a minimum rate of 1.0%.

In March 2014, the Company entered into an interest rate swap agreement to hedge its floating interest rate on an aggregate of \$400 million of debt outstanding under its Term Loan Facility. On April 8, 2014, the Company completed a novation of a portion of its \$400 million swap agreement to two new counterparties, each in the amount of \$125 million. The original swap contract was not amended, terminated, or otherwise modified. The interest rate swap had an effective date of April 9, 2014, expired on April 9, 2018, and applied to the Term Loan Facility. The Company made payments based upon a fixed interest rate of 1.867% calculated on the notional amount of \$400 million. In exchange, the Company received interest on \$400 million at a variable interest rate that was based upon the three-month LIBOR, subject to a minimum rate of 1.0%.

The interest rate swaps were assessed for hedge effectiveness for accounting purposes and the Company determined the interest rate swaps qualify for cash flow hedge accounting treatment at March 31, 2018. The Company records the effective portion of the gain or loss on these derivative financial instruments in accumulated other comprehensive income (loss) as a component of stockholders' equity and records the ineffective portion of the gain or loss on these derivative financial instruments as interest expense. For the three months ended March 31, 2018 and 2017, there was no ineffectiveness related to the interest rate swaps.

The aggregate fair value of the interest rate swaps recorded in other current assets was \$7 million and \$3 million at March 31, 2018 and December 31, 2017, respectively. The fair value was determined by reference to a third party valuation and is considered a Level 2 input within the fair value hierarchy.

Capital Resources

Capital expenditures and acquisitions

Excluding acquisitions and including discontinued operations, routine capital expenditures (expenditures necessary to maintain existing facilities that generally do not increase capacity or add services) totaled \$16 million and \$12 million in the first quarter of 2018 and 2017, respectively. Kindred Hospital Rehabilitation Services development capital expenditures (primarily new IRF development) totaled \$0.6 million and \$0.5 million in the first quarter of 2018 and 2017, respectively. Support center development capital expenditures totaled \$3 million and \$5 million in the first quarter of 2018 and 2017, respectively. Excluding acquisitions, the Company anticipates that routine capital spending for 2018 should approximate \$60 million to \$70 million and development capital spending should approximate \$15 million to \$25 million. Management expects that substantially all of these expenditures will be financed through internal sources or borrowings under the ABL Facility. Management believes that its capital expenditure program is adequate to improve and equip existing facilities. At March 31, 2018, the estimated cost to complete and equip construction in progress approximated \$13 million.

Acquisition expenditures totaled \$3 million in the first quarter of 2017, which were financed with operating cash flows and the ABL Facility.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Other Information

Effects of inflation and changing prices

The Company derives a substantial portion of its revenues from patients covered by the Medicare and Medicaid programs. The Company has been, and could be in the future, materially adversely affected by the continuing efforts of governmental and private third party payors to contain healthcare costs.

The Company cannot provide assurance that reimbursement payments under governmental and private third party payor programs, including Medicare supplemental insurance policies, will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to these programs. Medicare reimbursement in LTAC hospitals, IRFs, home health, and hospice is subject to fixed payments under the Medicare prospective payment systems. In accordance with Medicare laws, CMS makes annual adjustments to Medicare payment rates in many prospective payment systems under what is commonly known as a "market basket update." Each year, the Medicare Payment Advisory Commission ("MedPAC"), a commission chartered by Congress to advise it on Medicare payment issues, recommends payment policies to Congress for a variety of Medicare payment systems. Congress is not obligated to adopt MedPAC recommendations and based on previous years, there can be no assurance that Congress will adopt MedPAC's recommendations in any given year. Generally, these rates are adjusted annually for inflation. However, those adjustments may not reflect actual increases of the cost of providing healthcare services. In addition, Medicaid reimbursement can be impacted negatively by state budgetary pressures, which may lead to reduced reimbursement or delays in receiving payments. There can be no assurance that the facilities operated by the Company, or the provision of goods and services offered by the Company, will meet the requirements for participation in such programs.

The Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act

Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (previously defined as the ACA). The reforms contained in the ACA have affected each of the Company's businesses in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of the Company's services, the methods of payment for the Company's services, and the underlying regulatory environment. These reforms include possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care, and the imposition of enrollment limitations on new providers.

The ACA also provides for: (1) reductions to the annual market basket payment updates for LTAC hospitals, IRFs, home health agencies, and hospice providers, which could result in lower reimbursement than in the preceding year; (2) additional annual "productivity adjustment" reductions to the annual market basket payment update as determined by CMS for LTAC hospitals and IRFs, home health agencies, and hospice providers; (3) a quality reporting system for hospitals (including LTAC hospitals and IRFs); and (4) reductions in Medicare payments to hospitals (including LTAC hospitals and IRFs) for failure to meet certain quality reporting standards or to comply with standards in new value-based purchasing demonstration project programs.

Further, the ACA mandates changes to home health and hospice benefits under Medicare. For home health, the ACA mandates creation of a value-based purchasing program, development of quality measures, a decrease in home health reimbursement that began in federal fiscal year 2014 and was phased-in over a four-year period, a reduction in the outlier cap, and reinstated a 3% add-on payment for home health services delivered to residents in rural areas on or after April 1, 2010 and before January 1, 2016.

In addition, the ACA requires the Secretary of the United States Department of Health and Human Services ("HHS") to test different models for delivery of care, some of which would involve home health services. It also requires the Secretary of HHS to establish a national pilot program for integrated care for patients with certain conditions, bundling payment for acute hospital care, physician services, outpatient hospital services (including emergency department services), and post-acute care services, which would include home health. The Secretary of HHS is also required to conduct a study to evaluate costs and quality of care among efficient home health agencies regarding access to care and treating Medicare beneficiaries with varying severity levels of illness and provide a report to Congress.

Potential efforts in the U.S. Congress to repeal, amend, modify, or retract funding for various aspects of the ACA create additional uncertainty about the ultimate impact of the ACA on the Company and the healthcare industry.

The healthcare reforms and changes resulting from the ACA (including any repeal, amendment, modification or retraction thereof), as well as other similar healthcare reforms, including any potential change in the nature of services the Company provides, the methods or amount of payment the Company receives for such services, and the underlying regulatory environment, could have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Other Information (Continued)

Effects of inflation and changing prices (Continued)

The Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (Continued)

Congress, MedPAC, and CMS will continue to address reimbursement rates for a variety of healthcare settings. The Company cannot predict the adjustments to Medicare payment rates that Congress or CMS may make in the future. Any downward adjustment to rates for the types of services the Company provides could have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

Congress continues to discuss additional deficit reduction measures, leading to a high degree of uncertainty regarding potential reforms to governmental healthcare programs, including Medicare and Medicaid. These discussions, along with other continuing efforts to reform governmental healthcare programs, could result in major changes in healthcare delivery and reimbursement systems on a national and state level, including changes directly impacting the government and private reimbursement systems for each of the Company's businesses. Healthcare reform, future healthcare legislation, or other changes in the administration or interpretation of governmental healthcare programs, whether resulting from deficit reduction measures or otherwise, could have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

The Company believes that its operating margins also will continue to be under pressure as the growth in operating expenses, particularly professional liability, labor, and employee benefits costs, exceeds any potential payment increases from third party payors. In addition, as a result of competitive pressures, the Company's ability to maintain operating margins through price increases to private patients is limited.

The Bipartisan Budget Act of 2018

The Bipartisan Budget Act of 2018 (the "BBA"), enacted on February 9, 2018, includes several provisions impacting Medicare reimbursement to home health, hospice, LTAC hospital and rehabilitation therapy services providers.

With respect to home health providers, the BBA (1) will base payment on a 30-day episode of care (beginning January 1, 2020), coupled with annual determinations by CMS to ensure budget neutrality (including taking into account provider behavior), (2) will eliminate retroactive payment adjustments based upon the level of therapy services required (beginning January 1, 2020), (3) extends the 3% add-on payment for home health services provided to residents in rural areas (beginning January 1, 2018), coupled with a reduction and phase out of such add-on payment over the following four fiscal years, and (4) will establish a market basket update of 1.5% for the federal fiscal year beginning January 1, 2020.

With respect to hospice providers, the BBA establishes a new payment policy related to early discharges to hospice care from hospitals. This policy will impose a financial penalty on hospitals for each early discharge to hospice care, beginning October 1, 2018.

With respect to LTAC hospital providers, the BBA extends the initial two-year phase-in period of the new LTAC patient criteria under the LTAC Legislation for an additional two-year period, and will impose a mandatory 4.6% reduction in payments for services provided to site-neutral patients over a nine-year period beginning October 1, 2017.

With respect to rehabilitation therapy services providers, the BBA (1) permanently repeals the Medicare Part B outpatient therapy cap (effective January 1, 2018), (2) continues the targeted medical review process, while reducing the applicable threshold triggering such review to \$3,000 (effective January 1, 2018), and (3) reduces payment for services provided by a physical or occupational therapy assistant to 85% of the amount currently payable under Medicare for such services (effective January 1, 2022).

LTAC Legislation

The LTAC Legislation creates new Medicare criteria and payment rules for LTAC hospitals. Medicare payments to LTAC hospitals are now based upon one of two methods: (1) LTAC PPS, or (2) a site-neutral formula based upon the lesser of what a short-term acute care hospital would be paid, or estimated cost. CMS classifies LTAC hospitals as a distinct provider type, separate from short-term acute care hospitals. Only providers certified as LTAC hospitals may be paid under the LTAC PPS system. CMS regulations classify LTAC hospital patients into diagnostic categories called Medicare Severity Diagnosis Related Groups ("MS-LTC-DRGs"). LTAC PPS is based upon discharged-based MS-LTC-DRGs similar to the prospective payment system used to pay general short-term acute care hospitals ("IPPS").

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Other Information (Continued)

Effects of inflation and changing prices (Continued)

LTAC Legislation (Continued)

Under the new criteria set forth in the LTAC Legislation, LTAC hospitals treating patients with at least a three-day prior stay in an acute care hospital intensive care unit and patients on prolonged mechanical ventilation admitted from an acute care hospital will continue to receive payment under LTAC PPS. Other patients will continue to have access to LTAC care, whether they are admitted to LTAC hospitals from acute care hospitals or directly from other settings or the community, and in such cases, LTAC hospitals will be paid at a site-neutral rate for these patients, based on the lesser of per diem Medicare rates paid for patients with the same diagnoses under IPPS or an estimate of cost. The Company expects that the majority of these site-neutral payments will be materially less than the payments provided under LTAC PPS. The BBA imposes a mandatory 4.6% reduction in payments for services provided to site-neutral patients over a nine-year period beginning October 1, 2017.

The effective date of the new patient criteria was October 1, 2015, tied to each individual LTAC hospital's cost reporting period, followed by an initial two-year phase-in period, which was extended by an additional two years by the BBA. During the four-year phase-in period, payment for patients receiving the site-neutral rate is based 50% on LTAC PPS and 50% on the site-neutral rate.

The majority of the Company's TC hospitals (all of which are certified as LTAC hospitals under the Medicare program) have a cost reporting period starting on September 1 of each year, and thus the phase-in of new patient criteria did not begin for a majority of the Company's TC hospitals until September 1, 2016, and, with the enactment of the BBA, full implementation of the new criteria will not begin until September 1, 2020. The Company expects that the full implementation of the new criteria on September 1, 2020 will have a further negative impact on Medicare payments to its TC hospitals.

Beginning in 2020, the LTAC Legislation requires that at least 50% of a hospital's patients must be paid under the new LTAC PPS system to maintain Medicare certification as a LTAC hospital. The failure of one or more of the Company's TC hospitals to maintain its Medicare certification as a LTAC hospital could have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

The new patient criteria imposed by the LTAC Legislation reduces the population of patients eligible for reimbursement under LTAC PPS and changes the basis upon which the Company is paid for other patients. In addition, the LTAC Legislation is subject to additional governmental regulations and the interpretation and enforcement of those regulations. The LTAC Legislation, the implementation of new patient criteria, changes in referral patterns, and other associated elements has had, and will continue to have, an adverse effect on the Company's business, financial position, results of operations, and liquidity.

The Medicare Access and CHIP Reauthorization Act of 2015

The Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA") was signed into law on April 16, 2015. Among other items, MACRA: (1) permanently replaced the sustainable growth rate formula previously used to determine updates to Medicare physician reimbursement, replacing these updates with quality and value measurements and participation in alternate payment models; (2) extended the Medicare Part B outpatient therapy cap exception process until December 31, 2017; (3) extended the 3% add-on payment for home health services delivered to residents in rural areas until December 31, 2017; and (4) set payment updates for post-acute providers at 1% after other adjustments required by the ACA for 2018.

For additional information regarding Medicare and Medicaid reimbursement and other government regulations impacting the Company, see the Company's Annual Report on Form 10-K for 2017 as filed with the SEC.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Other Information (Continued)

Effects of inflation and changing prices (Continued)

Kindred at Home

Home health. On November 1, 2017, CMS issued final regulations regarding Medicare payment rates for home health agencies effective January 1, 2018. Included in the final regulations is a net 0.4% reduction, consisting of a market basket update of 1.0% as required by MACRA, less (1) a 0.9% reduction adjustment to account for industry wide case mix growth, and (2) an additional 0.5% reduction for the elimination of the rural add-on provision.

On October 31, 2016, CMS issued final regulations regarding Medicare payment rates for home health agencies effective January 1, 2017. These final regulations implement a net 0.7% reduction, consisting of a market basket update of 2.8%, less (1) a 0.3% productivity reduction, (2) a 2.3% rebasing adjustment mandated under the ACA, and (3) an additional 0.9% reduction adjustment to account for industry wide case mix growth.

On October 29, 2015, CMS issued final regulations regarding Medicare payment rates for home health agencies effective January 1, 2016. These final regulations implement a net 1.4% reduction consisting of a 2.3% market basket inflation increase, less (1) a 0.4% productivity reduction, (2) a 2.4% rebasing adjustment mandated under the ACA, and (3) a 0.9% reduction to account for industry wide case mix growth. The regulations also implement a value-based purchasing demonstration model to be tested in nine states (Massachusetts, Maryland, North Carolina, Florida, Washington, Arizona, Iowa, Nebraska and Tennessee) through payment year 2022.

Hospice. On April 27, 2018, CMS issued proposed regulations for Medicare reimbursement for hospice providers effective October 1, 2018. These proposed regulations implement a net market basket increase to the standard federal payment rate of 1.8%, consisting of: (1) a market basket increase of 2.9%; (2) a multifactor productivity reduction of 0.8%; and (3) an additional 0.3% reduction as mandated by the ACA.

On August 1, 2017, CMS issued final regulations for Medicare reimbursement for hospice providers effective October 1, 2017. These final regulations implement a net market basket increase to the standard federal payment rate of 1.0%, as required by MACRA.

On July 29, 2016, CMS issued final regulations for Medicare reimbursement for hospice providers effective October 1, 2016. Included in these final regulations are: (1) a market basket increase of 2.7%; (2) a multifactor productivity reduction of 0.3%; and (3) an additional 0.3% reduction as mandated in the ACA.

On July 31, 2015, CMS issued final regulations for Medicare reimbursement for hospice providers for the federal fiscal year beginning October 1, 2015. These final regulations implement a net market basket increase of 1.6% consisting of: (1) a market basket inflation increase of 2.4%, less (2) offsets to the standard payment conversion factor mandated by the ACA of: (a) a 0.5% adjustment to account for the effect of a productivity adjustment, and (b) 0.3% as required by statute. In addition, there is a 0.2% increase resulting from the blend of wage index values under the updated core based statistical areas and a 0.7% reduction for the final year of the phase-out of the wage index budget neutrality adjustment. The regulation also implements, effective January 1, 2016: (1) the creation of two different payment rates for routine home care, a higher base payment for the first 60 days and a reduced payment for days 61 and beyond; and (2) a new service intensity add-on which would pay an additional amount during the last seven days of life when a patient has direct care provided by a registered nurse or social worker.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

Other Information (Continued)

Effects of inflation and changing prices (Continued)

Hospital division

On April 24, 2018, CMS issued proposed regulations regarding Medicare reimbursement for LTAC hospitals for the federal fiscal year beginning October 1, 2018. Included in the final regulations are: (1) a net market basket increase to the standard federal payment rate of 0.25%; (2) a wage level budget neutrality factor of 0.999713 applied to the standard federal payment rate; (3) an additional budget neutrality adjustment of 0.990535 applied to the standard federal payment rate; (4) adjustments to area wage indexes; and (5) an increase in the high cost outlier threshold per discharge to \$30,639.

On August 2, 2017, CMS issued final regulations regarding Medicare reimbursement for LTAC hospitals for the federal fiscal year beginning October 1, 2017. Included in the final regulations are: (1) a net market basket increase to the standard federal payment rate of 1.0%, as required by MACRA; (2) a wage level budget neutrality factor of 1.0006434 applied to the standard federal payment rate; (3) an additional budget neutrality adjustment for impact of changes in short stay outliers; (4) adjustments to area wage indexes; and (5) an increase in the high cost outlier threshold per discharge to \$27,382. This final rule also extends the moratorium on the full implementation of the 25% rule until October 1, 2018.

On August 2, 2016, CMS issued final regulations regarding Medicare reimbursement for LTAC hospitals for the federal fiscal year beginning October 1, 2016. Included in the final regulations are: (1) a market basket increase to the standard federal payment rate of 2.8%; (2) offsets to the standard federal payment rate by the ACA of: (a) 0.3% to account for the effect of a productivity adjustment, and (b) 0.75% as required by the statute; (3) a wage level budget neutrality factor of 0.999593 applied to the adjusted standard federal payment rate; (4) adjustments to area wage indexes; and (5) an increase in the high cost outlier threshold per discharge to \$21,943.

On July 31, 2015, CMS issued final regulations regarding Medicare reimbursement for LTAC hospitals for the federal fiscal year beginning October 1, 2015. Included in the final regulations are: (1) a market basket increase to the standard federal payment rate of 2.4%; (2) offsets to the standard federal payment rate mandated by the ACA of: (a) 0.5% to account for the effect of a productivity adjustment, and (b) 0.2% as required by statute; (3) a wage level budget neutrality factor of 1.000513 applied to the adjusted standard federal payment rate; (4) adjustments to area wage indexes; and (5) an increase in the high cost outlier threshold per discharge to \$16,423.

Kindred Rehabilitation Services

Inpatient rehabilitation hospitals. On April 27, 2018, CMS issued proposed regulations regarding Medicare reimbursement for IRFs for the federal fiscal year beginning October 1, 2018. These proposed regulations implement a net market basket increase to the standard payment conversion factor of 0.9%, consisting of: (1) a market basket increase of 2.9%; (2) a productivity reduction of 0.8%; and (3) an additional reduction of 0.75% as required by the ACA. These proposed regulations also implement an increase in the high cost outlier threshold per discharge to \$10,509.

On July 31, 2017, CMS issued final regulations regarding Medicare reimbursement for IRFs for the federal fiscal year beginning October 1, 2017. These final regulations implement a net market basket increase to the standard payment conversion factor of 1.0%, as required by MACRA, less a 0.1% reduction related to recalibrating the outlier threshold.

On July 29, 2016, CMS issued final regulations regarding Medicare reimbursement for IRFs for the federal fiscal year beginning October 1, 2016. Included in these final regulations are: (1) a market basket increase of 2.7%; (2) a productivity reduction of 0.3%; (3) an additional reduction of 0.75% as required by the ACA; and (4) a decrease in the high cost outlier threshold per discharge to \$7,984.

On July 31, 2015, CMS issued final regulations regarding Medicare reimbursement for IRFs for the federal fiscal year beginning October 1, 2015. Included in these final regulations are: (1) a market basket increase of 2.4%; (2) a productivity reduction of 0.5%; (3) an additional reduction of 0.2% as required by the ACA; and (4) a decrease in the high cost outlier threshold per discharge to \$8,658.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Condensed Consolidated Statement of Operations
(Unaudited)
(In thousands, except per share amounts)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|---|-------------------|---------------------|--------------------|---------------------|---------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Revenues | \$ 1,539,490 | \$ 1,535,831 | \$ 1,477,820 | \$ 1,480,982 | \$ 6,034,123 | \$ 1,513,789 |
| Salaries, wages and benefits | 839,813 | 833,703 | 830,558 | 814,811 | 3,318,885 | 845,854 |
| Supplies | 80,101 | 77,784 | 73,344 | 72,694 | 303,923 | 75,008 |
| Building rent | 64,656 | 64,861 | 64,422 | 63,577 | 257,516 | 62,488 |
| Equipment rent | 8,887 | 8,861 | 8,537 | 8,571 | 34,856 | 8,689 |
| Other operating expenses | 158,824 | 182,161 | 155,949 | 143,830 | 640,764 | 135,717 |
| General and administrative expenses | 275,503 | 266,156 | 258,834 | 269,271 | 1,069,764 | 265,372 |
| Other (income) expense | 30 | (2,287) | (638) | (565) | (3,460) | (607) |
| Litigation contingency expense | - | - | 4,000 | 3,435 | 7,435 | - |
| Impairment charges | 474 | 135,829 | - | 244,876 | 381,179 | - |
| Restructuring charges | 10,006 | 5,050 | 16,500 | 53,305 | 84,861 | 8,109 |
| Depreciation and amortization | 29,820 | 25,651 | 24,808 | 24,526 | 104,805 | 24,789 |
| Interest expense | 59,328 | 60,801 | 61,146 | 60,136 | 241,411 | 61,032 |
| Investment income | (509) | (2,228) | (705) | (57) | (3,499) | (197) |
| | <u>1,526,933</u> | <u>1,656,342</u> | <u>1,496,755</u> | <u>1,758,410</u> | <u>6,438,440</u> | <u>1,486,254</u> |
| Income (loss) from continuing operations before income taxes | 12,557 | (120,511) | (18,935) | (277,428) | (404,317) | 27,535 |
| Provision (benefit) for income taxes | 2,234 | (16,116) | (1,225) | (142,009) | (157,116) | 1,228 |
| Income (loss) from continuing operations | <u>10,323</u> | <u>(104,395)</u> | <u>(17,710)</u> | <u>(135,419)</u> | <u>(247,201)</u> | <u>26,307</u> |
| Discontinued operations, net of income taxes: | | | | | | |
| Income (loss) from operations | 5,059 | 5,061 | (14,291) | (12,683) | (16,854) | (8,770) |
| Loss on divestiture of operations | (6,166) | (294,039) | (49,663) | (29,392) | (379,260) | (5,790) |
| Loss from discontinued operations | <u>(1,107)</u> | <u>(288,978)</u> | <u>(63,954)</u> | <u>(42,075)</u> | <u>(396,114)</u> | <u>(14,560)</u> |
| Net income (loss) | <u>9,216</u> | <u>(393,373)</u> | <u>(81,664)</u> | <u>(177,494)</u> | <u>(643,315)</u> | <u>11,747</u> |
| Earnings attributable to noncontrolling interests: | | | | | | |
| Continuing operations | (10,483) | (10,791) | (10,960) | (9,942) | (42,176) | (12,792) |
| Discontinued operations | (4,481) | (4,954) | (3,162) | (264) | (12,861) | (660) |
| | <u>(14,964)</u> | <u>(15,745)</u> | <u>(14,122)</u> | <u>(10,206)</u> | <u>(55,037)</u> | <u>(13,452)</u> |
| Loss attributable to Kindred | <u>\$ (5,748)</u> | <u>\$ (409,118)</u> | <u>\$ (95,786)</u> | <u>\$ (187,700)</u> | <u>\$ (698,352)</u> | <u>\$ (1,705)</u> |
| Amounts attributable to Kindred stockholders: | | | | | | |
| Income (loss) from continuing operations | \$ (160) | \$ (115,186) | \$ (28,670) | \$ (145,361) | \$ (289,377) | \$ 13,515 |
| Loss from discontinued operations | (5,588) | (293,932) | (67,116) | (42,339) | (408,975) | (15,220) |
| Net loss | <u>\$ (5,748)</u> | <u>\$ (409,118)</u> | <u>\$ (95,786)</u> | <u>\$ (187,700)</u> | <u>\$ (698,352)</u> | <u>\$ (1,705)</u> |
| Earnings (loss) per common share: | | | | | | |
| Basic: | | | | | | |
| Income (loss) from continuing operations | \$ - | \$ (1.32) | \$ (0.32) | \$ (1.65) | \$ (3.31) | \$ 0.15 |
| Discontinued operations: | | | | | | |
| Income (loss) from operations | - | - | (0.20) | (0.15) | (0.34) | (0.11) |
| Loss on divestiture of operations | (0.07) | (3.36) | (0.57) | (0.33) | (4.33) | (0.06) |
| Loss from discontinued operations | <u>(0.07)</u> | <u>(3.36)</u> | <u>(0.77)</u> | <u>(0.48)</u> | <u>(4.67)</u> | <u>(0.17)</u> |
| Net loss | <u>\$ (0.07)</u> | <u>\$ (4.68)</u> | <u>\$ (1.09)</u> | <u>\$ (2.13)</u> | <u>\$ (7.98)</u> | <u>\$ (0.02)</u> |
| Diluted: | | | | | | |
| Income (loss) from continuing operations | \$ - | \$ (1.32) | \$ (0.32) | \$ (1.65) | \$ (3.31) | \$ 0.15 |
| Discontinued operations: | | | | | | |
| Income (loss) from operations | - | - | (0.20) | (0.15) | (0.34) | (0.11) |
| Loss on divestiture of operations | (0.07) | (3.36) | (0.57) | (0.33) | (4.33) | (0.06) |
| Loss from discontinued operations | <u>(0.07)</u> | <u>(3.36)</u> | <u>(0.77)</u> | <u>(0.48)</u> | <u>(4.67)</u> | <u>(0.17)</u> |
| Net loss | <u>\$ (0.07)</u> | <u>\$ (4.68)</u> | <u>\$ (1.09)</u> | <u>\$ (2.13)</u> | <u>\$ (7.98)</u> | <u>\$ (0.02)</u> |
| Shares used in computing earnings (loss) per common share: | | | | | | |
| Basic | 87,085 | 87,506 | 87,597 | 87,902 | 87,525 | 88,526 |
| Diluted | 87,085 | 87,506 | 87,597 | 87,902 | 87,525 | 88,526 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Operating Data
(Unaudited)
(In thousands)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|---|---------------------|---------------------|---------------------|---------------------|---------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Revenues: | | | | | | |
| Kindred at Home: | | | | | | |
| Home health | \$ 450,831 | \$ 459,176 | \$ 453,684 | \$ 458,666 | \$ 1,822,357 | \$ 453,759 |
| Hospice | 179,378 | 185,281 | 188,414 | 190,370 | 743,443 | 183,628 |
| | <u>630,209</u> | <u>644,457</u> | <u>642,098</u> | <u>649,036</u> | <u>2,565,800</u> | <u>637,387</u> |
| Hospital division | 556,646 | 540,809 | 503,138 | 505,782 | 2,106,375 | 547,630 |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services | 178,115 | 178,439 | 173,638 | 173,723 | 703,915 | 178,219 |
| RehabCare | 198,126 | 194,715 | 179,774 | 172,852 | 745,467 | 172,519 |
| | <u>376,241</u> | <u>373,154</u> | <u>353,412</u> | <u>346,575</u> | <u>1,449,382</u> | <u>350,738</u> |
| | <u>1,563,096</u> | <u>1,558,420</u> | <u>1,498,648</u> | <u>1,501,393</u> | <u>6,121,557</u> | <u>1,535,755</u> |
| Eliminations: | | | | | | |
| Kindred Hospital Rehabilitation Services | (21,148) | (20,086) | (18,376) | (17,788) | (77,398) | (19,321) |
| RehabCare | (1,878) | (1,867) | (1,893) | (1,895) | (7,533) | (1,993) |
| Hospitals | (580) | (636) | (559) | (728) | (2,503) | (652) |
| | <u>(23,606)</u> | <u>(22,589)</u> | <u>(20,828)</u> | <u>(20,411)</u> | <u>(87,434)</u> | <u>(21,966)</u> |
| | <u>\$ 1,539,490</u> | <u>\$ 1,535,831</u> | <u>\$ 1,477,820</u> | <u>\$ 1,480,982</u> | <u>\$ 6,034,123</u> | <u>\$ 1,513,789</u> |
| Income (loss) from continuing operations: | | | | | | |
| Segment adjusted operating income (loss): | | | | | | |
| Kindred at Home: | | | | | | |
| Home health | \$ 63,750 | \$ 76,592 | \$ 66,431 | \$ 69,445 | \$ 276,218 | \$ 59,512 |
| Hospice | 27,581 | 32,784 | 34,761 | 34,147 | 129,273 | 28,943 |
| | <u>91,331</u> | <u>109,376</u> | <u>101,192</u> | <u>103,592</u> | <u>405,491</u> | <u>88,455</u> |
| Hospital division | 93,438 | 91,580 | 61,455 | 91,014 | 337,487 | 104,250 |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services | 51,760 | 53,422 | 49,151 | 49,059 | 203,392 | 53,409 |
| RehabCare | 8,704 | (13,492) | 8,298 | 3,374 | 6,884 | 3,931 |
| | <u>60,464</u> | <u>39,930</u> | <u>57,449</u> | <u>52,433</u> | <u>210,276</u> | <u>57,340</u> |
| Support center expenses | (60,014) | (62,572) | (60,323) | (66,098) | (249,007) | (57,600) |
| Litigation contingency expense | - | - | (4,000) | (3,435) | (7,435) | - |
| Impairment charges | (474) | (135,829) | - | (244,876) | (381,179) | - |
| Restructuring charges | (8,101) | (3,116) | (14,375) | (14,751) | (40,343) | (6,931) |
| Building rent | (64,656) | (64,861) | (64,422) | (63,577) | (257,516) | (62,488) |
| Equipment rent | (8,887) | (8,861) | (8,537) | (8,571) | (34,856) | (8,689) |
| Restructuring charges - rent | (1,905) | (1,934) | (2,125) | (38,554) | (44,518) | (1,178) |
| Depreciation and amortization | (29,820) | (25,651) | (24,808) | (24,526) | (104,805) | (24,789) |
| Interest, net | (58,819) | (58,573) | (60,441) | (60,079) | (237,912) | (60,835) |
| Income (loss) from continuing operations before income taxes | 12,557 | (120,511) | (18,935) | (277,428) | (404,317) | 27,535 |
| Provision (benefit) for income taxes | 2,234 | (16,116) | (1,225) | (142,009) | (157,116) | 1,228 |
| | <u>\$ 10,323</u> | <u>\$ (104,395)</u> | <u>\$ (17,710)</u> | <u>\$ (135,419)</u> | <u>\$ (247,201)</u> | <u>\$ 26,307</u> |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Operating Data (Continued)
(Unaudited)
(In thousands)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|---|------------------|------------------|------------------|------------------|-------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Rent: | | | | | | |
| Kindred at Home: | | | | | | |
| Home health: | | | | | | |
| Building | \$ 8,147 | \$ 8,078 | \$ 7,993 | \$ 8,251 | \$ 32,469 | \$ 8,025 |
| Equipment | 306 | 274 | 251 | 197 | 1,028 | 272 |
| | <u>8,453</u> | <u>8,352</u> | <u>8,244</u> | <u>8,448</u> | <u>33,497</u> | <u>8,297</u> |
| Hospice: | | | | | | |
| Building | 4,256 | 4,118 | 4,139 | 4,212 | 16,725 | 4,278 |
| Equipment | 84 | 88 | 82 | 77 | 331 | 78 |
| | <u>4,340</u> | <u>4,206</u> | <u>4,221</u> | <u>4,289</u> | <u>17,056</u> | <u>4,356</u> |
| Hospital division: | | | | | | |
| Building | 43,271 | 43,662 | 43,193 | 41,914 | 172,040 | 41,072 |
| Equipment | 7,474 | 7,480 | 7,193 | 7,223 | 29,370 | 7,289 |
| | <u>50,745</u> | <u>51,142</u> | <u>50,386</u> | <u>49,137</u> | <u>201,410</u> | <u>48,361</u> |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services: | | | | | | |
| Building | 8,423 | 8,481 | 8,559 | 8,623 | 34,086 | 8,647 |
| Equipment | 375 | 381 | 399 | 530 | 1,685 | 526 |
| | <u>8,798</u> | <u>8,862</u> | <u>8,958</u> | <u>9,153</u> | <u>35,771</u> | <u>9,173</u> |
| RehabCare: | | | | | | |
| Building | 323 | 320 | 317 | 321 | 1,281 | 340 |
| Equipment | 621 | 610 | 585 | 516 | 2,332 | 494 |
| | <u>944</u> | <u>930</u> | <u>902</u> | <u>837</u> | <u>3,613</u> | <u>834</u> |
| Support center: | | | | | | |
| Building | 236 | 202 | 221 | 256 | 915 | 126 |
| Equipment | 27 | 28 | 27 | 28 | 110 | 30 |
| | <u>263</u> | <u>230</u> | <u>248</u> | <u>284</u> | <u>1,025</u> | <u>156</u> |
| Totals: | | | | | | |
| Building | 64,656 | 64,861 | 64,422 | 63,577 | 257,516 | 62,488 |
| Equipment | 8,887 | 8,861 | 8,537 | 8,571 | 34,856 | 8,689 |
| | <u>\$ 73,543</u> | <u>\$ 73,722</u> | <u>\$ 72,959</u> | <u>\$ 72,148</u> | <u>\$ 292,372</u> | <u>\$ 71,177</u> |
| Depreciation and amortization: | | | | | | |
| Kindred at Home: | | | | | | |
| Home health | \$ 3,128 | \$ 2,491 | \$ 2,662 | \$ 2,478 | \$ 10,759 | \$ 2,101 |
| Hospice | 1,285 | 1,102 | 946 | 1,027 | 4,360 | 867 |
| | <u>4,413</u> | <u>3,593</u> | <u>3,608</u> | <u>3,505</u> | <u>15,119</u> | <u>2,968</u> |
| Hospital division | 10,874 | 10,357 | 10,637 | 9,959 | 41,827 | 10,042 |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services | 3,843 | 3,555 | 3,808 | 3,675 | 14,881 | 3,566 |
| RehabCare | 1,845 | 1,596 | 338 | 382 | 4,161 | 427 |
| | <u>5,688</u> | <u>5,151</u> | <u>4,146</u> | <u>4,057</u> | <u>19,042</u> | <u>3,993</u> |
| Support center | 8,845 | 6,550 | 6,417 | 7,005 | 28,817 | 7,786 |
| | <u>\$ 29,820</u> | <u>\$ 25,651</u> | <u>\$ 24,808</u> | <u>\$ 24,526</u> | <u>\$ 104,805</u> | <u>\$ 24,789</u> |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Operating Data (Continued)
(Unaudited)
(In thousands)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|--|------------------|------------------|------------------|------------------|------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Capital expenditures, excluding acquisitions (including discontinued operations): | | | | | | |
| Kindred at Home: | | | | | | |
| Home health: | | | | | | |
| Routine | \$ 1,038 | \$ 1,066 | \$ 1,105 | \$ 1,114 | \$ 4,323 | \$ 1,835 |
| Development | - | - | - | - | - | - |
| | <u>1,038</u> | <u>1,066</u> | <u>1,105</u> | <u>1,114</u> | <u>4,323</u> | <u>1,835</u> |
| Hospice: | | | | | | |
| Routine | 629 | 414 | 674 | 662 | 2,379 | 655 |
| Development | - | - | - | - | - | - |
| | <u>629</u> | <u>414</u> | <u>674</u> | <u>662</u> | <u>2,379</u> | <u>655</u> |
| Hospital division: | | | | | | |
| Routine | 3,123 | 3,877 | 3,325 | 7,979 | 18,304 | 6,924 |
| Development | - | - | - | - | - | 102 |
| | <u>3,123</u> | <u>3,877</u> | <u>3,325</u> | <u>7,979</u> | <u>18,304</u> | <u>7,026</u> |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services: | | | | | | |
| Routine | 418 | 1,225 | 621 | 479 | 2,743 | 1,197 |
| Development | 482 | 2 | 14 | 49 | 547 | 610 |
| | <u>900</u> | <u>1,227</u> | <u>635</u> | <u>528</u> | <u>3,290</u> | <u>1,807</u> |
| RehabCare: | | | | | | |
| Routine | 187 | 183 | 264 | 1,186 | 1,820 | 315 |
| Development | - | - | - | - | - | - |
| | <u>187</u> | <u>183</u> | <u>264</u> | <u>1,186</u> | <u>1,820</u> | <u>315</u> |
| Support center: | | | | | | |
| Routine: | | | | | | |
| Information systems | 4,109 | 9,000 | 8,511 | 11,444 | 33,064 | 4,837 |
| Other | 842 | 66 | 396 | 221 | 1,525 | 147 |
| | <u>4,951</u> | <u>9,066</u> | <u>8,907</u> | <u>11,665</u> | <u>34,589</u> | <u>4,984</u> |
| Development | 4,951 | 5,833 | 6,386 | 7,913 | 25,083 | 2,830 |
| | <u>9,902</u> | <u>14,899</u> | <u>15,293</u> | <u>19,578</u> | <u>59,672</u> | <u>7,814</u> |
| Discontinued operations - nursing centers: | | | | | | |
| Routine | 1,595 | 1,565 | 1,567 | 921 | 5,648 | 500 |
| Development | 6 | 22 | 15 | 222 | 265 | - |
| | <u>1,601</u> | <u>1,587</u> | <u>1,582</u> | <u>1,143</u> | <u>5,913</u> | <u>500</u> |
| Totals: | | | | | | |
| Routine | 11,941 | 17,396 | 16,463 | 24,006 | 69,806 | 16,410 |
| Development | 5,439 | 5,857 | 6,415 | 8,184 | 25,895 | 3,542 |
| | <u>\$ 17,380</u> | <u>\$ 23,253</u> | <u>\$ 22,878</u> | <u>\$ 32,190</u> | <u>\$ 95,701</u> | <u>\$ 19,952</u> |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Operating Data (Continued)
(Unaudited)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|--|---------------|------------|------------|------------|--------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Kindred at Home: | | | | | | |
| Home health: | | | | | | |
| Sites of service (at end of period) | 379 | 377 | 376 | 375 | | 375 |
| Revenue mix %: | | | | | | |
| Medicare | 76.7 | 75.7 | 74.0 | 73.8 | 75.0 | 72.8 |
| Medicaid | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.5 |
| Commercial and other | 11.5 | 11.4 | 12.7 | 12.7 | 12.1 | 13.1 |
| Commercial paid at episodic rates | 10.1 | 11.2 | 11.6 | 11.9 | 11.2 | 12.6 |
| Episodic revenues (\$ 000s) | \$ 326,881 | \$ 334,420 | \$ 320,279 | \$ 332,595 | \$ 1,314,175 | \$ 328,634 |
| Total admissions | 94,510 | 89,018 | 87,156 | 88,224 | 358,908 | 94,913 |
| Same-store total admissions | 94,446 | 88,300 | 86,312 | 88,004 | 357,062 | 94,697 |
| Total episodic admissions | 73,270 | 69,657 | 67,790 | 67,858 | 278,575 | 73,206 |
| Same-store total episodic admissions | 73,233 | 69,207 | 67,191 | 67,650 | 277,281 | 73,022 |
| Medicare episodic admissions | 62,404 | 58,575 | 56,772 | 56,829 | 234,580 | 60,294 |
| Total episodes | 114,964 | 113,579 | 111,488 | 111,411 | 451,442 | 114,658 |
| Episodes per admission | 1.57 | 1.63 | 1.64 | 1.64 | 1.62 | 1.57 |
| Revenue per episode | \$ 2,843 | \$ 2,944 | \$ 2,873 | \$ 2,985 | \$ 2,911 | \$ 2,866 |
| Hospice: | | | | | | |
| Sites of service (at end of period) | 180 | 177 | 178 | 178 | | 176 |
| Admissions | 13,649 | 12,561 | 12,236 | 12,274 | 50,720 | 13,853 |
| Same-store admissions | 13,436 | 12,363 | 11,997 | 12,162 | 49,958 | 13,701 |
| Average length of stay | 96 | 94 | 97 | 96 | 96 | 96 |
| Patient days | 1,193,061 | 1,215,619 | 1,239,094 | 1,243,574 | 4,891,348 | 1,217,227 |
| Average daily census | 13,256 | 13,358 | 13,468 | 13,517 | 13,401 | 13,525 |
| Revenue per patient day | \$ 150 | \$ 152 | \$ 152 | \$ 153 | \$ 152 | \$ 151 |
| Community Care and other revenues (included in home health business segment) (\$ 000s) | \$ 74,095 | \$ 74,222 | \$ 79,720 | \$ 69,974 | \$ 298,011 | \$ 68,959 |

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

**Operating Data (Continued)
(Unaudited)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|--|----------------|----------------|----------------|----------------|------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Hospitals (excluding sub-acute units and skilled nursing facility): | | | | | | |
| End of period data: | | | | | | |
| Number of transitional care hospitals | 82 | 81 | 77 | 75 | | 75 |
| Number of licensed beds | 6,107 | 6,041 | 5,797 | 5,553 | | 5,553 |
| Revenue mix %: | | | | | | |
| Medicare | 52.8 | 50.3 | 50.6 | 50.2 | 51.0 | 49.7 |
| Medicaid | 3.9 | 5.0 | 4.3 | 4.1 | 4.3 | 3.6 |
| Medicare Advantage | 12.2 | 12.3 | 12.3 | 13.5 | 12.6 | 14.1 |
| Medicaid Managed | 9.1 | 9.1 | 10.1 | 10.1 | 9.6 | 10.1 |
| Commercial insurance and other | 22.0 | 23.3 | 22.7 | 22.1 | 22.5 | 22.5 |
| Patient criteria data: | | | | | | |
| Revenues: | | | | | | |
| Compliant patients | 86.0% | 88.3% | 89.1% | 91.8% | 88.7% | 93.7% |
| Site neutral | 14.0% | 11.7% | 10.9% | 8.2% | 11.3% | 6.3% |
| Revenues per patient day: | | | | | | |
| Compliant patients | \$ 1,816 | \$ 1,806 | \$ 1,799 | \$ 1,835 | 1,814 | \$ 1,861 |
| Site neutral | 1,041 | 1,053 | 1,067 | 1,047 | 1,051 | 1,057 |
| Total | 1,645 | 1,667 | 1,674 | 1,729 | 1,677 | 1,776 |
| Admissions: | | | | | | |
| Medicare | 7,529 | 6,743 | 6,073 | 5,862 | 26,207 | 6,201 |
| Medicaid | 354 | 381 | 362 | 287 | 1,384 | 310 |
| Medicare Advantage | 1,354 | 1,239 | 1,197 | 1,225 | 5,015 | 1,464 |
| Medicaid Managed | 851 | 903 | 861 | 875 | 3,490 | 936 |
| Commercial insurance and other | 1,614 | 1,608 | 1,483 | 1,401 | 6,106 | 1,522 |
| | <u>11,702</u> | <u>10,874</u> | <u>9,976</u> | <u>9,650</u> | <u>42,202</u> | <u>10,433</u> |
| Patient days: | | | | | | |
| Medicare | 187,738 | 173,916 | 158,083 | 149,892 | 669,629 | 156,561 |
| Medicaid | 13,334 | 13,333 | 13,429 | 12,048 | 52,144 | 11,463 |
| Medicare Advantage | 41,020 | 40,555 | 38,338 | 41,488 | 161,401 | 46,098 |
| Medicaid Managed | 32,713 | 32,635 | 31,249 | 32,389 | 128,986 | 33,697 |
| Commercial insurance and other | 53,695 | 54,809 | 49,895 | 47,355 | 205,754 | 51,341 |
| | <u>328,500</u> | <u>315,248</u> | <u>290,994</u> | <u>283,172</u> | <u>1,217,914</u> | <u>299,160</u> |
| Average length of stay: | | | | | | |
| Medicare | 24.9 | 25.8 | 26.0 | 25.6 | 25.6 | 25.2 |
| Medicaid | 37.7 | 35.0 | 37.1 | 42.0 | 37.7 | 37.0 |
| Medicare Advantage | 30.3 | 32.7 | 32.0 | 33.9 | 32.2 | 31.5 |
| Medicaid Managed | 38.4 | 36.1 | 36.3 | 37.0 | 37.0 | 36.0 |
| Commercial insurance and other | 33.3 | 34.1 | 33.6 | 33.8 | 33.7 | 33.7 |
| Weighted average | 28.1 | 29.0 | 29.2 | 29.3 | 28.9 | 28.7 |
| Revenues per admission: | | | | | | |
| Medicare | \$ 37,867 | \$ 39,219 | \$ 40,577 | \$ 41,904 | \$ 39,746 | \$ 42,618 |
| Medicaid | 60,091 | 69,304 | 57,365 | 70,352 | 64,042 | 61,546 |
| Medicare Advantage | 48,555 | 51,958 | 50,301 | 53,834 | 51,102 | 51,063 |
| Medicaid Managed | 57,736 | 53,159 | 57,172 | 56,881 | 56,198 | 57,536 |
| Commercial insurance and other | 73,750 | 76,007 | 74,435 | 77,140 | 75,289 | 78,476 |
| Weighted average | 46,170 | 48,322 | 48,818 | 50,738 | 48,395 | 50,935 |
| Revenues per patient day: | | | | | | |
| Medicare | \$ 1,519 | \$ 1,521 | \$ 1,559 | \$ 1,639 | \$ 1,556 | \$ 1,688 |
| Medicaid | 1,595 | 1,980 | 1,546 | 1,676 | 1,700 | 1,664 |
| Medicare Advantage | 1,603 | 1,587 | 1,571 | 1,590 | 1,588 | 1,622 |
| Medicaid Managed | 1,502 | 1,471 | 1,575 | 1,537 | 1,521 | 1,598 |
| Commercial insurance and other | 2,217 | 2,230 | 2,212 | 2,282 | 2,234 | 2,326 |
| Weighted average | 1,645 | 1,667 | 1,674 | 1,729 | 1,677 | 1,776 |
| Medicare case mix index (discharged patients only) | 1.172 | 1.171 | 1.180 | 1.177 | 1.178 | 1.224 |
| Average daily census | 3,650 | 3,464 | 3,163 | 3,078 | 3,337 | 3,324 |
| Occupancy % | 67.6 | 64.3 | 59.9 | 61.1 | 63.3 | 66.7 |

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Operating Data (Continued)
(Unaudited)

| | 2017 Quarters | | | | Year | First quarter 2018 |
|---------------------------------------|----------------|----------------|----------------|----------------|------------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Same-hospital data: | | | | | | |
| End of period data: | | | | | | |
| Number of transitional care hospitals | 75 | 75 | 75 | 75 | | 75 |
| Number of licensed beds | 5,553 | 5,553 | 5,553 | 5,553 | | 5,553 |
| Revenue mix %: | | | | | | |
| Medicare | 52.6 | 50.1 | 50.6 | 50.4 | 51.0 | 49.7 |
| Medicaid | 3.8 | 4.9 | 4.2 | 3.5 | 4.0 | 3.6 |
| Medicare Advantage | 12.1 | 12.2 | 12.4 | 13.6 | 12.6 | 14.1 |
| Medicaid Managed | 9.4 | 9.4 | 10.2 | 10.3 | 9.8 | 10.1 |
| Commercial insurance and other | 22.1 | 23.4 | 22.6 | 22.2 | 22.6 | 22.5 |
| Patient criteria data: | | | | | | |
| Revenues: | | | | | | |
| Compliant patients | 86.4% | 88.8% | 89.2% | 91.8% | 89.0% | 93.7% |
| Site neutral | 13.6% | 11.2% | 10.8% | 8.2% | 11.0% | 6.3% |
| Revenues per patient day: | | | | | | |
| Compliant patients | \$ 1,818 | \$ 1,809 | \$ 1,799 | \$ 1,818 | \$ 1,811 | \$ 1,863 |
| Site neutral | 1,051 | 1,048 | 1,065 | 1,047 | 1,053 | 1,055 |
| Total | 1,654 | 1,673 | 1,675 | 1,715 | 1,678 | 1,778 |
| Admissions: | | | | | | |
| Medicare | 7,054 | 6,374 | 5,942 | 5,848 | 25,218 | 6,201 |
| Medicaid | 325 | 346 | 342 | 284 | 1,297 | 310 |
| Medicare Advantage | 1,273 | 1,180 | 1,181 | 1,222 | 4,856 | 1,464 |
| Medicaid Managed | 829 | 864 | 843 | 875 | 3,411 | 936 |
| Commercial insurance and other | 1,520 | 1,538 | 1,450 | 1,397 | 5,905 | 1,522 |
| | <u>11,001</u> | <u>10,302</u> | <u>9,758</u> | <u>9,626</u> | <u>40,687</u> | <u>10,433</u> |
| Patient days: | | | | | | |
| Medicare | 176,507 | 164,636 | 154,551 | 149,387 | 645,081 | 156,561 |
| Medicaid | 12,357 | 12,404 | 12,985 | 11,777 | 49,523 | 11,463 |
| Medicare Advantage | 38,520 | 38,490 | 37,678 | 41,378 | 156,066 | 46,098 |
| Medicaid Managed | 31,982 | 31,878 | 30,759 | 32,355 | 126,974 | 33,697 |
| Commercial insurance and other | 51,086 | 52,880 | 48,593 | 47,124 | 199,683 | 51,341 |
| | <u>310,452</u> | <u>300,288</u> | <u>284,566</u> | <u>282,021</u> | <u>1,177,327</u> | <u>299,160</u> |
| Average length of stay: | | | | | | |
| Medicare | 25.0 | 25.8 | 26.0 | 25.5 | 25.6 | 25.2 |
| Medicaid | 38.0 | 35.8 | 38.0 | 41.5 | 38.2 | 37.0 |
| Medicare Advantage | 30.3 | 32.6 | 31.9 | 33.9 | 32.1 | 31.5 |
| Medicaid Managed | 38.6 | 36.9 | 36.5 | 37.0 | 37.2 | 36.0 |
| Commercial insurance and other | 33.6 | 34.4 | 33.5 | 33.7 | 33.8 | 33.7 |
| Weighted average | 28.2 | 29.1 | 29.2 | 29.3 | 28.9 | 28.7 |
| Revenues per admission: | | | | | | |
| Medicare | \$ 38,305 | \$ 39,525 | \$ 40,600 | \$ 41,703 | \$ 39,942 | \$ 42,626 |
| Medicaid | 59,603 | 70,702 | 57,650 | 58,704 | 61,852 | 61,477 |
| Medicare Advantage | 48,898 | 51,845 | 50,144 | 53,851 | 51,163 | 51,053 |
| Medicaid Managed | 58,086 | 54,505 | 57,535 | 56,830 | 56,720 | 57,580 |
| Commercial insurance and other | 74,650 | 76,443 | 74,433 | 76,948 | 75,607 | 78,786 |
| Weighted average | 46,672 | 48,751 | 48,843 | 50,237 | 48,563 | 50,986 |
| Revenues per patient day: | | | | | | |
| Medicare | \$ 1,531 | \$ 1,530 | \$ 1,561 | \$ 1,633 | \$ 1,561 | \$ 1,688 |
| Medicaid | 1,568 | 1,972 | 1,518 | 1,416 | 1,620 | 1,665 |
| Medicare Advantage | 1,616 | 1,589 | 1,572 | 1,590 | 1,592 | 1,621 |
| Medicaid Managed | 1,506 | 1,477 | 1,577 | 1,537 | 1,524 | 1,598 |
| Commercial insurance and other | 2,221 | 2,223 | 2,221 | 2,281 | 2,236 | 2,336 |
| Weighted average | 1,654 | 1,673 | 1,675 | 1,715 | 1,678 | 1,778 |
| Average daily census | 3,449 | 3,300 | 3,093 | 3,065 | 3,226 | 3,324 |

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Continued)**

**Operating Data (Continued)
(Unaudited)**

| | 2017 Quarters | | | | Year | First quarter 2018 |
|---|---------------|------------|------------|------------|------------|-----------------------|
| | First | Second | Third | Fourth | | |
| Kindred Rehabilitation Services: | | | | | | |
| Kindred Hospital Rehabilitation Services: | | | | | | |
| Freestanding IRFs: | | | | | | |
| End of period data: | | | | | | |
| Number of IRFs | 19 | 19 | 19 | 19 | | 19 |
| Number of licensed beds | 995 | 995 | 995 | 995 | | 995 |
| Discharges (a) | 4,775 | 4,766 | 4,755 | 5,011 | 19,307 | 5,029 |
| Same-hospital discharges (a) | 4,775 | 4,517 | 4,477 | 4,671 | 18,440 | 5,029 |
| Occupancy % (a) | 71.4 | 70.0 | 68.8 | 71.2 | 70.4 | 73.2 |
| Average length of stay (a) | 12.8 | 12.8 | 12.7 | 12.5 | 12.7 | 12.5 |
| Revenue per discharge (a) | \$ 20,097 | \$ 20,620 | \$ 20,329 | \$ 19,523 | \$ 20,134 | \$ 20,020 |
| Contract services: | | | | | | |
| Sites of service (at end of period): | | | | | | |
| Inpatient rehabilitation units (ARUs) | 101 | 102 | 101 | 99 | | 98 |
| LTAC hospitals | 119 | 116 | 110 | 104 | | 103 |
| Sub-acute units | 7 | 6 | 6 | 4 | | 4 |
| Outpatient units | 129 | 121 | 123 | 123 | | 123 |
| | <u>356</u> | <u>345</u> | <u>340</u> | <u>330</u> | | <u>328</u> |
| Revenue per site | \$ 227,100 | \$ 228,534 | \$ 222,504 | \$ 225,919 | \$ 904,057 | \$ 232,321 |
| RehabCare: | | | | | | |
| Sites of service (at end of period) | 1,703 | 1,734 | 1,624 | 1,616 | | 1,580 |
| Revenue per site | \$ 116,340 | \$ 112,292 | \$ 110,699 | \$ 106,963 | \$ 446,294 | \$ 109,189 |

(a) Excludes non-consolidating IRF.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The following discussion of the Company's exposure to market risk contains "forward-looking statements" that involve risks and uncertainties. Given the unpredictability of interest rates as well as other factors, actual results could differ materially from those projected in such forward-looking information.

The Company's exposure to market risk relates to changes in the prime rate, federal funds rate and LIBOR, which affect the interest paid on certain borrowings.

The following table provides information about the Company's financial instruments as of March 31, 2018 that are sensitive to changes in interest rates. The table presents principal cash flows and related weighted average interest rates by expected maturity date.

Interest Rate Sensitivity Principal (Notional) Amount by Expected Maturity Average Interest Rate (Dollars in thousands)

| | Expected maturities | | | | | | Total | Fair value March 31, 2018 |
|--|---------------------|-------------------|-------------------|---------------------|-------------------|-------------------|---------------------|------------------------------|
| | 2018 | 2019 | 2020 | 2021 | 2022 | Thereafter | | |
| Liabilities: | | | | | | | | |
| Long-term debt, including amounts due within one year: | | | | | | | | |
| Fixed rate: | | | | | | | | |
| Notes due 2020 (a) | \$ - | \$ - | \$ 750,000 | \$ - | \$ - | \$ - | \$ 750,000 | \$ 796,875 |
| Notes due 2022 (a) | - | - | - | - | 500,000 | - | 500,000 | 503,750 |
| Notes due 2023 (a) | - | - | - | - | - | 600,000 | 600,000 | 633,660 |
| Other | 247 | 257 | 18 | - | - | - | 522 | 522 (b) |
| | <u>\$ 247</u> | <u>\$ 257</u> | <u>\$ 750,018</u> | <u>\$ -</u> | <u>\$ 500,000</u> | <u>\$ 600,000</u> | <u>\$ 1,850,522</u> | <u>\$ 1,934,807</u> |
| Average interest rate | 3.1% | 3.3% | 8.0% | | 6.4% | 8.8% | | |
| Variable rate: | | | | | | | | |
| ABL Facility (c) | \$ - | \$ 119,500 | \$ - | \$ - | \$ - | \$ - | \$ 119,500 | \$ 119,500 |
| Term Loan Facility (a,d,e) | 10,525 | 14,034 | 14,034 | 1,313,326 | - | - | 1,351,919 | 1,355,299 |
| | <u>\$ 10,525</u> | <u>\$ 133,534</u> | <u>\$ 14,034</u> | <u>\$ 1,313,326</u> | <u>\$ -</u> | <u>\$ -</u> | <u>\$ 1,471,419</u> | <u>\$ 1,474,799</u> |

(a) The expected maturities exclude total debt issuance costs, net of accumulated amortization, of approximately \$37 million, comprised of \$4 million for the Notes due 2020, \$5 million for the Notes due 2022, \$6 million for the Notes due 2023, and \$22 million for the Term Loan Facility.

(b) Calculated based upon the net present value of future principal and interest payments using an average interest rate of 3.2%.

(c) Interest on borrowings under the ABL Facility is payable at a rate per annum equal to the applicable margin plus, at the Company's option, either: (1) LIBOR determined by reference to the costs of funds for Eurodollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs, or (2) a base rate determined by reference to the highest of: (a) the prime rate of JPMorgan Chase Bank, N.A., (b) the federal funds effective rate plus one-half of 1.00% and (c) LIBOR as described in subclause (1) plus 1.00%. At March 31, 2018, the applicable margin for borrowings under the ABL Facility was 2.00% with respect to LIBOR borrowings and 1.00% with respect to base rate borrowings. The applicable margin is subject to adjustment each fiscal quarter, based upon average historical excess availability during the preceding quarter.

(d) Interest on borrowings under the Term Loan Facility is payable at a rate per annum equal to an applicable margin plus, at the Company's option, either: (1) LIBOR determined by reference to the costs of funds for Eurodollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs, or (2) a base rate determined by reference to the highest of: (a) the prime rate of JPMorgan Chase Bank, N.A., (b) the federal funds effective rate plus one-half of 1.00% and (c) LIBOR described in subclause (1) plus 1.00%. LIBOR is subject to an interest rate floor of 1.00%. The applicable margin for borrowings under the Term Loan Facility is 3.50% with respect to LIBOR borrowings and 2.50% with respect to base rate borrowings. The expected maturities for the Term Loan Facility exclude the original issue discount of approximately \$5 million.

(e) In January 2016, the Company entered into three interest rate swap agreements to hedge its floating interest rate on an aggregate of \$325 million of debt outstanding under its Term Loan Facility. The interest rate swaps have an effective date of January 11, 2016, and expire on January 9, 2021. The Company is required to make payments based upon a fixed interest rate of 1.862% and 1.855% calculated on the notional amount of \$175 million and \$150 million, respectively. In exchange, the Company will receive interest on \$325 million at a variable interest rate that is based upon the three-month LIBOR, subject to a minimum rate of 1.0%. In March 2014, the Company entered into an interest rate swap agreement to hedge its floating interest rate on an aggregate of \$400 million of debt outstanding under its Term Loan Facility. On April 8, 2014, the Company completed a novation of a portion of its \$400 million swap agreement to two new counterparties, each in the amount of \$125 million. The original swap contract was not amended, terminated, or otherwise modified. The interest rate swap had an effective date of April 9, 2014, expired on April 9, 2018, and applied to the Term Loan Facility. The Company made payments based upon a fixed interest rate of 1.867% calculated on the notional amount of \$400 million. In exchange, the Company received interest on \$400 million at a variable interest rate that was based upon the three-month LIBOR, subject to a minimum rate of 1.0%.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control Over Financial Reporting

The Company has carried out an evaluation under the supervision and with the participation of management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2018, the Company's disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, are effective.

There has been no change in the Company's internal control over financial reporting during the Company's quarter ended March 31, 2018, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The Company provides services in a highly regulated industry and is a party to various legal actions and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including investigations resulting from the Company's obligation to self-report suspected violations of law). The Company cannot predict the ultimate outcome of pending litigation and regulatory and other governmental and internal audits and investigations. The DOJ, CMS, or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties (some of which may not be covered by insurance), which may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations, and liquidity. See note 16 of the notes to unaudited condensed consolidated financial statements for a description of pending legal proceedings, governmental reviews, audits, and investigations to which the Company is subject.

Shareholder derivative action

On March 16, 2016, a shareholder derivative action (previously defined as the "Complaint") was filed against certain of the Company's current and former officers and directors in circuit court for Jefferson County, Kentucky. The Complaint also named the Company as a nominal defendant. The Complaint alleged that the named current and former officers and directors breached their respective duties of good faith, loyalty, and candor, and other general fiduciary duties owed to the Company and its shareholders by, among other things, failing to exercise reasonable and prudent supervision over the management, policies, and controls of the Company in order to detect practices that existed at RehabCare resulting in the Company having to enter into two separate settlement agreements with the DOJ. The Complaint was settled in January 2018 in exchange for the Company's agreement to pay the plaintiff \$950,000 in fees and expenses. The Company previously recorded a loss reserve of \$1.0 million in the third quarter of 2017 related to this matter.

Six purported class action complaints related to the Merger were filed on behalf of putative classes of the Company's public stockholders (previously defined as the "Merger Complaints"). Four of these complaints were filed in the United States District Court for the District of Delaware: *Sehrgosha v. Kindred Healthcare, Inc., et al.*, filed on February 8, 2018; *Carter v. Kindred Healthcare, Inc., et al.*, filed on February 14, 2018; *Rosenfeld v. Kindred Healthcare, Inc., et al.*, filed on February 15, 2018; and *Einhorn v. Kindred Healthcare, Inc., et al.*, filed on February 21, 2018. The remaining two complaints were filed in the United States District Court for the Western District of Kentucky: *Tompkins v. Kindred Healthcare, Inc., et al.*, filed on February 9, 2018; and *Buskirk v. Kindred Healthcare, Inc., et al.*, filed on February 13, 2018. The Company and individual members of the Board are named as defendants in each of the actions. The *Tompkins* action also names as defendants TPG, WCAS, Humana, Parent, HospitalCo Parent and Merger Sub. The Merger Complaints generally allege that the defendants violated the Exchange Act by failing to disclose material information in the Company's preliminary proxy statement filed on February 5, 2018. The Merger Complaints seek, among other things, injunctive relief prohibiting the stockholder vote to approve the Merger and unspecified compensatory damages and attorneys' fees. On March 5, 2018, the plaintiffs jointly agreed to voluntarily dismiss the Merger Complaints in exchange for the Company's agreement to file supplemental disclosures with the SEC. The supplemental disclosures were filed on March 6, 2018. Negotiations concerning legal fees are ongoing.

On March 8, 2018, Brigade Capital filed a stockholder complaint in the Court of Chancery for the State of Delaware against the Company, each of the Board members, TPG, WCAS, and Humana alleging that the Company and the Board engaged in a flawed sales process, and filed a proxy and supplemental proxy that contain materially misleading disclosures and material omissions. Brigade Capital also filed a motion to expedite proceedings in support of anticipated motion to preliminarily enjoin the March 29, 2018 shareholder vote. The court permitted limited expedited discovery on one allegation concerning a potential conflict of interest involving one board member, and conducted a hearing on the injunction motion on March 27, 2018. Following argument, the court denied Brigade Capital's request for injunctive relief, but required the Company to hold the scheduled shareholder vote open for five additional business days (or to reschedule the shareholder vote five business days later) to permit shareholders to perfect their appraisal rights, should they so choose. On April 23, 2018, Brigade Capital filed its notice of dismissal with the court dismissing this matter with prejudice.

PART II. OTHER INFORMATION (Continued)

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

ISSUER PURCHASES OF EQUITY SECURITIES

| Period | Total number of shares (or units) purchased (a) | Average price paid per share (or unit) (b) | Total number of shares (or units) purchased as part of publicly announced plans or programs | Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs |
|-------------------------------------|--|---|--|--|
| Month #1 (January 1 – January 31) | 5,701 | \$ 9.69 | – | \$ – |
| Month #2 (February 1 – February 28) | 78,301 | 9.03 | – | – |
| Month #3 (March 1 – March 31) | 249,686 | 9.14 | – | – |
| Total | 333,688 | \$ 9.12 | – | \$ – |

- (a) These amounts represent shares of the Company’s Common Stock withheld to offset tax withholding obligations that are triggered upon the vesting and release of service-based and performance-based restricted share awards previously granted under the Company’s stock-based compensation plans for its employees (the “Withheld Shares”). The total tax withholding obligation is calculated by dividing the closing price of the Company’s Common Stock on the New York Stock Exchange on the applicable vesting date to determine the total number of Withheld Shares required to be withheld to satisfy such withholding obligation.
- (b) The average price per share for each period was calculated by dividing the sum of the aggregate value of the Withheld Shares by the total number of Withheld Shares.

Item 6. Exhibits

| Exhibit number | Description of document |
|-----------------------|--|
| 10.1*# | Amendment No. 3 to the Second Amended and Restated Master Lease Agreement No. 5, among Kindred Healthcare, Inc., Kindred Healthcare Operating, Inc., and Ventas Realty, Limited Partnership. |
| 31* | Rule 13a-14(a)/15d-14(a) Certifications. |
| 32* | Section 1350 Certifications. |
| 101.INS* | XBRL Instance Document. |
| 101.SCH* | XBRL Taxonomy Extension Schema Document. |
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. |

* Filed herewith.

The Company will furnish supplementally to the SEC upon request a copy of any omitted exhibit or schedule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KINDRED HEALTHCARE, INC.

Date: May 8, 2018

/s/ Benjamin A. Breier

Benjamin A. Breier
President and Chief Executive Officer

Date: May 8, 2018

/s/ Stephen D. Farber

Stephen D. Farber
Executive Vice President,
Chief Financial Officer

AMENDMENT NO. 3 TO THE SECOND AMENDED AND RESTATED MASTER LEASE AGREEMENT NO. 5

THIS AMENDMENT NO. 3 TO THE SECOND AMENDED AND RESTATED MASTER LEASE AGREEMENT NO. 5 is effective as of March 27, 2018 (this "Amendment"), by and among Kindred Healthcare, Inc., a Delaware corporation ("Kindred"), Kindred Healthcare Operating, Inc., a Delaware corporation and direct, wholly-owned subsidiary of Kindred ("Operator," and together with Kindred, the "Tenants"), and Ventas Realty, Limited Partnership, a Delaware limited partnership ("Ventas") and amends that certain Second Amended and Restated Master Lease Agreement No. 5, dated as of November 11, 2016 (as amended from time to time, the "Master Lease"). Each of Kindred, Operator and Ventas is referred to, individually, as a "Party" and, collectively, they are referred to as the "Parties".

RECITALS

WHEREAS, the Parties desire to amend the Master Lease; and

NOW, THEREFORE, in consideration of the premises and the agreements in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:

ARTICLE I
DEFINITIONS

Section 1.1 *Definitions.* Capitalized terms used in this Amendment and not otherwise defined herein have the respective meanings given to them in the Master Lease.

Section 1.2 *Rules of Construction.*

(a) The Parties acknowledge that each Party and its attorneys have reviewed this Amendment and that any rule of construction to the effect that any ambiguities are to be resolved against the drafting Party, or any similar rule operating against the drafter of an agreement, shall not be applicable to the construction or interpretation of this Amendment. Prior drafts of this Amendment are not an indication of the Parties' intent and shall not be applicable to the construction or interpretation of this Amendment.

(b) The words "includes" and "including" shall mean "including, without limitation" and the word "or" shall not be exclusive.

(c) Any reference to any Person in this Amendment shall, unless otherwise expressly provided in this Amendment, be a reference to such Person and its respective successors and assigns.

ARTICLE II
AMENDMENTS

Section 2.1 *Exhibit C.* Effective as of the date hereof, Exhibit C of the Master Lease is amended and restated in its entirety to read as set forth in Attachment 1 attached to and made a part of this Amendment.

ARTICLE III
MISCELLANEOUS

Section 3.1 *Entire Agreement.* This Amendment supersedes all prior discussions and agreements between the Parties with respect to the subject matter hereof and this Amendment contains the sole and entire agreement between the Parties hereto with respect to the subject matter hereof. Except as set forth in this Amendment, the Master Lease remains in full force and effect.

Section 3.2 *Expenses.* Except as otherwise expressly provided in this Amendment or the Master Lease, each Party shall pay its own costs and expenses incurred in anticipation of, relating to and in connection with the negotiation and execution of this Amendment.

Section 3.3 *Conflict; Unified Commercial Operating Lease.* In the event of a conflict between the Master Lease and this Amendment, this Amendment shall control in all events. Except as set forth in this Amendment, the Master Lease shall remain in full force and effect. It is acknowledged and agreed that, except as otherwise expressly provided herein or in the Master Lease, the inclusion of each of the Leased Properties on a continuing basis in the Master Lease is an essential element of the leasing transaction described in the Master Lease for Ventas, and that, except as otherwise expressly provided herein or in the Master Lease, Ventas shall not be obligated and may not be required to lease to Tenants less than all of the Leased Properties demised pursuant to the Master Lease. It is further acknowledged and agreed that the Master Lease is not a residential lease within the meaning of the U.S. Bankruptcy Code, as amended, and that the Master Lease is an operating lease, and not a capital lease, for all accounting, tax and legal purposes.

Section 3.4 *Amendment.* This Amendment may be amended, supplemented or modified only by a written instrument duly executed by or on behalf of each Party.

Section 3.5 *Waiver.* Any term or condition of this Amendment may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. No waiver by any Party of any term or condition of this Amendment, in any one or more instances, shall be deemed to be construed as a waiver of the same of any other term or condition of this Amendment on any future occasion.

Section 3.6 *No Third Party Beneficiary.* The Parties hereby agree that the terms and provisions of this Amendment are solely for the benefit of the other Party hereto and its successors and permitted assigns, in accordance with and subject to the terms of this Amendment, and this Amendment is not intended to, and does not, confer upon any Person other

than the Parties and their respective successors and permitted assigns any rights or remedies hereunder.

Section 3.7 *Binding Effect.* This Amendment is binding upon, inures to the benefit of and is enforceable by the Parties and their respective successors and permitted assigns.

Section 3.8 *Headings.* The headings used in this Amendment have been inserted for convenience of reference only and do not define or limit the provisions hereof.

Section 3.9 *Counterparts; Facsimile.* This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any facsimile or electronically transmitted copies hereof or signature hereon shall, for all purposes, be deemed originals.

Section 3.10 *Severability.* If any term or provision of this Amendment is to be invalid or unenforceable, such term or provision shall be modified as slightly as possible so as to render it valid and enforceable; if such provision, as modified, shall be held or deemed invalid or unenforceable, such holding shall not affect the remainder of this Amendment and the same shall remain in full force and effect.

Section 3.11 *Governing Law; Jurisdiction.*

(a) This Amendment, and all claims or causes of action (whether at law or in equity, in contract or in tort, or otherwise) that may be based upon, arise out of or relate to this Amendment or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of New York, other than its doctrine regarding conflicts of laws.

(b) Each of the Parties irrevocably submits to the personal jurisdiction of any federal or state court sitting in the Commonwealth of Kentucky with respect to any dispute or controversy arises out of this Amendment, or for recognition and enforcement of any judgment in respect thereof.

(c) EACH OF THE PARTIES HERETO KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF THIS AMENDMENT.

Section 3.12 *Authority.* The Parties represent and warrant to each other that each of them, respectively, has full power, right and authority to execute and perform this Amendment and all corporate action necessary to do so has been taken. In order to induce Ventas to enter into this Amendment, Tenants hereby represents and warrants to Ventas that Tenants' entry into this Amendment does not require that any consent or approval first be obtained from any lender of Tenants or their Affiliates.

[Signature page follows]

IN WITNESS WHEREOF, this Amendment has been duly executed and delivered by the duly authorized officer of each Party as of the date first above written.

KINDRED HEALTHCARE, INC.

By: /s/ Cristina E. O'Brien

Name: Cristina E. O'Brien

Title: Vice President & Real Estate Counsel

KINDRED HEALTHCARE OPERATING, INC.

By: /s/ Cristina E. O'Brien

Name: Cristina E. O'Brien

Title: Vice President & Real Estate Counsel

VENTAS REALTY, LIMITED PARTNERSHIP

By: Ventas, Inc., its general partner

By: /s/ Jason Simmers

Name: Jason Simmers

Title: Authorized Signatory

Attachment 1

Exhibit C

| Facility ID | Name | Base Rent as of Third Amendment Effective Date | Transferred Property Percentage as of Third Amendment Effective Date |
|--------------------|--|---|---|
| 4602 | Kindred Hospital - South Florida - Coral Gables | 4,271,887.82 | 3.54361% |
| 4628 | Kindred Hospital - Chattanooga | 1,014,283.15 | 0.84137% |
| 4637 | Kindred Hospital - Chicago (North Campus) | 3,360,519.20 | 2.78761% |
| 4652 | Kindred Hospital - North Florida | 3,555,316.05 | 2.94920% |
| 4680 | Kindred Hospital - St. Louis | 1,371,078.64 | 1.13734% |
| 4690 | Kindred Hospital - Chicago (Northlake Campus) | 4,192,547.75 | 3.47780% |
| 4653 | Kindred Hospital - Tarrant County (Fort Worth Southwest) | 8,598,754.70 | 7.13283% |
| 4674 | Kindred Hospital - Central Tampa | 5,580,211.04 | 4.62889% |
| 4635 | Kindred Hospital - San Antonio | 1,180,003.60 | 0.97883% |
| 4647 | Kindred Hospital - Las Vegas (Sahara) | 4,989,465.00 | 4.13885% |
| 4660 | Kindred Hospital - Mansfield | 1,663,464.47 | 1.37987% |
| 4662 | Kindred Hospital - Greensboro | 2,370,000.00 | 1.96596% |
| 4614 | Kindred Hospital - Philadelphia | 1,040,000.00 | 0.86270% |
| 4664 | Kindred Hospital - Albuquerque | 6,564,261.05 | 5.44518% |
| 4665 | Kindred Hospital - Denver | 2,738,686.23 | 2.27179% |
| 4871 | Kindred Hospital - Chicago - Lakeshore | 3,134,560.45 | 2.60018% |
| 4611 | Kindred Hospital - Bay Area St. Petersburg | 3,061,213.46 | 2.53933% |
| 4633 | Kindred Hospital - Louisville | 5,654,798.44 | 4.69076% |
| 4638 | Kindred Hospital - Indianapolis | 1,179,998.56 | 0.97883% |
| 4644 | Kindred Hospital - Brea | 5,450,914.05 | 4.52163% |
| 4822 | Kindred Hospital - San Francisco Bay Area | 10,000,000.00 | 8.29519% |
| 4876 | Kindred Hospital - South Florida - Hollywood | 4,039,801.22 | 3.35109% |
| 4842 | Kindred Hospital - Westminster | 7,801,435.64 | 6.47144% |
| 4848 | Kindred Hospital - San Diego | 3,379,185.20 | 2.80310% |
| 4615 | Kindred Hospital - Sycamore | 3,986,614.23 | 3.30697% |
| 4654 | Kindred Hospital (Houston Northwest) | 2,802,936.78 | 2.32509% |
| 4807 | Kindred Hospital - Ontario | 10,000,000.00 | 8.29519% |
| 4645 | Kindred Hospital - South Florida Ft. Lauderdale | 1,399,997.36 | 1.16132% |
| 4685 | Kindred Hospital - Houston | 6,169,915.31 | 5.11805% |
| Total | | \$120,551,849.40 | 100.00000% |

**Certification Required By Rules 13a-14(a) and 15d-14(a)
under the Securities Exchange Act of 1934**

I, Benjamin A. Breier, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kindred Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2018

/s/ Benjamin A. Breier

Benjamin A. Breier
President and Chief Executive Officer

**Certification Required By Rules 13a-14(a) and 15d-14(a)
under the Securities Exchange Act of 1934**

I, Stephen D. Farber, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kindred Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2018

/s/ Stephen D. Farber

Stephen D. Farber
Executive Vice President, Chief Financial Officer

Section 1350 Certifications
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Kindred Healthcare, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2018

/s/ Benjamin A. Breier

Benjamin A. Breier
President and Chief Executive Officer

Date: May 8, 2018

/s/ Stephen D. Farber

Stephen D. Farber
Executive Vice President, Chief Financial Officer

